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Zusammenfassung 
Antikörper sind ein überlebenswichtiger Teil unseres Immunsystems. Sie machen 
Eindringlinge unschädlich und schützen uns so Tag für Tag vor Krankheitserregern. Die 
Antikörper unseres humoralen Immunsystems können aber auch Schaden anrichten. In 
Autoimmunkrankheiten oder bei Gewebetransplantationen markieren sie körpereigene 
Strukturen, die daraufhin vom Immunsystem angegriffen werden.  
Alle diese Antikörper werden – bei Bedarf – von spezialisierten Plasmazellen in unser Blut 
sezerniert. Die Plasmazellen entstehen aus unreifen B Lymphozyten, die einen 
Reifungsprozess durchlaufen müssen, dann positiv, d.h. durch die Bindung an ein Antigen, 
selektiert und schließlich zur Teilung angeregt werden. Letztendlich sezerniert jede dieser 
Plasmazellen große Mengen identischer Antikörper mit einzigartiger Spezifität. Durch den 
Kontakt mit einem Antigen wird außerdem bei vielen B Lymphozyten eine somatische 
Hypermutation aktiviert, die letztendlich zu einer erhöhten Affinität des Antikörpers für sein 
Antigen führt. Bemerkenswert ist, dass die Menge der einzelnen Serumantikörper sehr 
variabel ist und sich so an geänderte Bedingungen anpasst (z.B. eine schwere Infektion oder 
ein Gewebetrauma). Dies ist darin begründet, dass in unserem Serum nur für eine begrenzte 
Zahl verschiedener Antikörper in therapeutischer Konzentration „Platz“ ist.  
Bisher war es aufgrund der großen Vielfalt einander sehr ähnlicher Antikörperspezies nicht 
möglich herauszufinden, genau welche Antikörperspezies in welchem Mengenverhältnis im 
Blut eines Patienten vorliegen und durch welches Ereignis diese entstanden sind. Wäre dies 
möglich, könnten durch den Vergleich von verschiedenen Patientenseren oder Seren von 
verschieden Zeitpunkten neu gebildete Antikörper (z.B. nach einer Infektion) identifiziert 
werden. Außerdem könnte untersucht werden, welche Antikörperspezies bei einem noch nicht 
verstandenen Krankheitsbild auftauchen oder welche Antikörper mit Schutz vor bestimmten 
Krankheiten korrelieren (die entsprechenden Antigene wären Kandidaten für Impfstoffe). 
Dafür müssen ohne Vorinformation über mögliche Krankheiten möglichst viele eindeutig 
voneinander unterscheidbare Antikörperspezies im Serum eines Patienten identifiziert 
werden. 
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Die vorliegende Arbeit soll die Voraussetzungen schaffen, genau dies in Zukunft 
erforschen zu können und beschäftigt sich daher mit der Untersuchung von Antikörper-
Antigen Wechselwirkungen und die detaillierten Auswirkungen einzelner Aminosäuren auf 
die Bindung. Durch diese Bindungsuntersuchung können Spezifitäten von Antikörpern, die 
sowohl das Antigen als auch den Antikörper zu charakterisieren beziehungsweise zu 
identifizieren vermögen, sehr genau bestimmt werden.  
Um die Spezifitäten möglichst vieler Antikörper zu bestimmen, eignen sich 
Hochdurchsatzverfahren wie beispielsweise Peptidarrays, die Peptide stellen dabei kurze 
Fragmente der Antigene nach. Peptidarrays haben den Vorteil, dass die Antikörper-Antigen 
Wechselwirkung in sehr großem Maßstab, mit geringem Probenverbrauch und minimaler 
Versuchsdauer pro Interaktion untersucht werden kann. Je nach Herstellungsmethode können 
bis zu mehrere Tausend Peptide auf einem Objektträger im Arrayformat präsentiert werden. 
Während die Untersuchung von Antikörper-Epitopen mit Peptidarrays bereits routinemäßig in 
der Ursachenforschung von Krankheiten und in der Impfstoffentwicklung eingesetzt werden, 
gab es bisher keine Vergleiche der exakten Spezifität von Antikörpern mehrerer Individuen. 
Um diese exakten Spezifitäten zu bestimmen, wird jede Aminosäure in einem gefundenen 
Epitop in einer sogenannten Substitutionsanalyse durch alle anderen Aminosäuren ersetzt und 
die Interaktion der neuen Peptide mit dem Antikörper untersucht. Dieser Ansatz ermöglicht 
es, die Rolle der einzelnen Aminosäuren in der Bindung zu analysieren und damit den 
„Fingerabdruck“ der Antikörper zu bestimmen. Mit dem Fingerabdruck, also den 
bindungsrelevanten Aminosäuren, kann in öffentlichen Protein-Datenbanken nach 
induzierenden und kreuzreagierenden Antigenen gesucht werden und damit können erstmals 
neue Einblicke in dieses Gebiet gewonnen werden.  
Im Fokus von drei Manuskripten stehen Antikörperspezifitäten verschiedener Patienten, 
die mit Substitutionsanalysen unter Verwendung von Peptidarrays bestimmt werden können. 
Zwei Manuskripte zeigen zum ersten Mal, dass die für eine Antikörper-Antigen Bindung 
essentiellen Aminosäuren krankheitsspezifisch und in verschiedenen Patienten nahezu 
identisch sind. Im dritten Manuskript wird evaluiert, ob eine große Peptidbibliothek in 
Kombination mit der Substitutionsanalyse geeignet ist, das Antikörperrepertoire eines 
Menschen ohne a priori Wissen auszulesen. 
Die Analysen erfolgten mit Peptidarrays der Firma PEPperPRINT GmbH aus Heidelberg. 
Die Synthese der Peptide an der Oberfläche von Objektträgern, auf denen ein Polymerfilm 
verankert ist, erfolgt dabei mit einem partikelbasierten Festphasenansatz nach Merrifield. 
Fmoc-geschützte und Opfp-aktivierte Aminosäurederivate sind in Polymerpartikel eingebettet 
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und werden mittels einer Art Laserdrucker auf einer Oberfläche strukturiert. Nach der 
Strukturierung aller 20 Aminosäuren in der ersten Lage, erfolgt die chemische Synthese. 
Diese Entkopplung von Strukturierung und chemischer Verarbeitung beschleunigt den 
Herstellungsprozess enorm. Für Peptide mit einer Länge von 15 Aminosäuren sind so nur 15 
chemische Syntheseschritte notwendig. Arrays, die auf diese Art hergestellt werden, weisen 
eine Dichte von bis zu 800 Peptiden pro cm
2
 auf. Neu entwickelte Verfahren erlauben die 
Erhöhung dieser Dichte auf bis zu 10.000 Peptidspots pro cm
2
 sowie den Einbau von 
Sonderbausteinen wie phosphorylierte Aminosäuren und das Zyklisieren der Peptide.  
Tetanus dient in dieser Arbeit aufgrund der hohen Impfrate als Modellsystem, um die 
Spezifitäten von Antikörpern in verschiedenen Individuen zu vergleichen. Die Impfung gegen 
Tetanus löst eine Immunantwort aus, die sehr zuverlässig und langfristig das Toxin zu 
neutralisieren vermag. Es handelt sich um ein extrazelluläres Toxin, das vom Bakterium 
Clostridium tetani produziert wird. Da noch nicht gänzlich geklärt ist, wie neutralisierende 
Antikörper das Toxin unschädlich machen, ist es außerdem unerlässlich, die Immunantwort 
genauer zu untersuchen. Für die Untersuchung der Immunantwort auf die Impfung gegen 
Tetanus wurde zunächst die lineare Aminosäuresequenz des Toxins in überlappende Peptide 
zerschnitten. Die Peptide haben dabei eine Länge von 15 Aminosäuren mit einer Überlappung 
von 14 Aminosäuren. Nach der Synthese der Peptide im Arrayformat wurden diese mit den 
Seren von 19 geimpften Europäern inkubiert. Der gesamte Vorgang wird als „Epitope 
Mapping“ bezeichnet und ermöglicht es, Antikörper-Epitope zu identifizieren. Die 19 
Individuen zeichneten sich durch eine breite Antikörperantwort aus. Da alle Seren einen 
ausreichenden Impfschutz gegen Tetanus aufwiesen, ist anzunehmen, dass verschiedenen 
Epitope eine neutralisierende Antikörperantwort hervorzurufen vermögen. Jedoch ist nicht 
auszuschließen, dass die breite Antikörpervielfalt nur bei einer Detektion mit linearen 
Peptiden auftritt und die Untersuchung der Antikörperantwort mit proteinähnlichen 
Strukturen ein anderes Ergebnis aufweist. Auffallend häufig wurde ein Epitop auf der C-
terminalen Domäne der schweren Kette des Tetanustoxins detektiert. Eine anschließende 
Substitutionsanalyse dieses Epitops zeigte, dass die Fingerabdrücke der Antikörper, in 8 von 
den beobachteten 9 Fällen nahezu identisch sind. Im Hinblick auf die zufällige Generierung 
des Antikörper-Repertoires ist dieses Ergebnis erstaunlich. Aminosäuren, die alternativ zur 
originalen Aminosäure ebenso eine Bindung des Antikörpers auslösten, waren in allen 
untersuchten Proben sehr ähnlich und wiesen häufig einen ähnlichen chemischen Charakter 
auf wie die originale Aminosäure. Der entsprechende Antikörper wurde aus einem Serum 
mittels Affinitätschromatographie im Batch-Verfahren isoliert und eine Reaktion mit dem 
nativen Toxoid im ELISA konnte nachgewiesen werden. Ob die identifizierte 
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Antikörperspezifität neutralisierende Eigenschaften in Bezug auf das Tetanustoxin aufweist, 
muss in weiteren Studien geklärt werden. Es konnte jedoch zum ersten Mal gezeigt werden, 
dass verschiedene Personen auf Sub-Antigen- und sogar Sub-Epitopebene, trotz zufälliger 
Bildungsprozesse, nahezu identische Antikörperspezifitäten ausbilden. 
Borreliose ist seit dem ersten gehäuften Auftreten in den 1970ern in Lyme, Connecticut, 
eine der häufigsten von Zecken übertragenen Krankheiten und gleichzeitig ein sehr 
kontroverses Thema. Es ist umstritten, ob späte Manifestationen der Krankheit durch 
autoimmune Reaktionen oder schwer diagnostizierbare, dauerhafte Infektionen mit den 
verursachenden Bakterien der Gattung Borreliella, ausgelöst werden. Auch die Diagnose, die 
in den meisten Fällen auf dem Nachweis von Serumantikörpern beruht, ist problematisch auf 
Grund von mangelnder Spezifität und/oder Sensitivität. Das immunogene Lipoprotein VlsE 
(vmp-like sequence expressed), das an der Oberfläche der Bakterien exprimiert wird, hat sich 
als hilfreich in der Diagnose erwiesen. Das Protein teilt sich in 3 Domänen, von denen eine 
variable Domäne in der Mitte von 2 konservierten Domänen am C- und N-Terminus flankiert 
wird. Die variable Domäne setzt sich dabei aus 6 variablen Bereichen und 6 konservierten 
Regionen zusammen. Ziel der im Manuskript beschriebenen Studie war es, die 
Fingerabdrücke der gegen VlsE induzierten Antikörper von an Borreliose erkrankten 
Patienten zu vergleichen. Hierfür wurde, wie im vorherigen Abschnitt beschrieben, ein 
„Epitope Mapping“ des VlsE Proteins mit anschließender Substitutionsanalyse der 
immunogenen Peptide durchgeführt. Die Peptide wurden mit den Seren von 17 VlsE 
positiven und 7 VlsE negativen Patienten inkubiert. Anhand ihrer Antikörperantwort, die 
entweder gegen Epitope auf der variablen oder konservierten Domäne gerichtet war, konnten 
13 der 17 positiven Patienten in zwei Gruppen eingeteilt werden. Die Substitutionsanalyse 
zeigte, dass die für die Bindung essentiellen Aminosäuren in den Epitopen, auch auf der 
variablen Domäne, in den konservierten Bereichen liegen. Zudem konnte gezeigt werden, 
dass nahezu identische Aminosäuren bindungsrelevant sind, falls das gleiche Epitop erkannt 
wird. Die Suche nach kreuzreagierenden humanen und viralen Antigenen in Protein-
Datenbanken zeigte, dass lange Fingerabdrücke spezifisch für B. burgdorferi sind. Die mit 
Substitutionsanalysen bestimmten Antikörperspezifitäten könnten als Biomarker eingesetzt 
werden, mit dem Vorteil der Vermeidung von kreuzreagierenden Signalen und daraus 
folgenden Falsch-Positiven Ergebnissen.  
In einer weiteren durchgeführten Studie wurden mit einer Kombination aus Screening mit 
Phage Display und Next Generation Sequencing sowie Validierung und Substitutionsanalyse 
mit Peptidarrays ohne Vorwissen 73 Antikörperspezifitäten bestimmt. Eines der dominanten 
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Motive konnte mit Hilfe einer Proteindatenbank dem antigenen Hüllprotein VP1 der 
Enteroviren zugeordnet werden. Aufgrund der weit verbreiteten Impfung gegen das Poliovirus 
aus dieser Familie ist es sehr wahrscheinlich, dass ein entsprechender Antikörper im Blut 
vorlag und identifiziert werden konnte. Experimente mit dem Serum eines weiteren 
Individuums zeigten, dass die Antikörperspezifitäten nicht nur krankheits-, sondern auch 
patientenspezifisch sind.  
Die vorliegenden Manuskripte zeigen demnach, dass Fingerabrücke von Antikörpern, wie 
sie mit Substitutionsanalysen auf Peptidarrays bestimmt werden können, biologisch relevant 
sind und die entwickelten Methoden zur Erforschung von Infektionskrankheiten und der 
Impfstoff- und Biomarkerentwicklung beitragen. 
Peptidarrays erlauben im Allgemeinen allerdings nur eine Aussage darüber, ob eine 
Bindung des Antikörpers an ein Peptid stattfindet, die Art der Interaktion kann nicht beurteilt 
werden. Dies ist darin begründet, dass die Bindung des Antikörpers an das Peptid nach 
Eintreten des Gleichgewichtszustands betrachtet wird. Falls eine Interaktion stattfindet, wird 
diese nach dem Prinzip eines Immuno-Assays mit fluoreszenzmarkierten 
Sekundärantikörpern nachgewiesen. In vielen Fällen sind allerdings auch die Affinität des 
Antikörpers zu seinem Antigen und die vorliegende Konzentration von Interesse. Es ist daher 
notwendig, den Vorgang der Antikörper-Peptid Bindung bereits vor Erreichen des 
Gleichgewichtszustands zu beobachten. Hierfür muss die Antikörperlösung kontinuierlich mit 
den Peptiden im Arrayformat in Kontakt gebracht werden, was in einem mikrofluidischen 
Kanal realisiert werden kann. Des Weiteren muss die Antikörper-Peptid-Wechselwirkung für 
die Dauer des Bindungsvorgangs sichtbar gemacht werden, wofür ein optisches System 
notwendig ist.  
Zu diesem Zweck wurde in der vorliegenden Arbeit zunächst die Basis für diese 
Messungen geschaffen. Eine mikrofluidische Anlage für die Inkubation des Peptidarrays 
wurde entwickelt und ein optischer Aufbau aufgebaut. Dieser detektiert auf Basis einer 
fluoreszenzanregenden LED und einer CCD Kamera zeitaufgelöst die Anlagerung von 
Antikörpern an Peptide. Das System wurde getestet, indem der monoklonale FLAG-M2 
Antikörper im mikrofluidischen Kanal mit dem FLAG-Epitop in Kontakt gebracht und die 
Anlagerung mit dem optischen System detektiert wurde. Aus den Messungen mit 
unterschiedlichen Konzentrationen konnte eine Assoziationskonstante bestimmt werden. Dies 
erlaubt in Zukunft möglicherweise auch die Analyse von Affinitäten oder Konzentrationen 
von Antikörpern in Patientenseren, was zu einer verbesserten Diagnostik und Forschung 
beitragen kann. 
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Abstract 
Antibodies against pathogenic agents shield us routinely from infections. They specifically 
incapacitate intruders and thus ensure our survival. At the same time, antibodies of our 
humoral immune system can do harm in autoimmune diseases or cause transplant rejections.  
Antibodies are secreted into our blood system by plasma cells. These plasma cells develop 
from immature B lymphocytes, which undergo maturation, positive selection by binding to an 
antigen and processes that stimulate cell division. Each of these plasma cells then produces 
thousands of identical antibodies with the same unique specificity. After contact with an 
antigen, most B lymphocytes additionally undergo somatic hypermutation, which leads to 
increased affinity of the antibody to its antigen. Remarkably, the amount of the individual 
antibodies is highly flexible and adapts to modified conditions (for instance an infection or 
tissue trauma). The reason for this is the limited space in our serum for a maximum number of 
different antibodies.  
Due to the large variety of very similar antibody species, it was not possible until now to 
find out precisely which antibody species are present in which quantity in the blood of a 
patient and by what events these have been induced. If this was possible, newly formed 
antibodies (e.g. following an infection) could be identified by comparing different patient sera 
or sera from different time points. In addition, it could be investigated which antibody species 
are present in a hitherto enigmatic disease pattern or which antibodies correlate with the 
protection against a disease (the corresponding antigens would be candidates for vaccines). 
For these investigations, as many clearly distinguishable antibody species as possible must be 
identified in the serum of a patient without prior information of possible diseases. 
The aim of this doctoral thesis is to create the prerequisites for exploring the stated topics 
and, therefore, to study the effects of antibody-antigen interactions in single amino acid 
resolutions. Antibody specificities that have the capacity of characterizing and identifying 
both antibody and antigen are in the focus of the investigations.  
In order to determine the specificities of as many antibodies as possible, high-throughput 
tools such as peptide arrays are particularly suitable. The peptides mimic fragments of 
antigens and the specificity of many different antibodies can be precisely determined in 
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parallel on a very large scale. Up to several thousand peptides can be investigated in a single 
experiment with low sample consumption and a minimum of time per investigated 
interaction. While investigations of antibody epitopes with peptide arrays are already 
routinely used in disease research and vaccine development, no attempts have been made to 
compare the exact specificities of antibodies in different individuals. To determine the exact 
specificity in a so-called substitution analysis, each amino acid in an identified epitope is 
sequentially replaced by all other amino acids, generating many different variants of the 
epitope. Then, each peptide variant is examined for antibody binding. With this approach, it 
becomes possible to analyze the role of individual amino acids regarding their importance for 
antibody binding to immunodominant epitopes and thus to determine the fingerprint of an 
antibody. The knowledge about binding relevant amino acids of the fingerprints enables 
queries of public protein databases for the identification of inducing or cross-reacting antigens 
and insights into this research area can be gained for the first time.  
The three following manuscripts focus on antibody fingerprints, determined by substitution 
analyses with single amino acid resolution. Two manuscripts demonstrate for the first time 
that the amino acids, essential for the antibody-antigen interaction, are disease-specific and 
almost identical in different patients. The third manuscript evaluates whether a large peptide 
library in combination with the substitution analysis is suitable for exploring the antibody 
repertoire of a person without a priori knowledge. 
The analyses were carried out using peptide arrays synthesized by the company 
PEPperPRINT GmbH from Heidelberg, Germany. The peptides are synthesized 
combinatorically on the solid surface, on which a polymer film is anchored, with a particle-
based solid-phase approach according to Merrifield. In brief, Fmoc-protected and Opfp-
activated amino acid derivatives are embedded in polymer particles and patterned on a surface 
by a device similar to a standard laser printer. After structuring all 20 amino acids in the first 
layer, the chemical synthesis takes place. The separation of structuring and chemical 
processing accelerates the manufacturing process enormously. Arrays produced in this 
manner have a density of up to 800 peptides per cm
2
. Newly developed methods allow for an 
increase in density to up to 10,000 peptide spots per cm
2
 as well as the incorporation of 
special building blocks such as phosphorylated amino acids and the cyclization of peptides. 
Tetanus serves in this thesis as a model system to compare antibody fingerprints in 
different individuals, due to the generally high vaccination rate. The vaccination against 
tetanus triggers a long term immune response, which can neutralize the toxin very reliably. 
The toxin is extracellularly released by the bacteria Clostridium tetani. Since it remains 
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elusive how antibodies neutralize the toxin, it is essential to investigate the immune response 
more closely. For the investigation of the immune response to the vaccination against tetanus, 
the linear amino acid sequence of the toxin was first cut in silico into overlapping 15mer 
peptides with a lateral shift of one amino acid. After synthesis of these peptides in the array 
format, the arrays were incubated with the sera of 19 vaccinated Europeans. This process is 
referred to as epitope mapping and enables to mimic and identify epitopes that are targeted by 
antibodies. A broad antibody distribution was observed in the immune response of 19 
individuals. Since all sera had protective antibody titers against tetanus, it can be assumed that 
different epitopes on the toxin are capable of inducing neutralizing antibody responses. 
However, it cannot be ruled out that the broad antibody diversity only occurs due to the 
detection with linear peptides and the investigation of the antibody response with protein-like 
structures might yield a different result. An epitope on the C-terminal domain of the heavy 
chain of the tetanus toxin was prominent in 9 individuals. The subsequent substitution 
analysis of this epitope showed that the antibody fingerprints are almost identical in 8 out of 9 
cases. This result is astonishing regarding the random generation of the antibody repertoire. 
Amino acids, which allowed binding besides the original amino acid, were also very similar 
in all tested samples. They often had a similar chemical character to the original amino acid, 
for example, hydrophobic valine could be exchanged for isoleucine without loss of binding. 
The respective antibody was isolated from one serum using affinity chromatography in a 
batch process and its reaction with the native toxoid in an ELISA could be demonstrated. 
Whether this identified antibody specificity has neutralizing properties with respect to the 
tetanus toxin should be clarified in further studies. However, it has been shown for the first 
time that different individuals develop almost identical antibody specificities on the sub-
antigen and even sup-epitope level. 
Lyme disease has been one of the most common diseases transmitted by ticks since the 
first observation of clustering in Lyme, Connecticut, in the 1970s. Diagnosis and treatment, 
however, remain a very controversial issue. It remains elusive, whether late manifestations of 
the disease are triggered by autoimmune reactions or permanent infections with the causative 
bacteria of the species Borreliella. The diagnosis, which in most cases is based on the 
detection of serum antibodies, is problematic due to a lack of specificity or sensitivity or both. 
The immunogenic lipoprotein VlsE (vmp-like sequence expressed) is expressed on the surface 
of the bacteria and has proven to be a reliable diagnostic marker. The protein possesses 3 
domains: one variable domain in the middle is flanked by two conserved domains at the C and 
N terminus. The variable domain consists of 6 variable and 6 conserved regions. The aim of 
the study described in the manuscript was to compare the antibody fingerprints against the 
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VlsE antigen of patients suffering from Lyme disease and to evaluate the disease specificity 
of these fingerprints. Therefore, as described in the previous section, an epitope mapping of 
the VlsE protein was carried out with subsequent substitution analyses of the immunogenic 
peptides. The peptides were incubated with the sera of 17 VlsE positive and 7 VlsE negative 
patients. Based on their antibody response, 13 of the 17 positive patients could be assigned to 
two groups. The antibodies of one group recognized preferentially epitopes at the N- and C-
terminal end of the protein, antibodies of the second group were mainly directed against 
epitopes on the variable domain. The substitution analysis showed that the amino acids crucial 
for binding are located on the conserved regions of the protein, even on the variable domain. 
As previously investigated in the tetanus vaccination study, it was shown that if the same 
epitope is targeted by antibodies, the fingerprints are almost identical. The query of public 
protein databases revealed that the longer fingerprints are very specific for B. burgdorferi. 
The precise antibody specificities could be used in the diagnosis of Lyme disease and other 
infectious diseases with the advantage of enabling studies of cross-reacting (human) proteins. 
In the third study, 73 antibody fingerprints were determined without a priori knowledge 
with a combination of pre-screening with phage display, next generation sequencing and 
validation and substitution analyses with peptide arrays. The query of one of the identified 
dominant motifs in a protein database led to the antigenic coat protein VP1 of enteroviruses. 
Due to the widespread vaccination against the poliovirus from this family, it is very likely that 
a corresponding antibody has been identified. Experiments in a similar manner, in which the 
antibody specificities in another individual were determined, show that the fingerprints are 
also patient specific. 
Thus, the present manuscripts show the biological relevance of antibody fingerprints 
regarding their disease and patient specificity. A study with multiple patients and the 
developed methods can contribute to the investigation of etiology in infectious diseases and 
the development of biomarkers and vaccines. 
In general, peptide arrays only allow for the determination of the binding of an antibody to 
a peptide. The nature of the interaction in terms of affinity cannot be assessed due to the 
detection of binding in equilibrium state. Interaction is visualized based on the principle of an 
immunoassay with fluorescently-labeled secondary antibodies. However, in many cases, the 
affinity of an antibody to its antigen and its concentration is of interest. Therefore, it is 
necessary to observe the process of antibody-antigen binding from the beginning until the 
equilibrium is reached. For this purpose, the antibody solution must be brought into 
continuous contact with the peptides in the array format, a task that can be realized in a 
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microfluidic channel. Furthermore, the interaction must be made visible for the duration of the 
binding process, which can be accomplished with an optical system. 
As the basis for these measurements, an automated microfluidic system with an optical 
setup was designed and established. The optical set-up detects the antibody-peptide 
interaction in a time-resolved manner, based on a fluorescence-exciting LED and a CCD 
camera. The system was validated by incubating the FLAG epitope in array format with the 
monoclonal FLAG-M2 antibody in the microfluidic channel. The interaction was detected 
with the optical system for different concentrations and the association rate constant was 
calculated. In the future, this system could be used to determine the affinities and 
concentrations of antibodies in patient sera and thus lead to better diagnostics. 
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1 Introduction 
Our immune system recognizes infectious intruders and defends us against them with a – 
hopefully adequate – immune response. One major part of this defense is the secretion of 
antibodies, which specifically target antigens and participate in the process of making them 
innocuous. For decades, scientists have striven to characterize the different antibody 
specificities that shield us from diseases or do harm in autoimmune disorders. It is of great 
interest, what these antibodies exactly target, and, if and how those specific antibodies 
correlate with disease etiology. This knowledge should help in the development of vaccines 
and biomarkers. The following chapters focus on principal aspects of the immune system, the 
humoral immune system and immune responses towards pathogens and vaccinations. The 
specificities of antibodies can be described with peptide arrays in unprecedented detail, and, 
in addition, for many different antibodies in parallel. Therefore, this work discusses high-
throughput methods for the detection of antibodies in general, with a focus on peptide arrays. 
1.1 Immune system and immune responses 
Viruses, bacteria, fungi, and parasites constantly challenge us, and we use our innate and 
adaptive immune system to defend ourselves against these pathogens. First, our innate 
immune system uses epithelial and chemical barriers, then macrophages, the complement 
system and the triggering of inflammation to shield us from harm. The second important task 
of the immune system is the elimination of malfunctioning endogenous cells. These issues 
are discussed in textbooks in sufficient detail [1, 2]. Vertebrates have an additional, adaptive 
immune system that is presumably activated by the innate immune system and comprises the 
development and deployment of dendritic cells and T and B lymphocytes. 
Clonal selection, random point mutations and somatic hypermutation lead to the adaption 
of the lymphocytes in such a way that they recognize their specific antigens with increasing 
affinity. The detection of antigens is primarily based on different receptors: While B-cell 
receptors simply bind to presented antigens, T-cell receptors demand a more specialized form 
of presentation: MHC (Major Histocompatibility Complex) class I and class II proteins 
anchor processed peptides from the inside of the cell to a groove on the MHC-molecules. 
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Those cells that specifically bind to presented peptides through their receptor and, in 
addition, receive signals through co-receptors start to proliferate in a process that is called 
clonal selection. Most B cells, improve the binding affinity of their B-cell receptor by first 
mutating the B cell receptor’s variable genes randomly, and then selecting B cells that bind to 
their waning antigens with higher affinity. This process is called somatic hypermutation. 
Many different of these positively selected B cell clones secrete antibodies into the blood 
serum, summed up as the humoral immune system, in which they have important roles. Some 
of these antibodies protect us from infections, others might be useful for diagnosis, but 
otherwise are irrelevant. Some antibodies can do harm, e.g. in dengue fever, or in 
autoimmune disorders, where autoantibodies target endogenous parts of our body, and, 
thereby, could be also diagnosed. Others, such as natural antibodies, have different tasks in 
homeostasis. 
1.1.1 The humoral immune system 
The humoral immune system comprises all macromolecules that are secreted into our body 
fluids. Major parts of the humoral immune system are complement and acute phase proteins 
that play an important role in the innate immunes system. The main tasks are the production 
and secretion of antibodies into our blood system, which are also referred to as 
immunoglobulins (Ig). The most abundant antibody class (IgG) has a Y-shaped structure with 
a molecular weight of about 150 kDa. They are secreted by short lived plasma cells that 
descend from B lymphocytes or B cells. For the successful defense of our body, the antibody 
repertoire must be versatile and at the same time avoiding auto-reactivity. The large diversity 
of B cell receptors (BCRs) is generated in the bone marrow, where B cells undergo V(D)J 
recombination. Auto-reactivity is avoided by negatively selecting those B cells that bind to 
autoantigens. Their BCR is edited until non-self-reactive cells can be released into the 
periphery [3, 4]. Another procedure to generate tolerant B-cells is anergy, meaning that those 
B-cells that are for instance generated through somatic hypermutation and bind to 
autoantigens are no longer stimulated by antigen binding. The antibodies produced by cells 
that have emerged without an immune response to an exogenous antigen are referred to as 
“natural antibodies”; they have tasks in homeostasis, e.g. targeting aging cells for removal by 
macrophages [5].  
While the entirety of B cells produces a variety of antibodies, each cell alone produces 
only one type of antibody with exactly the same amino acid sequence, a process that is called 
clonal expression [6]. The mature but naïve cells wander through our body fluids and 
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specialized lymphatic tissues, where they are activated by dendritic cells that present antigens 
to T and B cells [7]. The activation takes place in germinal centers of lymphatic organs and 
leads to proliferation and development of the naïve cells into Ig-secreting plasma or memory 
cells. Whereas memory cells are part of the immunological memory and help reacting 
towards repeated contact with the same antigen, plasma cells secrete the bulk of 11 mg IgG 
per ml blood serum [8]. Depending on costimulatory signals, a class switch from IgM or IgD 
to IgG, IgA or IgE can occur [9]. This switch preserves the antigen specificity, but changes 
the constant regions (Fc-region) of the antibody to one of five different isotypes that are used 
for specialized tasks. IgG antibodies patrol through the blood and lymphatic space, IgEs are 
tethered to the surface of mast cells that protect epithelia via high affinity Fc-receptors and 
IgA antibodies are secreted into the alveolar space or the intestine to tackle pathogens in 
these compartments. Antibodies exert their function in different ways. Neutralizing 
antibodies block a toxin or a virus from entering a cell. Opsonizing antibodies tag the surface 
of pathogens, and, thereby, help macrophages to ingest those pathogens, which is especially 
important in the fight against gram-negative bacteria. Another effector function is the 
activation of the complement system. 
 
Figure 1: Structure of an antibody, depicted using the PyMol (Schrödinger, pymol.org/dsc/) 
molecular visualization system, based on RCSB PDB (www.rcsb.org) ID 1IGT [10]. 
 
Different theories exist on the lifespan of plasma cells from several days to several months 
or a conditional survival [11]. In any case, short- or long-lived plasma cells can synthesize 
and secrete up to 1000 antibodies per second. Therefore, and due to limited space for 
A 
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antibodies in our serum, the actual repertoire, expressed at a certain time point, is most likely 
highly flexible. For a rough estimation of the number of different antibody species, we 
assume that all B cell clones together produce a bulk of 11 mg IgG per ml serum [8]. The 
efficient concentration of monoclonal antibodies in cancer therapies was investigated to be > 
10 µg/ml [12]. Assuming that each antibody must be present in a therapeutic concentration of 
at least 10 µg per ml, our blood serum offers space for about 1100 different therapeutic 
antibody species.  
1.1.2 Immune reactions towards pathogens 
The vast majority of invading pathogens is neutralized at an early stage by our innate 
immune system before doing any harm. They are kept away by natural barriers as the 
epithelial layer of the skin or by chemical barriers, such as the low pH of the stomach and a 
diversity of antibiotic peptides that are secreted into our intestine. The second line of defense 
is built up by macrophages that line up all the epithelial layers of our body, e.g. underneath 
the skin, in the lung, or in the intestine. Whenever these macrophages sense a “pathogen 
associated molecular pattern” (PAMP) through their receptors, they are activated and secrete 
cytokines as tumor necrosis factor alpha (TNF-α) or interferon gamma (INF-γ). Upon these 
signals, small blood vessels nearby are sealed to block the pathogens from invading the 
whole body. As a result, many macrophages, granulocytes, and natural killer cells assemble 
around the intruders that are phagocytosed, bombarded with reactive oxygen species (ROS), 
marked, and eventually pierced with activated complement components. 
The concept of PAMP recognizing receptors was first introduced by Janeway in 1989 
[13]. Known PAMPs are bacterial or fungal cell-wall components, such as peptidoglycans, 
lipopeptides and lipopolysaccharides. Other PAMPs are flagellin and regularly spaced sugar 
moieties, viral double stranded RNA, and bacterial DNA that is differently methylated when 
compared to our own DNA. These PAMPs are evolutionary conserved and cannot be found 
in higher eukaryotes. One of the best characterized and most important family of these 
PAMP recognition receptors are toll-like receptors (TLRs) that are found in many different 
multicellular eukaryotes from the sea urchin over insects to mammals. Their discovery in the 
mid-1990s was awarded with the Nobel Prize in physiology or medicine in 2011 [14, 15]. 
The TLRs provide protection against microbial infection even in organisms without adaptive 
immune system. In Drosophila, the synthesis of anti-fungal and anti-bacterial peptides can be 
induced by the activation of signaling pathways via two members of the TLR family [16, 17]. 
Signaling via PAMP-receptors enhances the innate immune response by the secretion of pro-
 Introduction 5 
 
inflammatory cytokines, which activates other immune cells. TLRs are expressed in dendritic 
cells and macrophages as well as in non-immune cells such as fibroblasts and epithelial cells 
[18].  
The third task of PAMP recognizing receptors from the innate immune system is the 
induction of adaptive immunity [19]. Here, dendritic cells (DCs) play a critical role. 
Depending on the signals, these DCs induce different T cell responses: cytotoxic CD8 T cells 
are needed to tackle viral infections and intracellular growing bacteria; CD4 helper T cells 
are needed to produce neutralizing antibodies that bind a bacterial toxin or opsonizing 
antibodies that stimulate macrophages to phagocytose gram negative bacteria [20]. The 
migration of activated DCs into lymph nodes is assumed to be the first step in activating the 
adaptive immune response by inducing the differentiation of T cells into effector cells.  
A critical step in this pathway is the mutual activation and control of lymphocytes, which 
has been described in various textbooks [1, 2]. Typically, a dendritic cell (DC) is first 
alarmed by its TLRs. This professional antigen-presenting cell (APC) then reorganizes its 
proteasome to load newly processed peptides onto MHC class I molecules, and, in addition, 
secretes cytokines to activate other cells. In parallel, the DC also loads newly processed 
peptides onto MHC class II molecules. Next, these DCs travel to specialized lymphatic 
organs, e.g. a lymph node, where T- and B-cells can specifically bind to presented antigens 
(T cells are restricted and bind only to peptides presented on MHC molecules). T helper cells 
1 (TH1) that recognize MHC class II molecules via their co-receptor CD4 can activate these 
APCs by binding to it. Thereby, they become activated themselves and turn into memory 
T cells and suppressor T cells. T helper cells 2 (TH2), activate B cells and stimulate them to 
differentiate into plasma or memory B cells. Other T cells recognize MHC class I presented 
peptides via their co-receptor CD8. When activated, these cytotoxic CD8 T cells specifically 
recognize and kill those cells that present a pathogen’s peptide on their MHC class I 
molecule.  
There is growing evidence that B cells and their secreted antibodies can specialize in a 
way that is analogous to the different T cell subsets. It is known that different antibody 
classes perform specialized tasks. In addition, the glycosylation of the antibody’s Fc-part 
decides upon the antibody’s affinity towards different Fc-receptors [21]. 
1.1.3 Vaccines and immunity 
Ever since Edward Jenner laid the foundation for vaccine-based immunization at the end of 
the 18
th
 century [22], vaccines have considerably prevented morbidity and mortality. The 
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vaccination against smallpox, which was the vaccine that Jenner developed, successfully 
eradicated the disease from the planet [23].  
Whereas some vaccines already elicit highly effective immune responses, capable of 
neutralizing the pathogen, some diseases still need be addressed. For three of the major 
global health issues - HIV, malaria and tuberculosis - no efficient or licensed vaccines are 
currently available. It still needs to be researched, how to focus the vaccine induced immune 
response to protective epitopes and how to elicit long-term memory responses [24]. 
Antibody-dependent enhancement of a disease [25] and cross-reactions induced by 
vaccination against viruses [26] [27, 28] are among the possible draw-backs of current 
vaccines.  
Many successful vaccines induce neutralizing antibodies that block the binding site of a 
toxin or virus to prevent entry into cells [29]. It is more difficult to develop vaccines for 
pathogens that are extremely variable. HIV-1 for instance has several mechanisms to evade 
the host’s immune response [30, 31]. However, after years of infection, broadly neutralizing 
antibody responses have been reported [32, 33]. Similarly, some patients are better protected 
by their immune system then others after repeated infection with P. falciparum, the causative 
agent of malaria [34].  
To benefit from the information that is deposited in the adaptive immune system of these 
patients, we need to develop methods to readout this information. Recently, tremendous 
progress has been made in monitoring the human immune response [24]. Microarrays, 
sequencing technologies, mass spectrometry-powered proteomics and bioinformatics are 
among the driving forces [35, 36].  
Vaccines based on antigenic peptides have several advantages. They are stable, easy and 
cheap to synthesize and focus the immune response on relevant epitopes; therefore, they elicit 
only neutralizing responses and avoid the formation of cross-reacting antibodies [37]. The 
identification of immunodominant epitopes and the elucidation of the combination of those 
for a successful neutralization of toxins or pathogens in different patients could be the first 
step towards a peptide based vaccine.  
1.2 Studying antibody – antigen interactions 
Proteins are key players in our organisms and for the understanding of fundamental 
biological processes, it is necessary to characterize protein-protein interactions. In particular, 
the antibody-antigen interaction needs to be studied for diagnostic purposes, for the treatment 
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and basic research of diseases and for the exploitation of the immune response in 
vaccinations. Antibody-binding patterns, for example, can be employed for distinguishing the 
health or disease condition of different individuals. Several techniques for the 
characterization of the humoral immune system have been developed. The following chapters 
focus on the characterization of antibody-antigen interaction, the principal detection of 
antibodies in a high-throughput manner and the antibody specificity that can be explored with 
peptide arrays.  
1.2.1 Characterization of antibody-antigen interaction 
To fully understand the molecular interaction of antibodies and antigens, it is necessary to 
describe and characterize the binding and dissociation processes with kinetic rate and 
equilibrium binding constants. The equilibrium binding constant defines the affinity of an 
antibody to its antigen, which can also be described as the strength of the interaction between 
an antibody and its epitope on an antigen or the sum of attractive and repulsive forces 
between them [38]. Several models have been developed to determine the equilibrium 
binding constants with an immobilized ligand and a ligate in solution [39, 40, 41]. 
If the antibody is monovalent, one epitope is targeted, the reactants have homogeneous 
binding sites and the reaction takes place in solution and equilibrium, all models can be 
derived from the law of mass action (1.1). In this equation, [Ab] is the molar antibody 
concentration and [X] the molar antigen concentration. The equilibrium rate constant Keq can 
be calculated by the ratio of association rate constant ka to dissociation rate constant kd (1.2).  
For a real-time analysis of antibody-antigen interaction, which is common for biosensors 
and continuous microfluidic systems, the kinetics can be either limited by the reaction or be 
dependent on the mass transport or both [39]. True association and dissociation rate constants 
can only be calculated if the mass transfer is much faster than the reaction time and, 
therefore, can balance concentrations differences at the surface and in the bulk. If the system 
is mass transport limited, meaning the diffusion is limiting the interaction, the reaction obeys 
Fick’s first law [42].  
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1.2.2 High-throughput technologies for antibody detection 
For the detection of antibody-antigen interactions in a high-throughput manner, different 
methods have been established. They either concentrate on the expressed antibodies, present 
in the serum of an individual or on gene segments encoding the antibody molecules.  
In western- or immunoblotting, proteins that have been separated according to their size or 
charge, are transferred from a gel to a membrane and are detected with antibodies. Today, 
nitrocellulose is routinely applied as membrane, which was introduced by Towbin, et al. in 
1979 [43]. Primary and secondary antibodies are used for the specific detection of a sample. 
There, the secondary antibody is either labelled radioactively or conjugated to a fluorescent 
dye or a peroxidase. The profiling of the complete antibody repertoire and the identification 
of antibody reactivity patterns were first performed using immunoblotting [44]. Furthermore, 
different autoimmune diseases have been analyzed using immunoblotting for the detection of 
antibody patterns against large panels of homologous auto-antigens, such as chronic 
lymphocytic leukemia [45] and idiopathic thrombocytopenic purpura [46].  
ELISA (Enzyme Linked Immunosorbent Assay) is an antibody based detection method 
with an enzymatically triggered quantitative color reaction. As the assays are simple to 
perform and easy to automate, they can be used in high-throughput screenings and are widely 
applied in analytics and diagnostics. In autoimmune research, ELISA tests in combination 
with bioinformatics were used for the detection of autoantibody patterns in healthy and 
diseased patients [47]. However, in both, ELISA and immunoblotting, the number of 
interaction partners that can be investigated in one experiment are limited.  
For many screenings with an unknown interaction partner, a sufficient number of potential 
targets are necessary. Therefore, several display techniques have been developed and are 
commonly used. Phage Display (PD), first published in 1990 [48, 49, 50], offers the 
possibility to screen a library of up to 10
9
 independent clones [51]. Randomly generated 
peptide libraries, presented on filamentous bacteriophage, have proven to be a powerful basis 
for the investigation of various aspects in many studies. In 2001, breast cancer specific B-
cell-epitopes could be identified with PD [52]. Some of these epitopes even correlated with 
patient survival time and may be interesting targets for vaccine development. Peptides that 
are targeted by autoantibodies and indicate a growing prostate cancer, were identified in 2005 
using peptide libraries displayed on phage [53]. Furthermore, PD was used to display the 
viral epitopes from all known human viruses to discover targets of by human serum 
antibodies [54]. PD has also been used to generate therapeutic antibodies as the FDA-
approved human anti-TNF IgG1 against rheumatoid arthritis (Adalimumab) [55]. Yet, low 
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reproducibility and insufficient controllability of the displayed interaction partners (bias of 
biological methods) are the limiting factors of display techniques. 
Next-generation sequencing or high-throughput sequencing are novel techniques for the 
rapid sequencing of RNA and DNA, accelerating the study of genomics and biological 
systems. In 2009, Joshua Weinstein et al. [56] used high-throughput sequencing to analyze 
the VDJ gene segment recombination in zebrafish to determine the immunoglobulin 
diversity. Besides different specific gene combinations, the majority of VDJ combinations 
were identified in all fish in low frequencies; only a small portion of different combinations 
per fish was found at similar high frequencies. Recently, high-throughput DNA sequencing 
of immunoglobulin genes (Ig-seq) was developed, allowing for the sensitive discovery of 
antibodies in autoimmunity, disease research and vaccine development [57, 58]. Yet, the 
gene expression at a certain time point might be different from the expressed diversity of 
proteins and antibodies. 
Microarrays with immobilized DNA, RNA, proteins, peptides or antibody molecules, are 
screening tools for the simultaneous investigation of large numbers of interactions in a single 
experiment with minimal sample consumption. Protein chips, for example, were employed 
for the identification of antigens after the production of monoclonal antibodies against human 
liver proteins [59]. They have also shown to be useful in the identification of biomarkers in 
various infectious diseases [60, 61, 62]. However, the commonly applied expression of the 
cell lysates in E. coli without purification and, therefore, reduction in sensitivity of the 
assays, are drawbacks of protein microarrays.   
1.2.3 Antibody detection with peptide arrays 
Ever since B. Merrifield [63] invented the solid phase peptide synthesis and R. Frank 
developed the first peptide arrays with the SPOT synthesis [64], peptide arrays have evolved 
and versatile screenings can be performed routinely. The possibility of producing a large 
variety of peptides allows for the addressing of different questions regarding antibodies, such 
as which part of a protein (epitope) is bound by an antibody and if there is potential cross-
reactivity. Thus, peptide arrays contribute to the understanding of basic immune reactions on 
a large scale with little sample consumption in minimal time.  
Peptide arrays are commercially available and various techniques are applied for the 
synthesis: they are either pre-synthesized and subsequently spotted onto a solid support or 
directly synthesized on functionalized surfaces (e.g. glass slides). In the first case, the quality 
of the peptides can be assured easily, but the procedure is complex, expensive and the spot 
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densities are limited. For the latter case, amino acid building blocks are deposited one by one, 
either with the SPOT synthesis method, photolithographic methods [65] or a laser printer 
[66]. With the development of the peptide laser printer, it became possible to produce 
customized peptide arrays that combine two important production characteristics: they can be 
manufactured rapidly and at low costs. The amino acid derivatives are embedded in particles 
consisting of a polymer material that is solid at room temperature and, therefore, can be 
easily structured on a solid substrate [67]. After structuring of all 20 different amino acids in 
the first layer, the chemical coupling steps are performed. For this purpose, the slides are 
heated and the particles become viscous, allowing the amino acid derivatives to diffuse and 
couple to free amino groups of the polymer film and to couple. Due to the temporal 
separation of structuring and coupling, only one coupling step needs to be performed for each 
layer of amino acids, which reduces the production time and increases coupling efficiency. 
Spot densities of up to 800 different spots per cm
2
 (250 x 500 µm) can be achieved by 
synthesizing arrays with the described method. 
Peptide libraries synthesized as microarrays have widely been used for antibody binding 
studies in a large variety of questions. Besides others, the have been employed for the 
identification of IgE epitopes of food allergens [68] and contributed to the understanding of 
autoimmunity in cardiovascular diseases [69]. Profiling of antitumor antibodies led to the 
identification of a biomarker in glioblastoma [70] and they were also used to detect epitope 
patterns in pulmonary tuberculosis, which are useful for the development of diagnostics and 
vaccines [71].  
1.2.4 Antibody specificity 
The specificity of an antibody allows it to discriminate between different antigens, whereas 
the term cross-reactivity describes the recognition of resembling antigens [72]. Historically, 
antibodies could be also distinguished between mono- and poly-specificity: Mono-specificity 
would imply that one molecule interacts with one specific other molecule much stronger than 
with all other molecules. Yet, the term mono-specificity has been abandoned by now, since 
the definition of a molecule to be mono-specific would imply that the binding character of all 
possible molecules has been tested, which is technically impossible. Studies investigating the 
binding of monoclonal antibodies towards synthetic peptides or proteins clearly showed that 
even these antibodies target cross-reacting antigens and, therefore, are poly- rather than 
mono-specific [73, 74]. Cohn and Langman [75] suggested that the selection pressure for a B 
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cell to preferably produce mono-specific antibodies is rooted in the necessity of 
distinguishing between self- and non-self-antigens.  
Substitution analyses, also referred to as replacement set analyses, were introduced in 
1987 by Geysen et al. [76]. All amino acids in one position of an antigenic peptide are 
replaced one by one by all other 19 amino acids and the resulting peptides are tested for their 
binding behavior to the antibody. For each position, one positive control with the original 
amino acid is synthesized. With these analyses, the role of each single amino acid in an 
antigenic peptide is elucidated and the amino acids that are essential for the binding of an 
antibody to its epitope are determined. Therefore, it is possible to determine essential and 
alternative amino acids that result in the binding of an antibody, which can be referred to as 
alternative specificities of an antibody. However, it needs to be validated, if these 
specificities correspond to real epitopes or mere mimotopes [77]. In both cases, the 
specificities allow for the identification of the originally inducing antigen and potential cross-
targeted (autoimmune) proteins.  
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2 Research proposal 
Antibodies are among the key players of our immune system, they shield us from infectious 
pathogens, but can also do harm in autoimmune disorders. An antibody can be sufficiently 
described by its specificity, which is of great value for diagnosis and etiology of infectious 
diseases and the development of vaccinations. The specificity of an antibody can be defined 
by the targeted epitope and, therefore, the specificity describes both, antigen and antibody. 
Several high-throughput techniques for the detection of antibodies have been developed and 
are commonly applied. However, due to the large variety of similar antibody species 
patrolling our blood, it was hitherto impossible to exactly determine all antibody species, 
their quantity and the inducing antigens. 
High-density peptide arrays can be employed for the parallel investigation of thousands of 
antibody-antigen interactions with minimal sample consumption. With epitope mappings, 
displaying the amino acid sequence of an antigen as short overlapping peptide fragments, the 
antigenic protein epitopes of a pathogen can be determined. These investigations recently led 
to the conclusion that antibodies of different individuals target the same limited number of 
protein epitopes of a pathogen. However, little is known about the antibody specificity on 
epitope and sub-epitope level. To overcome this gap, a subsequent substitution analysis of an 
antigenic peptide can determine the antibody specificity in single amino acid resolution. 
Every amino acid in such a peptide is replaced one by one by all other amino acids and the 
binding of antibodies to the altered sequences is investigated. Thereby, binding and non-
binding amino acids as well as alternative amino acids are pinpointed, which we call the 
antibody fingerprint. 
Antibody fingerprints offer new possibilities in the field of disease etiology, for the 
development of diagnostic markers and the design of vaccines. Correlating antibody species 
with a hitherto enigmatic disease due to an unknown infection could identify the antigen that 
was inducing the formation of the antibodies without a priori knowledge. For the 
identification of population-wide conserved antibody species, the immune responses of many 
individuals, suffering from the same disease, must be compared. The identification of those 
antibody species that correlate with protection of a disease could be candidates for new 
vaccines. Moreover, antibody fingerprints could allow for the identification of proteins 
14 Research proposal 
 
responsible for transplant rejections or for the exploration of autoimmune disorders. 
Additionally, the use of fingerprints would enable the identification of cross-targeted 
proteins.  
The aim of this doctoral thesis is to establish the foundation to comprehensively exploit 
antibody fingerprints: (1) The antibody fingerprints must correlate with a certain disease and 
be specific for it. For the evaluation of the disease specificity of antibody fingerprints, 
immune responses of several individuals to known disease antigens will be compared in two 
model studies. First, it will be investigated, whether specific antibody fingerprints against the 
tetanus toxin after a vaccination can be identified with epitope mappings and subsequent 
substitution analysis. In a similar approach, the antibody fingerprints of Lyme disease 
patients against antigens of the inducing pathogen will be compared. (2) It must be possible 
to identify inducing and cross-reacting antigens and pathogens with antibody fingerprints 
without a priori knowledge. For the evaluation of the suitability of antibody fingerprints for 
this task, queries of public protein databases with fingerprints against known and unknown 
antigens will be performed. For the identification of antibody fingerprints against unknown 
antigens, the humoral immune system of an individual will be screened with random peptide 
sequences and substitution analyses. Since many peptides are required to possibly determine 
all antibody species of the examined individual, a pre-screening with peptide phage display 
will be established. (3) Knowing the concentration and affinity of the specific antibodies 
could expand the application possibilities in disease etiology. To investigate the kinetics of 
antibody-peptide interactions, a microfluidic system with optical setup for time-resolved 
detection will be established. 
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Figure 1: Principal approach of research - workflow of epitope mapping (a) and substitution analysis 
(b) on high density peptide arrays. For the epitope mapping, the linear sequence of an antigen is cut in 
silico in peptides with overlapping amino acid sequences. The array consisting of these peptides is 
incubated with patient serum and fluorescently labelled secondary antibodies. In the second step, 
antigenic peptides that have been identified in the epitope mapping are investigated in a substitution 
analysis. Each amino acid in such an antigenic peptide is one by one substituted by all other amino 
acids, while the rest of the sequence remains conserved. The array of the resulting substituted peptides 
is again incubated with the patient serum and secondary antibodies. 
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3 Published scientific material and manuscripts 
Identification of a tetanus toxin specific epitope in single amino acid resolution  
Andrea Palermo*, Laura K. Weber*, Simone Rentschler, Awale Isse, Martyna Sedlmayr, 
Karin Herbster, Volker List, Jürgen Hubbuch, Felix F. Löffler, Alexander Nesterov-Müller, 
Frank Breitling (*contributed equally)  
 
This manuscript describes the combination of epitope mapping and substitution analysis for 
the investigation of antibody responses in 19 vaccinated Europeans towards the tetanus toxin. 
Besides a broad interaction of antibodies with various epitopes, one distinct epitope on the 
tetanus toxin was detected in 9 individuals on the C-terminal domain of the heavy chain. The 
substitution analysis revealed almost identical fingerprints in 8 of those 9 individuals. 
Furthermore, it was possible to isolate the respective antibody species from the serum of one 
individual with affinity chromatography using the identified peptide. The tetanus specificity 
of the isolated antibody was proven in an additional ELISA experiment. This study 
demonstrated for the first time the disease specificity of antibody fingerprints. 
Published in revised form in Biotechnology Journal 2017, 12 (10), 1700197 
 
Antibody fingerprints in Lyme disease deciphered with high density peptide arrays 
Laura K. Weber, Awale Isse, Simone Rentschler, Richard E. Kneusel, Andrea Palermo, 
Jürgen Hubbuch, Alexander Nesterov-Müller, Frank Breitling, Felix F. Löffler 
 
In this paper, the results of a study with 24 Lyme disease patients are described. The antibody 
responses of 17 VlsE positive and 7 negative sera were investigated in an epitope mapping 
with subsequent substitution analysis of the immunodominant epitopes. The analysis revealed 
that in Lyme disease, the antibody fingerprints of different individuals towards shared 
epitopes of the VlsE antigen are almost identical. The antibody specificities on sub-epitope 
level can serve as biomarkers enabling the study of inducing and cross-reacting proteins.  
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This paper describes a novel approach for the identification of causing pathogenic agents in 
enigmatic infectious diseases. The pipeline of prescreening with phage display, next 
generation sequencing and validation with peptide arrays in combination with substitution 
analyses revealed 73 antibody specificities in the serum of an individual without a priori 
knowledge. The query of public protein databases with the fingerprints allows for the 
identification of potential antigens. One of the most abundant motifs in our study led to the 
antigenic capsid protein of the enteroviruses. Due to common vaccination against the polio 
virus, a member of the enterovirus genus, the corresponding antibody species was most likely 
identified.   
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Clemens Bojničić-Kninski, Daniela Althuon, Felix F. Löffler, Frank Breitling, Jürgen 
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In this manuscript, a microfluidic system for the automated incubation of peptide arrays is 
introduced. The combination with an optical set up allows for the detection of antibody-
peptide interactions in array format in a time-resolved manner. The interaction of the 
monoclonal FLAG antibody with its epitope was investigated in different concentrations as 
proof of principle. 
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Abstract 
Vaccinations are among the most potent tools to fight infectious diseases. However, cross-
reactions are an ongoing problem and there is an urgent need to fully understand the 
mechanisms of the immune response. For the development of a methodological workflow, we 
investigated linear epitopes in the immune response to the tetanus toxin in sera of 19 
vaccinated Europeans applying epitope mapping with peptide arrays. The most prominent 
epitope, appearing in 9 different sera (923IHLVNNESSEVIVHK937), was investigated in a 
substitution analysis to identify the amino acids that are crucial for the binding of the 
corresponding antibody species– the antibody fingerprint. The antibody fingerprints of 
different individuals were compared and found to be strongly conserved (929ExxEVIVxK937), 
which is astonishing considering the randomness of their development. Additionally, the 
corresponding antibody species was isolated from one serum with batch chromatography 
using the amino acid sequence of the identified epitope and the tetanus specificity of the 
isolated antibody was verified in an ELISA experiment. Studying antibody fingerprints with 
peptide arrays should be transferable to any kind of humoral immune response towards 
protein antigens. Furthermore, antibody fingerprints have shown to be highly disease-specific 
and, therefore, can be employed as reliable biomarkers enabling the study of cross-reacting 
antigens. 
 
Novelty Statement 
Antibody fingerprints that can be deciphered with substitution analyses on peptide 
microarrays, define the specificity of antibodies in the resolution of single amino acids. In our 
study, we compared the immune response of different individuals towards the tetanus 
vaccination with epitope mappings and subsequent substitution analyses of a dominant 
epitope. We combined several steps in a pipeline and demonstrated that the identified 
antibody species is specific for the tetanus toxin. We believe that disease-specific antibody 
fingerprints will be employed for the development of biomarkers and vaccines in the future. 
  
3.1 Identification of a tetanus toxin specific epitope in single amino acid resolution 21 
 
1. Introduction 
Very effective vaccinations shield us from a lot of common infectious diseases [78]. It is 
known that vaccines protect us amongst others by inducing long-lived plasma cells [79, 80]. 
However, the precise mechanism of the immune response and the exact composition of 
antibodies elicited by vaccinations remain unclear. It has been shown in several studies that 
vaccinations against viruses can enhance other diseases by cross-reaction [27, 28, 26], or lead 
to antibody-dependent enhancement of the same disease [25]. The vaccination against the 
tetanus toxoid elicits a highly efficient neutralizing antibody response [81] and tetanus can be 
considered as eradicated in developed countries [82]. In 2011, a global coverage of 84 % was 
reached for the diphtheria-tetanus-pertussis combination vaccination, yet poor coverage was 
reported in low- and middle-income countries [83]. The tetanus toxin or tetanospasmin is an 
exotoxin, produced by the Gram-positive bacillus Clostridium tetani, which can normally be 
found in soil [82]. It consists of 1315 amino acids [84] and is structured in a heavy chain 
(Mw: 100 kDa) and a light chain (Mw: 50 kDa) [85]. The exact mechanism of how antibodies 
are able to neutralize the tetanus toxin is not fully understood, but early studies of monoclonal 
antibodies from mice suggest that different epitopes are targeted and also synergistic effects 
of different antibodies lead to its neutralization [86].  
In this study, we compared the humoral immune response of 19 individuals towards the 
vaccination against tetanus with peptide microarrays in single amino acid resolution. In an 
epitope mapping, displaying the amino acid sequence of the tetanus toxin with overlapping 
peptides, we identified an immunodominant epitope on the heavy chain. Then, we compared 
the specificity of the antibodies towards this epitope with full substitution analysis. Thereby, 
those amino acids that are essential for the interaction of an antibody with an antigenic 
peptide are determined – the antibody fingerprint. We validated this specific antibody-peptide 
interaction on a second platform and, then, isolated the identified antibody species from the 
serum of one individual to prove that it interacts with the complete toxin in an ELISA 
experiment. The workflow of the project is depicted in Figure 1. Additionally, the antibody 
fingerprint was employed to query protein databases for the identification of cross-targeted 
antigens. Substitution (or replacement) analyses were introduced by Geysen et al. [76]. 
Recently, we published the potential of these fingerprints for the research in disease etiology 
and the read-out of the human antibody repertoire [87]. 
For the here described study, arrays were synthesized with a laser printer by the 
PEPperPRINT GmbH (Heidelberg, Germany). The solid-material-based synthesis methods 
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allow for the synthesis of high-density peptide arrays with over 10,000 spots per cm
2 
[88, 89, 
90, 91, 67]. 
Our experiments revealed that antibody fingerprints are highly disease-specific and can be 
employed to compare the immune responses of different individuals toward vaccinations or 
infections in unprecedented detail. Therefore, they can serve as reliable diagnostic tool and 
support the development of biomarkers and vaccines. 
 
Figure 1: Workflow of the study. A: The linear amino acid sequence of a protein is cut in silico into 
peptides with overlapping sequences. B: The resulting sequences are synthesized onto a peptide array. 
C: The peptide array is incubated with human serum and subsequently with fluorescently labeled 
secondary antibodies. A fluorescence scan reveals the information which peptides are bound by serum 
antibodies. D: Information of bound epitopes is mapped onto the 3D protein structure. E: The 
antibody-peptide interaction is validated on a second platform with pre-synthesized and spotted 
peptides. F: In a substitution analysis, every amino acid of an antigenic peptide is systematically 
exchanged by all other amino acids to assess the antibody binding fingerprint. G. An antibody species 
is isolated with the antigenic peptide and its ability to bind to the native toxin is verified in an ELISA 
experiment. Parts of the figure are based on [92], reprinted with permission. 
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2. Material und Methods 
2.1 Peptide arrays – design & synthesis 
For the epitope mapping the amino acid sequence of the tetanus toxin [84] was synthesized as 
1315 15mer peptides with an overlap of 14 amino acids in duplicates. 15mere peptides were 
chosen to cover all linear epitopes, which are reported to be up to 12 amino acids long [93], 
with at least 3 consecutive peptides. To enable interactions with the N- and C-terminal parts 
of the toxins spacer of alternating glycine and serine (GSGSGSG) were added respectively. 
Peptide arrays were purchased from PEPperPRINT, Heidelberg, Germany. Arrays were 
manufactured in a combinatorial solid-phase peptide synthesis process with a laser printer. To 
simplify the data analysis, a frame of Hemaggluttinin (HA) epitope peptides 
(YPYDVPDYAG) and FLAG epitope peptides (DYKDDDKGG) or polio peptides 
(KEVPALTAVETGAT) was synthesized around the array content. For the substitution 
analysis, each amino acid of a 15mer peptide is replaced by all other 19 proteinogenic amino 
acids, one after another, while the rest of the sequence is conserved. For this analysis, we 
selected a peptide that was targeted by antibodies from 8 of the 19 sera in the epitope 
mapping. To verify the interaction of serum antibodies with the identified epitope, the 
peptides IHLVNNESSEVIVHK-ßA-D-ßA-Peg-CCOOH, IHLVNNESSEVIVHR- ßA-D-ßA-
Peg-CCOOH (negative control 1) and IHLVNNESSEVIAHK- ßA-D-ßA-Peg-CCOOH 
(negative control 2), purchased by Peps4LS (Heidelberg, Germany), were spotted onto a 3D 
Maleimid surface (PolyAn, Berlin, Germany) using a NanoPlotter 2.1 (GeSiM, Radeberg, 
Germany). The spotting was conducted with a Nano Tip J A070-401 20310. The peptides 
were diluted to 100 µM in PBS containing 10 % glycerol (99+ %) (Alfa Aeser, Karlsruhe, 
Germany). After spotting, the slides were dried for 2 h and subsequently blocked in PBS 
containing 0.4 % 2-Mercaptoethanol (Merck, Darmstadt, Germany). The washing was 
performed at 70 rpm on an orbital shaker (Orbital Shaker DOS-20S, Elmi Ltd., Riga, 
Lettland) for 3 min with PBS, 3 min deionized water, 5 min acetonitrile (VWR Chemicals, 
Radnor, USA) containing 0.1 % Trifluoroacetic acid (99%) (Honeywell Chemicals, 
Morristown, USA), 5 min Dimethylformamid (DMF) (99,8+ %) (VWR Chemicals, Radnor, 
USA) containing 0.5 % N,N-Diisopropylethylamine (Merck, Darmstadt, Germany), 3x5 min 
DMF and 2x3 min Methanol (Merck, Darmstadt, Germany). Slides were dried in an argon gas 
stream and stored at 4 °C until further usage. 
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2.2 Incubation of peptide arrays 
The incubation of peptide arrays was carried out as described in Weber et al. [87]. Peptide 
arrays are rotated with a rotation speed of 140 RPM. Secondary antibodies (Goat anti-human 
IgG-Fc-Fragment DyLight®680 conjugated, Biomol, Hamburg, Germany) were diluted to 0.2 
µg/mL. The secondary antibody mixture additionally contained DL800 conjugated 
(fluorescently labeled using a DyLight™ 800 Microscale Antibody Labeling Kit, Thermo 
Fisher Scientific, Rockford, USA) monoclonal anti-HA antibodies (provided by Dr. Gerd 
Moldenhauer, DKFZ, Heidelberg) diluted to 1 μg/mL and/or monoclonal anti-FLAG M2 
antibodies (Sigma Alderich, Saint Louis, USA) diluted to 0.2 µg/mL. 
Sera of 19 human donors, vaccinated against tetanus, were provided by Dr. List from the 
medical services at KIT. The study was approved by the state chamber of physicians of 
Baden-Wuerttemberg (reference number: F-2011-044 and F-2011-044#A1). Blood was 
extracted, centrifuged at 4000 g in BD Vacutainer R SST TM tubes (by BD Plymouth, UK) 
and stored at 4 °C until usage. 
 
2.3 Image & data analysis 
Fluorescence scanning with an Odyssey scanner (LI-COR Biosciences, Lincoln, USA) and 
evaluation with the PepSlide Analyzer (Sicasys Software GmbH, Heidelberg, Germany) was 
done as described in Weber et al. [87]. The foreground median intensities of spot duplicates 
were averaged. Dust on the surface of the arrays results in outliers which can be identified by 
differences in the signal intensities of spot duplicates. The average intensity of such spots is 
set to zero under the following two conditions: (1) the intensities of spot duplicates differ by 
more than 65 % in the average spot intensity and (2) the intensities of spot duplicates are 
higher than 50 % of the average intensity of all spots of the array. Additionally, the 
fluorescence scans were revised manually for outliers that are not detected by the before 
described criteria. For a better comparison of different sera, which show different maximum 
intensities, the spot intensities are normalized to the maximum spot intensity of the array for 
each serum. In the substitution analysis, the intensities of the peptide spots with the 
substituted amino acid are normalized to the intensity of the spots with the original amino 
acid for each row position respectively. If the substitution of an amino acid leads to a decrease 
in the signal of more than 40 %, the binding is considered as inhibited.  
 
 
3.1 Identification of a tetanus toxin specific epitope in single amino acid resolution 25 
 
2.4 Serum purification 
16 mL of serum 11 were purified using a two-step batch chromatography with protein G and 
pre-synthesized peptides immobilized on beads. The interaction of the isolated antibody with 
the native toxin was verified in a tetanus ELISA with the dilution of 1:2 and 1:10 according to 
the protocol. Protein G batch chromatography was conducted with a NAB Protein G Spin kit 
(Thermo Scientific, Rockford, USA) according to the protocol. The first four fractions were 
pooled and a buffer exchange to PBS was performed with a ZebaSpin Desalting kit 7K 
MWCO (Thermo Scientific, Rockford, USA) according to the protocol. Subsequently, an 
affinity purification was conducted using the SulfoLink Immobilization Kit for Peptides 
(Thermo Scientific, Rockford, USA) according to the protocol. The peptide used for the 
isolation (IHLVNNESSEVIVHK-ßA-D-ßA-Peg-spacer-CCOOH) was purchased by Peps4LS 
(Heidelberg, Germany). The additional peg-spacer was chosen to increase the solubility and 
decrease steric effects. The column was loaded 6 times with 3 mL of serum each time. The 
concentration of antibodies after purification (2nd and 3rd fraction pooled) was determined to 
be 0.053 mg/mL by optical density measurement at 280 nm in a Jenway 7305 
spectrophotometer (Bibby Scientific, Staffordshire, UK). After elution, the buffer was 
exchanged as described before. 
 
2.5 Tetanus titer determination by ELISA 
IgG anti-tetanus antibody levels were determined by ELISA using a tetanus IgG ELISA kit 
(Sekisui Virotech GmbH, Rüsselsheim, Germany) according to the protocol. Evaluation was 
done according to the instructions; titers were calculated by the mean of three different 
dilutions in duplicates. 
 
3. Results 
3.1 Epitope Mapping 
Peptide arrays containing 1315 peptides each, representing the tetanus toxin and synthesized 
as spot duplicates were incubated with sera of 19 vaccinated Europeans. All serum samples 
were positive by IgG tetanus ELISA; titers are shown in Supplementary Table S1. Figure 2 
shows the results of the epitope mappings as heatmaps, displaying the interaction of serum 
antibodies with peptides representing the amino acid sequence of the tetanus toxin from left to 
right. The data was normalized to the maximum intensity of each array respectively. A broad 
distribution of interaction between antibodies of different patients and peptides was observed. 
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Figure 2: Heatmap of the epitope mapping of the light and heavy chain of the tetanus toxin. Sera of 19 
vaccinated Europeans were incubated on peptide arrays, containing overlapping peptide fragments 
covering the linear amino acid sequence of the tetanus toxin. Peptides have the length of 15 amino 
acids and a lateral shift of one amino acid. Fluorescence intensities were normalized to the respective 
maximum intensity of each array. Almost no coinciding epitopes can be observed on the light chain. 
The white ellipses highlight the most prominent epitope of the heavy chain that can be found in 
several patients and was selected for the substitution analysis and isolation of the respective antibody. 
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One epitope is targeted in a band of successive peptide spots by antibodies of 8 individuals. 
Antibodies of one serum (serum 9) showed weak interaction with only the first of these 
successive peptide spots (see Figure 2 and Supplementary Figure S2-A). The identified 
epitope with the amino acid sequence 923IHLVNNESSEVIVHK937 is located on the N-terminal 
domain of the C-terminal part of the heavy chain (HC-N) of the tetanus toxin. This epitope 
was further investigated in a substitution analysis. 
 
3.2 Substitution analysis 
In a substitution analysis, every amino acid in a known antibody-binding peptide is one by 
one exchanged by all other 19 amino acids (see Figure 3). For 15mer peptides, the resulting 
300 peptides (15 x 20 amino acids) are synthesized on an array and incubated with the same 
serum as in the epitope mapping. Besides the variants, each row also contains the peptide with 
the original sequence of amino acids. The fluorescence intensity was normalized to the 
original peptide in each row, which is set to 100 %. 
In the epitope mapping (see Figure 2), antibodies of 9 out of 19 sera showed interaction 
with the peptide 923IHLVNNESSEVIVHK937. This peptide was substituted; the resulting arrays 
were synthesized in triplicates and incubated with the respective sera. Evaluation was done as 
described in Figure 3. The resulting antibody fingerprint of 8 sera is highly conserved and 
consists of the amino acids 929ExxEVIVxK937, of which “x” represents an amino acid that is 
not crucial for the antibody-antigen interaction. The individual fingerprints of all sera are 
summed up in Table 1. Supplementary Figure S1 shows the evaluation of all substitution 
analyses as heatmaps. The role of the amino acid H936 in the identified fingerprint is less 
stringent then the role of other positions. A broad range of interaction was observed across 
different sera. No conclusive correlation of the characteristics of the amino acids leading to 
binding or preventing the interaction in this position (hydrophobicity, charge and size) can be 
observed. The substitution analysis of serum 9 revealed a different fingerprint and is shown in 
Supplementary Figure S2. The fingerprint consists of only 3 amino acids (923IxxVN927) and 
the essential amino acids are shifted to the N-terminal part of the peptide.  
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Figure 3: A: Example fluorescence scan image of an epitope mapping. A selected epitope, which was 
chosen for substitution analysis, is shown in detail. Scale bar 0.5 cm. B: Example fluorescence scan 
image of the corresponding substitution analysis of a 15mer peptide. Each amino acid position is 
substituted by all 19 other amino acids resulting in an array of 15 rows and 20 columns. From top to 
bottom left, the original sequence is shown. Those amino acid positions that are essential for binding 
of the antibody are highlighted with a green circle. C: Heatmap of the evaluation of the substitution 
analysis. The intensity of the peptide with the original amino acid in each row is set to 100 %. The 
relative fluorescence intensities are calculated in relation to these intensities. From top to bottom left, 
the original sequence is shown; letters in red indicate original amino acids that are essential for 
binding. In some positions two or more amino acids allow for the binding. Amino acids with similar 
binding effect are shown at the left side, sorted by binding intensity from left (lower) to right (higher). 
 
3.3 Validation of antibody-peptide interaction 
The interaction of serum antibodies with the identified prominent epitope of the heavy chain 
from the tetanus toxin was verified using a pre-synthesized peptide with the amino acid 
sequence IHLVNNESSEVIVHK-ßA-D-ßA-Peg-CCOOH, spotted onto functionalized surfaces. 
Arrays were incubated with those sera that showed interaction with the identified antigenic 
peptide (sera 2, 3, 7, 8, 9, 10, 11, 16, 17). The median fluorescence intensity of these peptide 
spots is depicted in Supplementary Figure S3. All sera showed interaction with the peptide in 
the validation experiment, except for serum 9. As negative control two peptides with 
substituted amino acids were synthesized and spotted. The substituted peptides were derived 
from the substitution analysis with the amino acid sequences IHLVNNESSEVIVHR-ßA-D-
ßA-Peg-CCOOH and IHLVNNESSEVIAHK-ßA-D-ßA-Peg-CCOOH. Very little to no interaction 
of serum antibodies with these peptides was detected. Supplementary Figure S4 shows 
examples of fluorescence scan images of peptide arrays incubated with serum 11 (positive) 
and serum 19 (negative control). 
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Table 1. Antibody fingerprints of 8 sera for an identified epitope. All amino acids that lead to the 
binding of the antibody are printed according to the relative fluorescence intensity from left to right 
(top to bottom) in increasing manner. If all substitution variants in a row lead to the binding of the 
antibody, the position is depicted with an x. If 15 or more amino acids allow for the binding in a 
certain position, only amino acids that prevent the binding are printed with a preceding exclamation 
mark. Amino acid positions that are essential for the binding of the antibodies of all individuals are 
highlighted in grey. 
Serum Original amino acid sequence 
 I H L V N N E S S E V I V H K 
2 x !I x x x x 
AQSTW
YGHP 
LCDE 
x x E LEVI VI VI 
CSIV 
HETD 
K 
3 !A x !A !A !AKQ x ME 
!AG
R 
!GP E VI I VI 
KQYHCMEFI
VSNTD 
K 
7 EVHCWIN 
TCIEKGL
RVH 
WFY 
x x x x 
ILNSTV
DE 
x x E 
TLV
EI 
VI VI 
QACF 
MKHN 
ESITD 
K 
8 !AV !A !A x !AFGMY 
ESDNIPT
L 
EDGL !D !G E VI FID V !GP CK 
10 x x x x x x DE x x E VIE I VI 
IVTH 
END 
K 
11 !A x x x x x DE x x E VIE I VI 
FQHMCKSVE
I 
NTD 
K 
16 
FNDMRQT
HLWYWVI 
!C x 
!CFG
K 
QIHFWD
STNYL 
HAYNW
ETGSD 
E 
!GN
P 
MAFTS
LDE 
E V I IV x K 
17 x x x x x x TNQDE x !G E EVI I VI 
QSFMHIVTED
N 
K 
 
3.4 Isolation of epitope specific antibodies and verification of toxin specificity 
To verify, that the identified antibody species was induced by the vaccination against tetanus, 
an antigenic peptide of the epitope (IHLVNNESSEVIVHK) was pre-synthesized, purified and 
immobilized on beads to isolate the corresponding antibodies of serum 11 by batch affinity 
chromatography. The isolated antibody species was tested for its ability to bind to the native 
tetanus toxin in an ELISA experiment. Therefore, an individual received a tetanus vaccination 
before the donation and the IgG anti-tetanus titer increased from 1.02 IU/ml before 
vaccination to 4.7 IU/ml six months after vaccination. The post-vaccination serum was 
purified by protein G batch chromatography prior to affinity chromatography. The 
concentration of isolated antibodies was calculated from OD (280 nm) to be 0.053 mg/mL. To 
control the efficiency of the affinity batch chromatography, the isolated antibodies were 
incubated on an array containing the peptides of the epitope mapping. The results of this 
epitope mapping are shown in Supplementary Figure S5. Fluorescent signals were observed 
only with peptides containing the essential amino acids that were identified in the substitution 
analysis. In the tetanus ELISA experiment, the purified antibodies resulted in an OD (450 nm) 
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of 0.85 at a dilution of 1:2, which is comparable to the OD (450 nm) of 0.74 for the respective 
serum prior to purification at a dilution of 1:1000. 
 
3.5 Bioinformatic analysis of identified fingerprint 
Antibody fingerprints allow for the query of public protein databases to identify cross-
reacting antigens and organisms that might have induced the formation of the antibody in the 
first place. A query of the ”UniProtKb/Swiss-Prot” protein database with the “ScanProsite 
tool” [94] for the motif “(DE)-x-x-E-(IV)-I-(IV)-(CDEHIMNSTV)-K” resulted in 47 hits (see 
Supplementary Table S2). This motif consists of the amino acids that are most conserved 
among all 8 individuals. Almost all of the resulting protein/organism hits are very unlikely to 
be the causative antigen, because they are either from exotic organisms or they would derive 
from an autoimmune reaction. However, the human rhinovirus 3 and 14 also share the 
identified motif, which is considered in the discussion. 
 
3.6 Spatial position of fingerprint 
Figure 4 shows the mapping of the identified fingerprints onto the three-dimensional structure 
of the tetanus toxin. It reveals that the amino acids of the identified epitope are either part of 
beta strands (923IHLV926 and 933VIVH936) or coils between beta strands (927ENNESSE932 and 
K936). The conformation of the sequence 923IHLVNNESSEVIVHK937 is a U-turn, as can be 
seen in Figure 4A. The amino acid E932 is the tip of the U-turn and 929ESSEVIVHK937, 
representing the relevant part of the epitope, is fairly extended and might be the best fit for the 
CDR-grove of the antibody. The amino acids H924, V926-S930, E932, I934 and H936 are protruding 
from the protein. The conformation of the epitope hints to an extended or protruding surface 
as antigen binding site on the antibody. 
 
4. Discussion 
Clostridial neurotoxins, such as the botulinum and tetanus toxins are among the most 
poisonous toxins known [95]. To understand, how antibodies are able to neutralize toxins or 
any other infection, the mode of action of an antibody and the exact binding site is of great 
interest. To gain further insights into immune responses, we investigated potential binding 
sites of the tetanus toxin with the combination of epitope mappings and substitution analyses 
on peptide arrays. Furthermore, we verified the specificity of the identified epitope towards 
the tetanus toxin by conducting a tetanus ELISA with the isolated antibody species.  
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Our analyses of the antibody activity in 19 individuals towards the tetanus toxin revealed a 
broad distribution, ranging from the recognition of single peptides to distinct bands consisting 
of several consecutive peptides. These findings of a wide range of different antibodies are 
consistent with those of a recent study [96]. We found that the most distinct epitope 
(923IHLVNNESSEVIVHK937), recognized by antibodies of 9 different sera, is located on the N-
terminal domain of the C-terminal part of the heavy chain (HC-N). The C-terminal part of the 
heavy chain (HC), consisting of two subdomains (HC-C and HC-N), facilitates neurospecific 
binding, the N-terminal part (HN) is responsible for membrane translocation [95]. The exact 
role of the HC-N domain remains elusive [97]. Even though, monoclonal antibodies, capable 
of neutralizing the toxin in mice, were found to be binding to the C domain of the C-terminal 
part of the heavy chain (HC-C) [98, 99], antibodies binding to the identified epitope might 
play a synergistic role in the neutralization process. Polysialogangliosides and integral 
membrane protein receptors have shown to be involved in the binding process [95, 100, 101, 
102]. The simultaneous binding of antibodies to ensure neutralization was described earlier 
[86, 103]. The role of the identified epitope should be further investigated in neutralization 
studies. 
The homology of the identified antibody fingerprint (929ExxEVIVxK937), between different 
individuals is astonishing, especially when taking into account the randomness of the 
antibody development. The analysis of one serum revealed a different, less stringent antibody 
fingerprint, which could be explained by unspecific binding or a different HLA type of this 
patient. A larger pool of samples with determined HLA type should be investigated in future 
studies, to examine, if more individuals produce antibodies with this different fingerprint and 
if HLA types play a role in this context. The sequencing of the identified and isolated 
antibody species and a structural analysis of the antibody-antigen-complex could give further 
insights into the mechanism of binding, such as induced fit, and the role of less stringent 
amino acid positions, such as H936. 
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Figure 4: Three-dimensional structure of the heavy chain of the tetanus toxin. Conformation of the 
investigated epitope (A) and molecular surface (B) are depicted using BIOVIA Discovery Studio 
client [104], based on RCSB PDB (www.rcsb.org) ID 1A8D [105]. Fingerprint regions identified in 
the substitution analysis are highlighted in color.  
 
Antibody fingerprints allow for the identification of potentially cross-reacting or cross-
inducing antibodies and a database query with ScanProsite [94] revealed that the identified 
motif can also be found on the human rhinovirus strains 3 and 14. The sequence is located on 
the N-terminal part of the structural capsid protein VP1 [106]. The N-terminal part was shown 
to be immunogenic in rhinovirus strain 89, but it does not contain the specific amino acid 
sequence. VP1 of rhinovirus strain 14, which does contain the fingerprint, is less 
immunogenic [107]. Furthermore, the specific part is located on the inside of the virus, which 
is not part of the proposed receptor binding or neutralization site [107, 108]. Therefore, due to 
the great rhinovirus diversity of over 100 strains [98, 109] and the low protection against 
reinfection [110], we assume that the fingerprint does originate from the tetanus toxoid 
vaccination. It is very unlikely that 8 of our 19 individuals share the exact same antibody 
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specificity towards only two rhinovirus strains. Furthermore, we could verify the ability of the 
identified antibody species to bind to the native toxin with an additional ELISA experiment 
using the antibody after isolation in affinity batch chromatography.  
Our study proves the suitability of peptide arrays to identify antibody species. Furthermore, 
these peptide targets might also serve as candidates for peptide based vaccines. The 
substitution analysis also revealed a new immunological insight that antibody species are 
highly conserved between different individuals. Antibody fingerprints enable queries of 
public protein databases for the identification of cross-reacting antigens and therefore, the 
fingerprints can serve as reliable, highly disease-specific biomarkers. 
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Practical application 
Antibody fingerprints define the specificities of antibodies in the resolution of a single amino 
acid and allow for the comparison of antibody responses in different individuals on sub-
epitope level. They can be deciphered with substitution analyses, carried out with flexible 
high density peptide arrays by substituting every amino acid in an antigenic peptide with all 
other amino acids. As these fingerprints enable queries of public protein databases, the study 
of cross-targeted (human) proteins becomes possible. Therefore, the readout of antibody 
fingerprints can serve as a novel diagnostic tool to investigate disease etiology. As a proof-of-
principle, this study evaluated the feasibility of antibody fingerprints for diagnostic purposes 
in Lyme disease. 
 
Abstract 
Lyme disease is the most common tick-borne infectious disease in Europe and North 
America. Previous studies discovered the immunogenic role of a surface-exposed lipoprotein 
(VlsE) of Borreliella burgdorferi. We employed high density peptide arrays to investigate the 
antibody response to the VlsE protein in VlsE-positive patients by mapping the protein as 
overlapping peptides and subsequent in-depth epitope substitution analyses. These 
investigations led to the identification of antibody fingerprints represented by a number of key 
residues that are indispensable for the binding of the respective antibody. This approach 
allows us to compare the antibody specificities of different patients to the resolution of single 
amino acids. Our study revealed that the sera of VlsE-positive patients recognize different 
epitopes on the protein. Remarkably, in those cases where the same epitope is targeted, the 
antibody fingerprint is almost identical. Furthermore, we could correlate two fingerprints with 
human autoantigens and an Epstein-Barr virus epitope; yet, the link to autoimmune disorders 
seems unlikely and must be investigated in further studies. The other three fingerprints are 
much more specific for B. burgdorferi. Since antibody fingerprints of longer sequences have 
proven to be highly disease specific, our findings suggest that the fingerprints could function 
as diagnostic markers that can reduce false positive test results. 
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1. Introduction 
Lyme disease is the most common tick-born disease in Europe and North America and yet 
remains a problematic topic [111, 112]. The illness is caused by different species of the 
spirochete Borreliella burgdorferi, referred to as B. burgdorferi sensu lato. Diagnosis in 
absence of the one distinct clinical marker “erythema migrans” remains controversial and 
lacks in either sensitivity, specificity, or both [113, 114]. Due to limited success in direct 
detection of B. burgdorferi sensu lato, serological antibody-based tests are mainly applied for 
clinical diagnosis [115]. The Centers for Disease Control and Prevention (CDC) in the USA 
recommend two-tier testing [116]. This diagnosis applies enzyme immunoassays or 
immunofluorescent assays as a pre-test and Western immunoblotting for validation. 
Differential expression of proteins and observer-dependent results are among the limiting 
factors of western blotting [117]. The use of recombinant proteins in line immunoblot assays 
[118] partly overcomes those problems. Yet, cross-reacting proteins are a drawback of all 
serological methods [119, 120]. False positive results may occur especially when the patients 
suffer from other illnesses, such as syphilis [121] or viral infections [122]. Antigenic diversity 
of the sensu lato species [123, 124, 125] ] and antigenic variation of these spirochetes, which 
refers to the ability of a single strain to express different variants of antigens at a much higher 
rate than the mutation rate [126] make diagnosis even more difficult. The Vmp-like sequence 
expressed (VlsE) antigen has shown to be very immunogenic and, yet, also very variable, due 
to genetic recombination of the vlsE cassette region [127]. The VlsE antigen (see Figure 2) 
consists of two invariable domains at the N- and C-terminal end and a variable domain in 
between, interspersed by 6 conserved invariable regions (IR 1 – IR6) [127]. Previous studies 
suggested that most immunodominant epitopes are located on conserved parts of VlsE, 
however, the variable parts influence the overall antigenicity [128]. Diagnosis, based on VlsE 
and a synthetic 26mer peptide (C6), which essentially represents the IR6 sequence derived 
from the VlsE antigen, is promising [129] especially regarding the discrimination between 
early and chronic Lyme disease patients [130]. 
Diagnosis and consequent treatment with antibiotics, especially in early stages of the 
illness, are necessary to prevent late manifestation and complications [131, 132]. Therefore, 
the development of simple and accurate tests for serodiagnosis, for example, based on a 
diagnostic peptide marker, is urgently needed. 
In this study, we combined a peptide array-based epitope mapping of the VlsE antigen with 
subsequent in-depth epitope substitution analyses to determine the antibody fingerprints to 
immunodominant epitopes. We employed a solid-material based synthesis with a laser printer 
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[133] to display the whole antigen with 15mer peptides that overlap by 14 amino acids. In the 
second step, every position of an identified antigenic peptide is substituted by all other amino 
acids and the resulting peptides are incubated again with the patient serum. The evaluation of 
the fingerprints with the substitution analysis defines the antibody specificity with single 
amino acid resolution and allows for the query of public protein databases to identify 
potentially cross-targeted proteins. The substitution (or replacement) analysis was established 
in 1987 by Geysen et al. [76]. In a recent study, these fingerprints were used to determine the 
specificity of antibodies towards the viral capsid protein (VP1) of enteroviruses [134]. They 
have shown to be helpful in the identification of potential cross-reactivity of these antibodies, 
e.g. with human proteins. However, this fine mapping has not yet been applied to investigate 
serum antibodies of large groups of individuals.  
Our experiments revealed that similar epitopes on the VlsE antigen are targeted, as shown 
in previous studies [130]. However, for the first time, we compared the antibody specificities 
on sub-epitope level. The findings that fingerprints are almost identical in different patients 
give new immunological insights. Besides a limited number of proteins and epitopes of a 
pathogen, we show that also a limited number of amino acids are commonly preferred by the 
immune systems of different individuals. Furthermore, the investigation of antibody 
fingerprints could help in elucidating the remaining question, why some Lyme disease 
patients show persistent symptoms despite antibiotic treatment, possibly caused by 
autoimmune cross-reactions. To address the latter, we performed queries of public protein 
databases and the human autoantigen atlas, which revealed potentially cross-targeted human 
proteins that play a role in autoimmune disorders. Additionally, the public protein databases 
were queried for typical cross-reacting viral proteins and three of five fingerprints are specific 
for B. burgdorferi. Therefore, our study serves as proof-of-principle for the investigation of 
antibody responses in groups of diseased individuals with epitope mappings, substitution 
analyses, and subsequent bioinformatics for diagnostic purposes and etiology. 
 
2. Material & Methods 
2.1 Study Design 
In this study, we investigated the antibody response of 24 individuals towards 15mer peptides, 
representing the whole amino acid sequence of the VlsE antigen of B. burgdorferi strain B31 
with a lateral shift of one amino acid. Commercially available patient sera from Europe and 
Northern America were provided by the company DIARECT AG (Freiburg, Germany). 17 of 
these sera were tested VlsE positive with protein arrays by the company DIARECT AG 
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(Freiburg, Germany). Sera of 7 VlsE negative patients served as negative controls. Peptide 
arrays were produced in spot duplicates by the company PEPperPRINT GmbH (Heidelberg, 
Germany) with a particle-based solid-phase peptide synthesis approach in a laser printer 
[133]. In the second step, immunodominant epitopes shared by several patients were fine 
mapped in a substitution analysis to investigate the antibody specificity in a single amino acid 
resolution, which we call the antibody fingerprint. The antibody fingerprints were visualized 
on the three-dimensional structure of the antigen with PyMol (Schrödinger, pymol.org/dsc/) 
to reveal the spatial position and accessibility of the epitopes. 
 
2.2 Peptide arrays – design & synthesis 
The linear amino acid sequence of the VlsE antigen of B. burgdorferi (accession number 
O06878, integrated into UniProtKB/TrEMBL: July 1, 1997, access February 2016) was 
synthesized as overlapping peptides in spot duplicates (15mer peptides with an overlap of 14 
amino acids). To ensure proper interaction with the C-terminal part of the antigen, a spacer, 
consisting of glycine and serine (GSGSGS), was added. As controls, alternating 
Hemagglutinin (HA) peptide spots (YPYDVPYAG) and a peptide, derived from the polio 
virus (KEVPALTAVETGAT), were synthesized surrounding the array content. The peptide 
spot size was 200 µm x 400 µm with a spot-to-spot distance of 250 µm x 500 µm. For the 
substitution analysis, amino acids of the immunodominant epitopes were substituted one by 
one by all other amino acids and synthesized in spot duplicates. Thereby, only one amino acid 
at a time is exchanged, the rest of the sequence remains conserved. 
 
2.3 Incubation of peptide arrays 
For all incubation, washing, and blocking steps, glass slides with peptide arrays are mounted 
into PEPperCHIP incubation trays (PEPperPRINT, Heidelberg, Germany). The trays allow 
for the subdivision of a glass slide into separate wells. The tray is placed on an orbital shaker 
and rotated at 140 rpm (Orbital Shaker DOS-20S, Elmi Ltd., Riga, Lettland). Prior to the 
initial incubation, the slide is swelled in phosphate buffered saline with Tween 20 (PBS-T: 1 x 
PBS, Sigma Aldrich, Saint Louis, USA, pH 7.4; 0.05 % v/v Tween 20, Sigma Aldrich) for 10 
min and blocked with blocking buffer for fluorescent western blotting (Rockland 
Immunochemicals Inc., Pottstown, USA) to inhibit unspecific binding. To determine the 
potential interaction of the fluorescently labelled secondary antibodies with any peptide, a 
pre-staining after blocking is performed. Secondary antibodies (Goat anti-human IgG-Fc-
Fragment DyLight®680 conjugated, Biomol, Hamburg, Germany) diluted to 0.2 µg/mL in 
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PBS-T with 10 % v/v blocking buffer are incubated for 30 min followed by a washing and a 
subsequent scanning step (see 2.4). After a short washing step with PBS-T, the slides are 
incubated with serum diluted 1:500 for the epitope mapping and 1:100 for the substitution 
analysis in PBS-T with 10 % v/v blocking buffer over night at 4 °C. Afterwards, the slides are 
washed again in PBS-T and incubated with secondary antibodies at the same concentration as 
mentioned above and monoclonal Anti-HA antibodies (provided by Dr. Gerd Moldenhauer, 
DKFZ, Heidelberg) labelled with a DyLight™ 680 Microscale Antibody Labeling Kit 
(Thermo Fisher Scientific, Rockford, USA) and diluted to 1 μg/mL. Finally, the slides are 
washed with PBS-T, dipped into ultra-pure water and dried in a stream of argon. For storage, 
slides are kept under argon atmosphere at 4°C. 
 
2.4 Image analysis & evaluation 
Fluorescence scanning of the slides is performed using an odyssey scanner (LI-COR 
Biosciences, Lincoln, USA) with a resolution of 21 μm/pixel at a wavelength of 680 nm. The 
resulting 16-bit grayscale images are analyzed with the PepSlide Analyzer (Sicasys Software 
GmbH, Heidelberg, Germany). A grid, containing the information of sequence and position of 
a peptide, is positioned over the greyscale image. The median of the greyscale values of all 
pixels in a spot is measured and exported as raw intensity. A global background consisting of 
the intensity of 20 control spots above and 20 under the arrays respectively is subtracted from 
the raw intensity to give the foreground intensity. The intensity of spot duplicates is averaged. 
Outliers caused by dirt can be detected with differences in the foreground median intensity of 
spot duplicates. Therefore, the intensity of a peptide spot is set to twice the average spot 
intensity of an array if (1) the intensities of spot duplicates differ by more than 65 % and (2) 
the intensities of spot duplicates are higher than twice the average intensity of all spots of the 
array. In the substitution analysis, the intensity of the peptide with the original amino acid in 
each row is set to 100 %. The intensities of all other spots in a row are normalized with 
respect to the intensity of the peptide with the original amino acid. If the substitution leads to 
a decrease in intensity of more than 40 %, the binding is considered to be eliminated. 
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3. Results 
The workflow of this study is depicted in Figure 1. First, we performed an epitope mapping of 
the VlsE antigen of Borreliella Burgdorferi sensu stricto with sera from 24 different 
individuals (17 VlsE positive, 7 VlsE negative samples). The identified immunodominant 
epitopes (Figure 1-A) were fine mapped in a substitution analysis (Figure 1-B). The 
substitution analysis was evaluated as described in the Image analysis & evaluation section 
and reveals the antibody fingerprint (Figure 1-C). This fingerprint defines the antibody 
specificity at single amino acid resolution.   
 
Figure 1: Workflow of the epitope mapping (A) and subsequent substitution analysis of an identified 
epitope (B) with evaluation (C). For the epitope mapping, the amino acid sequence of the VlsE antigen 
of B. burgdorferi was displayed as 15mer peptides with a lateral shift of one amino acid. (A) 
Fluorescence scan image of a peptide array incubated with a VlsE positive patient serum and 
fluorescently labelled secondary antibodies. Peptide spots were produced as duplicates. The zoomed 
view shows one of the immunodominant epitopes, identified in several patients. Scale bar 0.5 cm. (B) 
Fluorescence scan image of a peptide array for the substitution analysis of the immunodominant 
epitope shown in detail in (A). The original amino acids of the peptide sequence are substituted one by 
one by all other amino acids. The resulting peptides are printed as array duplicates (not shown) and 
incubated with the corresponding serum. (C) The results of (B) visualized as a heat map. Evaluation of 
the substitution analysis reveals the antibody fingerprint, showing the antibody specificity at single 
amino acid resolution. The relative fluorescence intensities of all peptides in a row are calculated 
according to the intensity of the peptide with the original amino acid set to 100 %. (B and C) The 
original sequence is shown from top to bottom left; essential amino acids are indicated in red. 
Substituted amino acids are shown from left to right on top of the substitution arrays. 
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3.1 Epitope Mapping  
The antibody response of 24 different individuals towards the VlsE antigen was investigated 
with peptide microarrays. Figure 2 shows the results of this epitope mapping in form of a heat 
map. Seven VlsE negative patients (NC 1-7) served as controls. Two main groups of patients 
were identified based on the epitopes that were targeted by antibodies. Antibodies of group 1 
(PS 1 – 7) preferably targeted N- or C-terminal parts of the antigen or both, highlighted in 
orange and green. These parts comprise the amino acid positions 20 to 40 with the sequence 
INCKSQVADKDDPTNKFYQSV and positions 338 to 357 with the sequence 
LRKVGDSVKAASKETPPALN. In the second group (PS 9 – 14), the antibodies preferably 
bound to regions on the variable domain of the antigen (pink and cyan), comprising positions 
228 to 242 (VSGEQILSAIVTAAD) or positions 249 to 267 (KKPEEAKNPIAAAIGDKDG) 
or both. The antibody responses of PS 8 and 15 – 17 are not classifiable as part of the two 
main groups. Only little interaction was observed with peptides of the IR6. For a better 
comparison of the sera, the fluorescence intensities were normalized to the respective 
maximum intensity of each array. Maximum fluorescence intensities are listed in 
Supplementary Table S1. Figure 3 shows four examples of original fluorescence scan images 
of the peptide array epitope mappings. Please note the different maximum intensities. The 
negative controls did not show any significant fluorescent signals compared to patient 
samples 1 to 15. The antibody response of two patients (PS 16 and 17) were comparable with 
the negative controls with regard to the maximum signal intensities and the distribution of 
fluorescence signals over the array. 
 
3.2 Substitution analysis 
In the second step, 5 immunodominant epitope regions (highlighted in different colors in 
Figure 2) were fine mapped in a substitution analysis. Table 1 gives an overview of the 
specific peptides that were targeted by antibodies of different sera, which were investigated in 
the analysis to reveal the antibody fingerprints. Epitopes that were only targeted by antibodies 
of one serum were not substituted. Due to the very weak overall interaction of PS 16 and 17 
that was similar to the negative controls, no substitution analysis was performed.  
The antibody fingerprints of patients towards different epitopes on the VlsE antigen are 
listed in Table 2. The evaluation of all fingerprints, as shown in Figure 1, is depicted in 
Supplementary Figures S1 – S5. 
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Figure 2: Epitope mapping of 17 VlsE positive patient sera (PS) and 7 negative control sera (NC). 
From left to right, the position for each peptide in the VlsE protein is depicted. Fluorescence 
intensities were normalized to the maximum of each array. Increasing relative intensities are depicted 
from black to yellow. Patients were grouped according to the antibody response (Group 1: PS 1-7 and 
Group 2: PS 9-14, PS 8 and 15 – 17 not classifiable). The five immunodominant parts of the VlsE 
antigen that were chosen for fingerprint analyses are highlighted in different colors. Top part of the 
figure is based on [135].  
Figure 3: Original fluorescence scan images of 4 exemplary epitope mappings. Peptide microarrays 
were incubated with sera and fluorescently labelled secondary antibodies. Maximum intensities differ 
from 130 a.u. (NC 4) to 65,300 a.u. (PS 12). Control frames consisted of alternating peptide spots with 
an amino acid sequence derived from the polio virus. Antibodies of most individuals show strong 
interaction with this peptide due to the common vaccination against polio (scale bar 0.5 cm). 
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Table 1: Overview of peptides and sera that were investigated in substitution analyses. Peptides are 
grouped according to the position of the amino acids in the antigen. For each serum and epitope, the 
peptide with the highest fluorescence intensity was chosen for the substitution analysis. 
 VlsE 20 - 40 VlsE 171–186 VlsE 228-242 VlsE 249-267 VlsE 338-357 
PS 1 VADKDDPTNKFYQSV     
PS 2 VADKDDPTNKFYQSV    RKVGDSVKAASKETP 
PS 3 INCKSQVADKDDPTN   KKPEEAKNPIAAAIG DSVKAASKETPPALN 
PS 4 INCKSQVADKDDPTN    DSVKAASKETPPALN 
PS 5  KGIKEIVEAAGGSEK   DSVKAASKETPPALN 
PS 6 INCKSQVADKDDPTN    LRKVGDSVKAASKET 
PS 7 INCKSQVADKDDPTN    LRKVGDSVKAASKET 
PS 8  GIKEIVEAAGGSEKL    
PS 9   VSGEQILSAIVTAAD PEEAKNPIAAAIGDK  
PS10   VSGEQILSAIVTAAD   
PS 11   VSGEQILSAIVTAAD PEEAKNPIAAAIGDK LRKVGDSVKAASKET 
PS 12  GIKEIVEAAGGSEKL VSGEQILSAIVTAAD EAKNPIAAAIGDKDG  
PS 13   VSGEQILSAIVTAAD PEEAKNPIAAAIGDK  
PS 14   VSGEQILSAIVTAAD   
 
3.3 Spatial position of antibody fingerprints 
Amino acids that were identified in the substitution analysis to be essential for the binding of 
antibodies of several patients are highlighted in color on the three-dimensional structure of 
two chains of the tetrameric VlsE antigen (Figure 4). These amino acids are part of the 5 
epitopes that were identified in the epitope mapping. All essential amino acids are part of 
conserved alpha-helical structures. The structure of the N- and C-terminal parts seems to be 
quite flexible [135]. The N- and C-terminal epitopes (green and orange) are located on the 
surface at the membrane proximal site of the antigen. The other 3 epitopes (pink, cyan and 
blue) are oriented primarily towards the inside of the protein, partly shielded by variable loop 
structures. However, the molecular surface depicted in Figure 4-B and 4-D also contains some 
residues that are accessible from the outside. The amino acids that are essential for the 
binding of the antibodies are preferably located on only one side of the helical structures. 
 
3.4 Bioinformatic analysis of fingerprints 
The investigation of the exact amino acids that are essential for the binding of the antibody to 
its epitope, allows for a bioinformatic analysis of potential cross-reacting proteins. Therefore, 
the query can either help in ruling out cross-targeted organisms for diagnostic purposes or 
serve for the identification of cross-targeted antigens. A query of the ”UniProtKb/TrEMBL” 
(release 18-Jan-17: 73711881 entries) and “UniProtKB/Swiss-Prot” (release 18-Jan-17: 
553474 entries) protein databases with the “ScanProsite tool” [106] for the identified 
fingerprints resulted in numerous hits on human proteins. All potentially cross-reacting 
human proteins are listed in Supplementary Tables S2 – S6. Table 3 lists the fingerprints, 
which were used for the database query.  
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For the identification of human proteins that are involved in already known autoimmune 
disorders, all database entries of the query were cross-checked with the AAgAtlas, an online 
database of the National Center for Protein Sciences (Beijing) [136]. The database contains 
1,126 autoantigens that were collated from the literature. Table 3 additionally lists all proteins 
of the database query that potentially play a role in autoimmune disease and might be 
connected to antibodies induced by the VlsE antigen.  
It has been reported that among others, infections with the human parvovirus 19 [137], 
herpes simplex virus 2 [138], varicella-zoster virus [139], Epstein-Barr virus, and 
cytomegalovirus [140] cause similar symptoms as Lyme disease and also cause false positive 
Lyme disease test results due to antibody-based cross-reactions. Therefore, the 
”UniProtKb/TrEMBL” (release 18-Jan-17: 73711881 entries) and “UniProtKB/Swiss-Prot” 
(release 18-Jan-17: 553474 entries) protein databases were queried with the “ScanProsite 
tool” for homologies of the fingerprints with the latter viruses. The short motif D-P-T-N can 
be found on proteins of cytomegalovirus and varicella-zoster virus. The fingerprint I-x-
(ADE)-I-x-(ADE)-A-A is shared by the EBN_A-3A protein of Epstein-Barr virus 
(A0A0C7T0J9), all other fingerprints are specific for B. burgdorferi, when compared to the 
mentioned viruses. 
 
4. Discussion 
The role of the VlsE antigen in Lyme disease remains elusive. Nonetheless, it serves as a 
reasonable diagnostic marker either as protein or as peptide fragments (C6 of IR6 region) 
[129]. With substitution analyses, we have investigated the role of single amino acids 
regarding their importance for antibody binding to immunodominant epitopes (also see 
[120]). In this present study, we demonstrated for the first time that, if the same VlsE epitope 
is targeted by antibodies, almost identical amino acids of the epitope are crucial for the 
formation of the antibody-antigen complex in different individuals. A comparison of these 
essential amino acids in three epitopes located on the variable domain with a sequence 
similarity analysis [127] revealed that these amino acids are located on conserved regions on 
the antigen between its variable parts.  
However, our epitope mapping revealed little to no interaction with peptides covering the IR6 
region. The established C6 ELISA test is based on a 26mer peptide, which could explain our 
lack of antibody responses with only 15mer peptides. Yet, Chandra et al. [130] observed 
interactions of almost all investigated PTLDS and post-Lyme healthy patients with 14mer 
peptides covering the IR6 region. These differences can be explained with (1) in our case 
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lower concentrations of antibodies and (2) different surface properties. It is known that 
surface properties such as the density of peptides influence peptide array experiments [141]. 
In comparison to Chandra et al., our number of positive signals was much lower, which is 
most likely caused by a specific surface modification. 
Figure 4: Three-dimensional structure of the VlsE antigen. Detailed view of the secondary structure 
(A and C) and molecular surface (B and D) are depicted using the PyMol (Schrödinger, 
pymol.org/dsc/) molecular visualization system, based on RCSB PDB (www.rcsb.org) 1L8W [135] 
Conserved amino acids of the fingerprint regions identified in the substitution analysis are highlighted 
in the specific colors from Fig.2 and face mainly to one side of the protein. The figure shows two of 
four subdomains of the tetrameric protein. The structure of the N- and C-terminal end has not been 
completely defined and differs in the subdomains. To illustrate the spatial position of the epitope at the 
N-terminal amino acid position 20 – 40, the fingerprint PTN (orange) was extended by the amino 
acids KFY. 
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Especially, peptides with one or more positively charged (e.g. lysine) residues tend to 
induce strong unspecific interaction (personal communication). To prevent unspecific 
antibody interaction with peptides containing positively charged residues, PEPperPRINT 
usually synthesizes an aspartic acid as the C-terminal amino acid to every peptide. This may 
cause a loss in binding events in this particular case, but it also increases the overall 
specificity of the assay. 
In the study of Chandra et al. [130], the N- and C-terminal parts of VlsE were preferably 
targeted by one patient group, in addition to the epitopes on the variable domain, which were 
targeted by both groups. Based on 4 prominent epitopes, we could identify in a similar 
manner two main groups targeting either the N- and C-terminal parts (7 patients) or conserved 
regions in the variable domain (6 patients). However, due to the lack of patient disease 
history, no conclusion can be drawn from these findings. Two patients only recognize 
epitopes that cannot be classified as part of the two main groups. Another two of the 17 VlsE 
positive patients show similar signal intensities as the negative controls, leaving the questions 
open, whether these are truly positive samples or whether a linear peptide approach is 
applicable for these samples. 
Nevertheless, our fingerprint analyses enable queries of databases for potentially cross-
targeted human proteins. The query of the “UniProtKb/TrEMBL” and “UniProtKB/Swiss-
Prot” protein database with the “ScanProsite tool” revealed several human proteins sharing 
the identified fingerprint D-P-T-N of the epitope VlsE 20 – 40, of which 5 proteins have 
shown to play a role in autoimmune disorders. The number of identified proteins for this 
epitope is large due to the short sequence of the fingerprint of only four amino acids. 
However, a relation between antibodies induced to this epitope and autoimmune reactions 
cannot be ruled out and must be investigated in further studies. Additionally, the substitution 
analysis allows for the identification of microorganisms and viruses inducing cross-reacting 
antibodies that cause false positive results in standard Lyme disease tests. As three of the 
identified fingerprints are specific only for B. burgdorferi, they can serve as reliable 
diagnostic marker preventing false positive results. Future studies with peptide arrays, 
representing all known variations of the antigen, can give further insights. 
Concluding, our results clearly show that there are at least two groups of individuals 
targeting two different domains of the VlsE antigen. Yet, if the same domain is targeted, the 
essential amino acids responsible for the epitope binding are highly conserved. Therefore, the 
study serves as proof-of-principle for the disease specificity of fingerprints on VlsE sub-
epitope level and proves their potential for diagnostic purposes and cross-reactivity studies. 
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Table 2: Antibody fingerprints of sera for the substituted epitopes on the VlsE antigen. The bold and 
colored printed rows show the original amino acid sequence of the substituted peptides. The colors 
(compare Figure 2) indicate different positions on the antigen. For each serum and position, the amino 
acids that allow for the binding of the antibody (≥ 60 % relative fluorescence intensity) are listed in 
ascending order of the relative intensity. If 7 or more amino acids allow for the binding, the position is 
indicated with an x. The exact fingerprints with all amino acids allowing for the binding are shown in 
Supplementary Figure S1 – S5. Conserved amino acids required for detection by the sera are 
highlighted in grey. 
Serum Amino acid sequence 
 I N C K S Q V A D K D D P T N K F Y Q S V 
1       x x x K x D P T N x F x x x x 
2       x x x x x 
SYW 
RD 
x 
SDW 
YT 
x x x x x x x 
3 
DFAC
I 
x x x x x x x D x D D P T N       
4 x x x x x x x x D x D D P x x       
6 x x x x x x x x x x x D P MT N       
7 x x x x x x x x x x EFYD D P T N       
 K G I K E I V E A A G G S E K L      
5 x 
NGS 
TED 
I x DE I V ED AE A x x x x x       
8  x x x x x x x x x x x x E x IL      
12  x 
VWFI
L 
x AED I x ADE A A AG 
DTG
AS 
TAS x x x      
 V S G E Q I L S A I V T A A D       
9 x x x ADE x 
FDAV
I 
LS 
QYT
AS 
SA AIV x x x x ID       
10 
PIYS
TV 
RVSP
T 
ATGS SDE x IV L x x LVI IVST SVT x x x       
11 x S G DE 
SMQ 
ED 
VI L x x x ITEV SVET x x 
VETY
D 
      
12 x x QGP E x I L x A VLI 
MSI 
VLT 
EST x x 
YVE 
DST 
      
13 x EDST AGPS DE x LIV L 
AMT
DSE 
A I VT 
DVTS
E 
x x 
STYE
D 
      
14 x x G 
TSNE
D 
x I L x 
LDA 
ME 
I VI ST MTS x x       
 K K P E E A K N P I A A A I G D K D G   
3 x x AIQP AE E x K x P x x x x VPTI x       
9   x x x x x N APT I 
DQT 
MAE 
x A IL x ESTD x     
11   x x x x MK N P I 
SAM 
QE 
ADE A LI x MIED x     
13   x x x x x N P I 
MDQ 
SAE 
VTDS
AE 
A 
MTIV
L 
x x x     
12     x x x N P I 
QSM 
AE 
x x MTLI x x x x x   
 L R K V G D S V K A A S K E T P P A L N  
2  x x x x x x x x 
WYC
FDA 
A x x x x x      
6 x x x x G ED SGA x RMK A A IVTS K x x       
7 x x x x G ED SGA x 
VSR 
TKM 
A EA VEST K x x       
11 x x x x G DTSN S x DK x X x x 
KLFC
DE 
x       
3      x x x x x x x K E x P P x L N  
4      x x x x x x x x E x P ASP x PL N  
5      x x x x x x x K x TDS P 
QAN 
SPD 
GDT 
APS 
FYL N  
3.2 Antibody fingerprints in Lyme disease deciphered with high density peptide arrays 49 
 
Table 3: Fingerprints used for the query of the “UniProtKb/TrEMBL” and “UniProtKb/Swiss-Prot” 
protein databases with the “ScanProsite tool” on all human proteins. The fingerprints with the 
respective amino acid sequences that were used for the queries are shown in column 2. All resulting 
hits are listed in Supplementary Tables S2 – S6. Human autoantigens that potentially cross-react with 
antibodies assumed to be originally induced by the VlsE antigen of B. burgdorferi are listed in column 
3. Column 5 shows exemplary autoimmune disorders that are presumably connected with the 
respective autoantigen.   
Epitope Fingerprint Protein (Gene Code) Exemplary disease 
VlsE 20 – 40 D-P-T-N 
Epididymis secretory sperm binding 
protein Li94n, Stress-induced-
phosphoprotein 1 (Hsp70/Hsp90-
organizing protein) (STIP1) 
Autism spectrum disorder 
[142] 
Glycoprotein receptor gp330, 
Megalin, (LRP2) 
Thyroiditis [143] 
Proprotein convertase 
subtilisin/kexin type 1 (NEC1) 
(PCSK1) 
Endocrine system disease 
[144] 
Ubiquitin conjugation factor E4A 
(UBE4A) 
Crohn's disease [145] 
Ubiquitin Specific Peptidase 4, 
Proto-oncogene (USP4) 
Systemic lupus 
erythematosus and 
Sjogren's syndrome [146] 
VlsE 171 – 186 
I-x-(ADE)-I-x-(ADE)-
A-A 
  
VlsE 228 – 242 
(GP)-(ADE)-x-(LIV)-
L-x-A-(LAVI)-(ISVT)-
(SVET)-x-x-(DTSVE) 
  
VlsE 249 – 267 
N-P-I-(SAMQE)-x-A-
(TLI) 
Carboxypeptidase E (CPE) 
Acquired metabolic 
disease [147] 
VlsE 338 – 357 
Part 1 
G-(ED)-(SGA)-x-K-A-
A-x-K 
  
VlsE 338 – 357 
Part 2 
K-E-x-P-(ASP)-x-L-N   
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Abstract 
The antibody species that patrol in a patient's blood are an invaluable part of the immune 
system. While most of them shield us from life-threatening infections, some of them do harm 
in autoimmune diseases. If we knew exactly all the antigens that elicited all the antibody 
species within a group of patients, we could learn which ones correlate with immune 
protection, are irrelevant, or do harm. Here, we demonstrate an approach to this question: 
First, we use a plethora of phage-displayed peptides to identify many different serum 
antibody binding peptides. Next, we synthesize identified peptides in the array format and 
rescreen the serum used for phage panning to validate antibody binding peptides. Finally, we 
systematically vary the sequence of validated antibody binding peptides to identify those 
amino acids within the peptides that are crucial for binding “their” antibody species. The 
resulting immune fingerprints can then be used to trace them back to potential antigens. We 
investigated the serum of an individual in this pipeline, which led to the identification of 73 
antibody fingerprints. Some fingerprints could be traced back to their most likely antigen, for 
example the immunodominant capsid protein VP1 of enteroviruses, most likely elicited by the 
ubiquitous poliovirus vaccination. Thus, with our approach, it is possible, to pinpoint those 
antibody species that correlate with a certain antigen, without any pre-information. This can 
help to unravel hitherto enigmatic diseases. 
 
1. Introduction 
Evolution designed our antibody-based immune system to tackle infectious diseases, which is 
shown by the fact that we are likely to die – especially from infections with encapsulated 
bacteria – if our humoral immune system is compromised [148]. Depending on his or her 
individual history of infections, every person clonally expands presumably thousands of 
different antibodies producing B cell clones, which secrete the bulk of the 11 mg IgG 
antibodies per mL blood serum [8].  
These “amplified” antibody species are selected from a plethora of different antibodies. 
The antibody repertoire stems from the random combination of gene segments and clonal 
selection, which is triggered by specific binding to a pathogen's antigen. Eventually, most of 
these selected antibody species are further refined in their binding characteristics by random 
point mutations and somatic hypermutation [1].  
In today's typical antibody-based diagnostics, the disease status is concluded from the 
binding of a patient's serum antibodies to one or a few proteins [149]. This protein-specific 
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binding is possible despite the randomness in antibody generation: Immunoblotting 
techniques validate that only a limited number of proteins of a pathogen are targeted [44, 
150]. Thus, the immune systems of different individuals seem to commonly prefer only a few 
proteins out of thousands of potential antigens of a bacterial pathogen or in autoimmune 
disease. However, quite a few basic scientific questions are still unanswered: Do the immune 
systems of different patients not only target the same proteins, but also similar epitopes? And, 
more importantly, could we get clues about the cause of an enigmatic disease from a 
determination of all epitopes of the “amplified” antibodies? 
There have been many different approaches to analyze the diversity of a patient's 
individual antibody repertoire. In 2009, Weinstein et al. [56] used high-throughput sequencing 
to find out that the majority (> 50%) of all possible V, D, J gene segment combination is 
indeed present in zebrafish to constitute its immunoglobulin diversity, adding support to the 
idea of an essentially random generation of antibody species. Recently, high-throughput DNA 
sequencing of immunoglobulin genes (Ig-seq) has been introduced, which allows for the 
quantitative read out of molecular information of the humoral immunity [57, 58]. However, 
both techniques rely on the conclusion that the full antibody repertoire can be deduced from 
the gene expression at a certain time point. This expression might be somewhat different to 
the actual diversity and specificities of antibodies.  
Functional screens have been used to directly determine the antigen targets. Crompton et 
al. used protein arrays to find out that up to 41% of the displayed proteins from the malaria 
pathogen Plasmodium falciparum are targeted by the serum antibodies of patients [151]. By 
focusing antigenic attention upon irrelevant or highly variable epitopes, also referred to as 
deceptive imprinting [152], the malaria pathogen makes it extraordinarily challenging to 
develop an efficient and targeted vaccine. The Johnston group used spotted arrays with some 
10,000 random peptides that were stained with patient sera to discover patterns of stained 
peptides that indicated a growing cancer, a vaccination, or an infection [153, 154, 155]. In a 
similar approach, Wang et al. used phage displayed peptide libraries [156, 49, 50] to identify a 
pattern of targeted peptides that indicated a growing prostate cancer [53]. Xu et al. generated a 
phage library, displaying proteome-wide peptides from all known human viruses, to discover 
viral epitopes that are targeted by serum antibodies from human sera [54]. Screening random 
peptide libraries with mouse or human serum antibodies also allowed to distinguish healthy 
mice from mice that were infected with helminth parasites [157] or to pinpoint rheumatoid 
arthritis specific antigens [158]. Moreover, Reineke et al. used the SPOT method from Ronald 
Frank [64] to synthesize arrays with some 5500 random peptides to identify linear peptides, 
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which served as surrogate binders (“mimotopes”) for known conformational antibody 
epitopes [73].  
Figure 1: Workflow. In an initial pre-screen, up to 10
9
 random peptides displayed on phage were 
screened for their binding to serum antibodies, immobilized on beads. Next, the identified epitope 
peptides were validated with solid material-based peptide microarray technology. Finally, the 
validated epitopes were fine mapped by comprehensive substitution analysis. The resulting “epitope 
fingerprints” enable the identification of those proteins that match the antibody specificity, and, 
eventually, the correlation to disease causing agents. 
 
However, two technical bottlenecks still have to be overcome before we can access the 
complete information embodied in antibodies patrolling in a patient: (i) the synthesis of 
peptide arrays is still expensive, and (ii) we would need to know exactly which amino acids 
within a binding peptide are crucial for the binding of many different antibody species. The 
second point is necessary to query data bases for potential target proteins of serum antibodies, 
which might play a role in an enigmatic disease. 
Here, we combined next generation sequencing of a phage display peptide library [159] 
with our novel solid-material-based synthesis method for high-density peptide arrays, 
enabling densities of over 10,000 peptide spots per cm
2 
[88, 67, 89, 91, 90]. For the latter, 
either a laser printer [67] or a laser scanning system [90] is used to structure a synthesis 
surface with ≥ 20 different amino acid building blocks, which are embedded in a solid matrix 
material. Then, a simple heating step starts the coupling reaction by melting the matrix 
material. Parallel synthesis on the same array surface is achieved by repeating these steps for 
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the different amino acid building blocks, until the desired peptide length is reached. This large 
number of peptides not only allows for an almost comprehensive coverage of entire genomes 
but also for substitution analyses: Systematically substituting every amino acid position in a 
sequence of a specific antibody-binding peptide with every other amino acid, it is possible to 
identify the key residues for each epitope. This approach allows us to evaluate the specificity 
of an antibody down to the individual amino acid level and refines the profiling of the 
antibody repertoire (see workflow in Figure 1). It reveals the original epitopes of a patient's 
antibodies or the mimotopes, and can also uncover potential cross-reactivity [73]. Thus, 
besides gaining knowledge on the antibody repertoire, our principle may be useful for 
elucidating clinical phenotypes with unknown disease antigens, without any a priori 
knowledge. 
 
2. Results 
In this study, we investigated the potential of a novel three step screening pipeline to 
comprehensively read out the antibody specificities in the serum of a donor subject. We 
combined phage display pre-screening with a subsequent two-step peptide microarray 
analysis. First, a serum was analyzed using an epitope phage display panning followed by 
DNA sequencing. Then, the resulting binders were synthesized on laser-generated high 
diversity peptide arrays and incubated with the original serum. Subsequently, epitopes of 
identified binders were synthesized again on laser-generated high diversity peptide arrays, but 
this time with variants representing a complete substitution analysis set: We generated 
12 × 19 = 228 individual variants of each 12mer peptide, where each amino acid position of 
the original sequence is substituted one by one with all other 19 amino acids. These analyses 
resulted in 73 antibody fingerprints. We could identify four different motifs that were present 
in several peptide binders. These four motifs were used to query public protein databases. 
 
2.1 Validation arrays 
Phage display with 12mer peptide presenting phage was carried out in three panning rounds. 
The peptide encoding DNA fragments of bound phage of panning rounds two and three were 
sequenced and in silico translated into amino acid sequences. For both panning rounds 
together, the sequencing resulted in a total of 38,533 different 12mer peptides. These peptides 
were synthesized on 10 different arrays with up to 4128 peptides as spot duplicates per array 
and incubated with the serum. Fig. 2A shows the fluorescence scan of an array that was 
stained with the serum. 
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The fluorescence intensity of each peptide was analyzed by calculating the average of spot 
duplicates. For each array, a threshold was defined. Peptides showing higher intensities than 
this threshold were further analyzed in the following substitution analysis. Fig. 2B shows the 
intensity distribution plot of the array in Fig. 2A. The threshold was set to an intensity value 
of 1000 a.u. and at least 0.15% of the peptides of each slide (4128 peptides) with the highest 
fluorescence intensity were substituted. The screens resulted in 97 peptides which exceeded 
the threshold. 
Figure 2: Example peptide array staining and intensity distribution plot. (A) Fluorescence scan image 
of a validation peptide array with 4128 peptide spots duplicates, which were identified by phage 
display on human serum. The array was stained with the same serum DL680 conjugated secondary 
antibodies. Bright double spots correspond to peptides that were strongly bound by antibodies. 
Contrast and brightness were optimized, scale bar 0.5 cm. (B) Intensity distribution plot of the peptide 
array with the threshold (red line). The mean fluorescence intensity of the spot duplicates was plotted 
over the peptides. Peptides were sorted according to the row and column on the slide. (For 
interpretation of the references to color in this figure legend, the reader is referred to the web version 
of this article.)  
 
2.2 Substitution analysis 
For the substitution analysis, each of the 97 validated 12mer binders was synthesized in 
12 × 19 = 228 peptide variants and 12 original sequences as 240 duplicate spots and incubated 
again with the serum. We screened a total of 23,280 different peptide double spots, resulting 
in 73 distinct fingerprints. Fig. 3 shows the fluorescence scan of a comprehensive substitution 
analysis of a typical peptide in spot duplicates. Each row represents the substitution at one 
position of the original peptide with 19 different amino acids (plus the original one), whereas 
each column corresponds to one of the 20 amino acids in alphabetical order in the one letter 
abbreviation. Thus, the impact of individual amino acids on the binding of the antibody can 
be assessed and the crucial amino acids identified. In several cases, minor amino acid 
variations had no impact on the binding activity. Peptide variants that showed a drop in 
intensity of > 50% in comparison to the original binding intensity were not considered as 
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binders. If 5 or more substituted amino acids were found to allow for antibody binding, the 
position was considered as non-essential. 
Figure 3: Substitution analysis with each amino acid position substituted by all 19 other amino acids. 
(A) Example fluorescence scan image of a substitution analysis of a 12mer peptide, consisting of 12 
spot duplicate rows and 20 amino acid columns. From top to bottom left, the original sequence is 
shown in bold next to the scan image. Amino acids that were essential for the binding of the antibody 
are highlighted in green. Contrast and brightness were adjusted. (B) Relative fluorescence intensities 
in reference to the original amino acid in the substituted peptide sequence. Each peptide variant is 
represented by the letter of the amino acid that was synthesized at the respective position. The original 
sequence is depicted on the x-axis. The intensity of the peptide with the original amino acid was set to 
100%. Intensities of peptide variants were correlated to the intensity of the original peptide in each 
row respectively. 
 
2.3 Identified peptide binders 
All 73 peptides that showed distinct signals in the substitution analysis were re-validated on 
another microarray. The obtained intensity values were transformed with the inverse 
hyperbolic sine (arsinh) [160].  
Table1: Identified peptide binders. Essential amino acids at each position of the peptide are depicted 
and relative binding strength is indicated by the transformed fluorescence intensities. Amino acids of 
the original peptides are depicted in red. Peptides with similar binding motifs are grouped and 
separated; the last group is heterogeneous with no similarities. 
 
58 3.3 Single amino acid fingerprinting of the human antibody repertoire 
 
 
Original  
peptide  
sequence 
Amino acid position in epitope Transformed  
original intensity 
1 2 3 4 5 6 7 8 9 10 11 12 
NPVEXXX motif 
NPVEDYLDYSVI N P V,I E X X X X X X X X 8.371 
ESYYMNPVEMFV X X X X X N P V E X F,Y I,V 7.312 
LPTESNPVEDWI X X X X S,T,V,R N P V E E,D !P I,V 7.091 
NPIESYIASVFS N,D P X E X Y X X X X X X 6.774 
NPVELLLKTSSD A,N P V,A E X X X X X X X X 6.366 
NPVETQIVLSLV N P,N,Y V,P E,Y !P !P !P !P X X X X 5.937 
NPVEKWISMRTM N P,Q,Y V E !P !P I X X X X X 5.896 
NPVELLLLMGIS N P V E X X I,V,L,T X X X X X 5.733 
NGIERLLEEPVS X X I E !P L I,L,V X X X X X 5.729 
NPVENWIDPKSI N N,P,A V,A,P E,V,A !P !P X D,I,E X X X X 5.614 
VNPVEYYLDTMR X N T,P,S V E !P X L E,D X X X 4.912 
NPVEALLSKFHM N P D,E,V E E,D,A,F X X X X X X X 3.567 
NPVESYLANYTS N T,N,P X E,V X X X X X X X X 2.521 
VTNPYESLVQEK X X N,D,S,G P,Q Y,I X X L,F X X E K 2.285 
XPEFXGSXX motif 
SPPEFSGSTVGL X V,I,P P E F X G S X P,V X X 9.334 
MVPEFSGSFPMR X P,I,V,A P E F X G S,A X P X X 9.173 
RMPPEFMGSLPQ X X X P E F X G S,T X P X 9.107 
QLFVPEFAGSSP X X X V,P,I P E F X G S X X 8.373 
LVPEFTGSTPFR X I,P,V P E F X G S X P,V,A X X 7.461 
SHGAIEFDGAFP X X X X X E F D G A,S F X 7.05 
VPEFAGHVPSTA V,I,P P E F X G X X A,V,P,I X X X 6.803 
VPEMNGSLIARK V,P P P,E,Q F,Y,L,M X X S S,L,T X X X X 5.954 
KXXFPQXT motif 
HPIVKTYFAQTT X X X X K X Y,F F X Q T,K,M,V T,V,I 6.234 
APAKTYFGQTTD X X X K E,T,V F,Y F X Q T,F T X 6.223 
QMKAWFPQTTYD X X K !P X F P Q X T,V X X 3.911 
ATKVMFPQRIYV X X K,E X X F P Q X T,I,V X X 3.249 
QPAKTYFNQVTL X X X K T,E F,Y F,Y X Q,Y X T,I X 3.21 
QAAAKTMFPQNT X X X X K T,E,Q X F P Q !P T 2.336 
LXAXETX motif 
SPSIDAFETSIF X P,Q X L,M,I,W D A X E,S T S X X 9.261 
SWVLTATETGSS X X X L,F T A X E T G,S X X 8.425 
EMRFPSLSASDT X X X X P S,G,A,P L T,S,N A !P E,D T 7.349 
QAPTLDAQETAL X X P X L T,S,D,N A X S,E,T T S,G,A,N X 7.248 
TALDAVSTGFSW X P,A,E,S L D A X E,T,S T G,S X X X 6.61 
GAIGSLTADSTS X X I,V P,G P,S,A L S,T A X X T N,S,R 6.573 
SLGSLSAYETGR X X X X L,F X A X E,D T X X 6.53 
TLYRPPLTSAET X X X X X X L T A,S A E X 5.963 
LIADLNAESTSR X X X D F,L,I,Y N,S,D,T A X S,T,D,E T S,T,N,G X 5.934 
SLGAAGARVTTV X X X X X X X X V,W X T,Y,W V,W,Y 5.808 
ASGPLHAGATGL X X X P,A L X A X X T N,S,G X 5.778 
GHKPVLTALSTA X X X P A,V,P L T A X X T S,G,A 3.738 
VMPAIHAGVTGA X X P A L,I X A G,A A,V,E T S,G X 1.942 
Heterogeneous motifs 
VHPTLTVTSKEI I,V D,E,H,N I,K,P,V T L,V K,M,T,L V X X K X X 7.237 
ELDVSLRVMPKV X X D X T,S V,T,L,I X V X X K X 7.028 
SKLAMEIMSGPV X X X X !P !P I !P S G P X 6.995 
SNAVTSSKSPRM D,T,S,N D,N A I,V,W T D,S,E X K X X X X 6.935 
QADATVLTKPKT X X D X T V,L X V,T K P,A,S K X 6.798 
KAVSDASRGTVF K X V,I,T,L S,T X X S,T R X X X X 6.716 
DYPKIANFQEYA X Y P X I X N F,Y X X X X 6.683 
GGQVRSIHSGPT X X X X X X I !P S G P T 6.589 
QHWPTNVDSVTV X X X X X X V D,E X V X X 6.548 
ETKSDDMLLSNV X X K X D D X L,I X T,S X X 6.407 
MTVDRTVRVASK X X X D X T,S L,V,T X V X X K 6.366 
DLLIRDAITDTK X X X X X N,D A I,V,T T D,S X K 6.359 
AYHVDTVSDAGW X X X V X T,S,E V,I X X X X X 6.324 
VDTINLPQNTIQ V,I D,E X V,I,T X X X X X X X X 6.095 
VMSVNASTTAAN V X X V N,D,E X X X X X X X 6.067 
TLHAPMTIRSGP X X X X X X T C,I X S,T G P 5.692 
TNLHRVMTVVNM X X X X X V X T V,R,I,S X X X 5.372 
LRPNAVQTDTLA X X P D,N A V Q X X X X X 5.319 
QMRQLTEYGSEK X X X X X X X F,Y X X E K 4.917 
VLSSTAIKVDSV X X X X X X X X V,L D,E T,S V 4.832 
VHTVHDVFTAFG V D,H,E,N T,D,S X X X X X X X X X 4.538 
AKIRMFLDTDYK X X X X X F L D T D !P K 4.315 
ASWGPIAIDRVN X X X X X X X V,I D !P X N,F 4.054 
SQQYALTNSTTN X X X X X X X N,A X T T,N N 2.89 
QPQTKSFYPQYV X X X X K T,S,E F F,Y P Q X T,I,V 2.878 
NVVDRVNRTGVV X X A,V D !P V A,N X X X X X 2.693 
WSALPERTSLPV X X X X T,P N,E X T,W,Y S,W,Y X P,W,Y X 2.315 
RPAIVDQVSSSP X X X X V D X V,T S,N X X X 2.217 
QWNWRVRSVANV X X X X Q,R,N,H V X T,S V X X X 2.097 
AQLHPTTLVKHK X X X D,E,H,N X T V,T,L X V K,Q X K 0.925 
TSYRPPLNVCQD X X X X P,Q X L N,C X X X X 0.884 
QSHSLFYPHPYG X X X X X X F,Y P,D,E,A H P X G 0.545 
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Table 1 shows a list of the original amino acid sequences of all successfully substituted 
peptides with the essential amino acid positions. Peptides which exhibited similar antibody 
fingerprints are grouped, separated by breaks. The last group is heterogeneous without 
significant similarities in binding motifs. The list is ordered according to the staining 
intensities on the control slide. For a detailed view on each peptide binder (analogous to Fig. 
3B), we refer to the Supplementary materials (Figs. S3–S7). 
 
2.4 Statistical analysis of epitope properties 
For the dataset shown in Table 1, we compared the length of the epitopes (i.e. the number of 
amino acid positions from the first to the last crucial position) with the number of essential 
amino acids per epitope (Fig. 4A), and we also analyzed the relative frequency of the number 
of possible amino acids at the crucial positions according to the length of the epitope (Fig. 
4B). Epitopes with a length of 8 amino acids and 5, 6, or 7 essential positions had the highest 
frequency (19 of 73 peptides). Epitopes of 9 amino acids with 7 essential positions, 8 amino 
acids with 7 essential positions, and 4 amino acids with 3 essential positions were identified 7 
times each. 
Figure 4: Statistical epitope properties. (A) Heat map of the number of peptides with a specific 
epitope length and the number of essential amino acids in the respective epitope. (B) Heat map of the 
relative frequency of possible amino acids at essential positions of the epitopes. 
 
Fig. 4B shows that the relative frequency of possible amino acids at essential positions in 
the epitopes with lengths between 5 and 9 is low. Thus, epitopes with the length of 5–9 amino 
acids seem to have more conserved binding fingerprints, with mostly one possible amino acid 
at one position. 
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2.5 Meme analysis 
A meme analysis [161] compares different sequences in regard to correlating amino acids. 
Thereby, it is possible to pinpoint amino acids that potentially play a role in the antibody 
binding. Yet, the meme analysis lacks the ability to identify essential amino acids if there is 
only one sequence of one type. In Fig. 5, meme analyses for selected peptides are shown. 
Motif A “NPVEXXX” was found in 14, motif B “XPEFXGSXX” in 8, motif C 
“KXXFPQXT” in 6, and motif D “LXAXETX” in 13 sequences. This implies that 41 of the 
73 binders might be caused by only 4 sequences. However, motif D shows a rather low E-
value, which can be interpreted as a coincidental finding. Thus, we assume that we found 48 
unique fingerprints or antibody binders respectively. 
 
Figure 5: Meme analysis of substituted peptide binders. Only motifs with a prevalence of > 3 and an 
E-value < 0.1 are shown, which results in 4 sequences. The sequences cover 41 of the 73 binders. 
 
2.6 Epitope binding variance over time 
Next, we evaluated the variance of the antibody response of a serum donor at different points 
in time. For the previous screens and analyses, the serum from the time point t = 24 months 
was used. Now, identical laser-generated high diversity peptide arrays, containing the above 
identified epitopes, were incubated with three different serum samples collected at 3 different 
time points, each about 24 months apart. Each serum was incubated on 9 arrays containing the 
previously identified epitopes as spot duplicates, resulting in 18 data points per epitope and 
serum. The intensity values were transformed with the arsinh function [160] and the average 
transformed intensity values were calculated for each serum. Fig. 6 and Fig. 7 show the 
average transformed intensity values of two groups: in the first group of peptides (Fig. 6) the 
average intensities at different time points do not differ significantly, in the second group 
(Fig. 7) at least two of the intensities of different time points show a significant difference. 
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Figure 6: Epitope profile of an individual donor at three different time points – group 1. Results are 
shown as transformed intensities for each peptide. Serum staining intensities at different time points 
do not differ significantly (Student's t-test two-tailed), 18 data points were acquired for each peptide 
and serum, mean values and standard deviations are shown. 
 
2.7 Validation of biological significance 
To validate that the fingerprint analysis can be performed with other patient samples, and also 
reveal different peptide binders, we have analyzed a second patient serum in a similar 
approach (see Supplementary materials Figs. S1, S2, and Table S1). We generated a peptide 
array with random amino acid sequences, incubated this array with the donor sample from the 
previous experiments, and stained with secondary antibodies. Afterwards, we incubated this 
array with a sample from a different patient, and also stained with secondary antibodies (Fig. 
S1). We selected those peptide binders, which showed a high reactivity only with the serum 
of the second patient. Finally, these peptides were screened in a substitution analysis, 
resulting in patient specific antibody fingerprints (Fig. S2, Table S1). 
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Figure 7: Epitope profile of an individual donor at three different time points – group 2. Results are 
shown as transformed intensities for each peptide. 18 data points were acquired for each peptide and 
serum. For at least two time points per peptide the differences in intensities were significant (Student's 
t-test two-tailed) with different p-values: ***p < 0.001; **p < 0.01; *p < 0.05. 18 data points were 
acquired for each peptide and serum, mean values and standard deviations are shown. 
 
2.8 Bioinformatic analysis of fingerprints 
The four most abundant fingerprints, shown in Fig. 5, were queried in the “UniProtKb/Swiss-
Prot” protein database (release 2016_11 of 30-Nov-16: 553231 entries) with the “ScanProsite 
tool” [106]. The query included splice variants (Swiss-Prot) and excluded fragments. All 
results of the query are listed in Supplementary tables S2–S5. However, most proteins are 
very unlikely to be the causative agent of the antibody species since they are either part of 
exotic organisms or would probably cause a noticeable autoimmune reaction. Therefore, the 
results that are most likely to be the causative antigen are listed in Table 2. 
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Table 2: Results of the query of the “UniProtKb/Swiss-Prot” protein database with the “ScanProsite 
tool” for the identified most prominent motifs. The amino acid sequences that were used for the 
queries are shown in column 2. The resulting number of hits and the respective Supplementary table, 
including all results, are listed in columns 3 and 4. Furthermore, the table shows the most likely 
causative agent and antigen, the amino acids of the epitope, and the position on the antigen. 
 
Motif 
Sequence for 
query 
Hits Table 
Potential 
causative agent 
Potential 
antigen 
Aa residues 
Aa 
position 
NPVEXXX 
A,N,D-N,P-
V-E-E,D,A,F-
F,Y-I,V,L 
32 S2 
Human 
cytomegalovirus 
Protein HHLF1 ANVEDYL 
575 - 
581 
Protein TRS1 ANVEDYL 
576 - 
582 
XPEFXGSXX 
V,I,P-P-E-F-
x-G-A,S-x-
V,P 
14 S3 
Staphylococcus 
aureus 
Extracellular 
matrix protein-
binding protein 
emp. 
VPEFkGSlP 
328 - 
336 
KXXFPQXT 
K,E-x-F,Y-
F,Y-P-Q,Y-
T,K,M,V,F-
T,V,I 
31 S4 - - - - 
LXAXETX 
L-D,T-A-x-E-
T-G,S 
102 S5 
Coxsackievirus 
Capsid protein 
VP1 
LTAvETG 620-626 
Echovirus 
Capsid protein 
VP1 
LTAvETG 600-606 
Human 
rhinovirus 
Capsid protein 
VP1 
LTAnETG 601-607 
Poliovirus 
Capsid protein 
VP1 
LTAvETG 623-629 
 
3. Discussion 
Antibodies protect us from life-threatening infections, but may also do harm in autoimmune 
diseases or, in an unfortunate genetic setting, lead to transplant rejection. Moreover, some 
antibody species have homeostatic tasks, for example band 3 specific IgG antibodies that 
mark old erythrocytes for phagocytosis [162] or antibodies that mark those cells for 
destruction that endured an oxygen deficiency in a stroke [163] or in a growing tumor. In any 
case it would be interesting to know the exact epitopes of all the antibody species that patrol 
in the blood of a patient, especially if the patient suffers from a clinical picture caused by an 
unknown antigen. We present a pipeline of methods that allows for a comprehensive read out 
of the human antibody repertoire and their specificities without a priori knowledge. We 
identified 73 antibody fingerprints from one patient serum by sequentially employing a pre-
screen with a phage displayed peptide library (38,533 binders), validating these potential 
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peptide binders in the array format, and finally identifying those amino acids that are crucial 
for antibody binding (97 binders in substitution analysis as 23,280 different peptides, 73 
validated and 48 unique fingerprints). The serum antibody specificities of the same donor at 
three different points in time over 4 years revealed that all found peptides were similarly 
targeted by serum antibodies at all time points. This might have two reasons: (1) Our method 
only allows for the identification of very stable antibody species, or, (2) our serum is mainly 
composed of a limited number of stable antibody species, whereas in times of infection, the 
repertoire is rapidly expanded. 
To identify the specificity of every antibody species in a patient's serum, we hypothesize 
that each type of antibody has at least one linear peptide binding epitope, whether or not it 
belongs to the original antigen or is a mimotope which binds due to a cross-reaction [73]. We 
also hypothesize that only a limited number of important epitopes per pathogen are shared by 
most patients. Previous studies could demonstrate that most of these epitopes consist of short 
motifs with a limited number of key residues [93, 164, 165]. Thus, if the diversity of a peptide 
library is large enough, it should be possible to characterize each antibody by at least one 
binding event. Recently, we have introduced a new technology which enables us to synthesize 
peptide arrays with a very high density of > 17,000 spots per cm
2
 [90] and thus makes studies 
with very high numbers of peptides affordable. Since this new flexible production method 
also allows for the synthesis of modified amino acids, together with recent developments in 
the synthesis of cyclic peptides, the search scope will even be expanded further in the future. 
We queried a public protein database for the four most abundant motifs that were found in 
several peptides in the substitution analyses, which were additionally identified in a MEME 
analysis. The resulting hits pointed to potential causing antigens. Most antigens are very 
unlikely to be the cause: They would either cause autoimmune reactions or originate from 
exotic organisms, which usually do not come into contact with the immune system. However, 
for three motifs, a potential causing antigen could be identified. Sophisticated bioinformatics 
should improve the interpretation of the database results. The capsid proteins VP1 of four 
viruses share the LXAXETX motif with the amino acids L-T-A-n/v-E-T-G. The epitope 
LTAVETG, part of the poliovirus, can be also found in the human epitope database 
(iedb.org). From personal communication with the company PEPperPRINT, we learned that 
the peptide KEVPALTAVETGAT shows interaction with > 90% of all European individuals, 
most likely due to the common polio vaccination. Furthermore, Cello et al. showed that all 
their investigated serum samples reacted preferably with the peptide PALTAVETGATNPL 
(underlined amino acids are conserved between different enterovirus types) in a peptide 
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ELISA [166]. Therefore, we are capable of identifying an antibody species that is very likely 
to be present in the investigated serum. For one of the four queried motifs, no obvious antigen 
could be detected. 
 
Conclusion 
We developed an approach which theoretically allows us to read out the complete humoral 
immune response of a patient without any a priori knowledge. Thereby, we can determine the 
specificity of an antibody to the single amino acid level, which we call the antibody 
fingerprint. We discovered 73 of these antibody fingerprints in a patient's serum. The 
bioinformatical analysis of one of the most abundant fingerprints led us to the antigenic 
capsid protein VP1 of the poliovirus. Due to the ubiquitous vaccination, it is very likely for 
the patient to have an antibody of this specificity. 
A study with a large group of healthy versus diseased patients and appropriate 
bioinformatics should allow for the identification of specific fingerprints that are 
characteristic for many different diseases or antigens and could help to elucidate enigmatic 
diseases. These studies might also answer the question if our approach can identify antibody 
species with low affinity and/or low concentration. Considering the diversity of still enigmatic 
diseases human mankind is facing, our approach could contribute to a better understanding of 
their symptoms or etiology. 
 
4. Material and methods 
4.1 Study design  
In this study, we investigated the potential of a novel screening pipeline approach to 
comprehensively read out the antibody specificities in the serum of a patient: We combine 
phage display pre-screening with a subsequent two-step peptide microarray analysis. The 
serum of a donor (approval by the ethics committee was acquired and informed consent was 
obtained) is analyzed in a phage display panning together with DNA sequencing. The 
resulting binders are then synthesized on peptide arrays and incubated with the original serum 
for validation of binding. Subsequently, these validated epitopes are synthesized again onto a 
peptide array, but this time in a substitution analysis mapping, by exchanging every amino 
acid at every position, to fine map the antibody binding. The validated peptide set was 
screened with two additional sera from the same donor from two other points in time, 
spanning a total of 48 months. The study was approved by the state chamber of physicians of 
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Baden-Wuerttemberg (reference number: F-2011-044 and F-2011-044#A1). The serum of a 
second individual (ethical clearance was obtained from the institutional review board (IRB) of 
the Medical Faculty of Heidelberg University and informed consent was obtained) was 
investigated in a similar approach to show biological significance. 
 
4.2 Phage display 
Panning round 1: Supernatant of 20 μL 30 mg/mL ProteinA Dynabeads (0.6 mg beads bind ~ 
5 μg hIgG) was removed in a magnetic base and beads were washed twice with 500 μL 
Phosphate buffered saline (PBS). 5 μL of serum was diluted in 200 μL PBS, added to the 
beads and incubated with end over end shaking for 30 min to allow the antibodies to bind to 
the protein A. 500 μL of blocking buffer (10 mg/mL BSA (Fraction V pH 7) in 1 × PBS with 
0.1% Tween20) was added with 5 μL of serum to the beads and again incubated with end 
over end shaking for 30 min at room temperature. Afterwards beads were washed 3 times 
with 500 μL PBS-T (0.1% Tween20). 1 × 1011 phage of a PhD12 library (NEB) (10 μL 1 × 
10
13
 pfu/mL, 100 × overrepresentation) in 200 μL PBS-T (0.1% Tween20) were added to the 
beads and incubated for 1 h at room temperature under shaking. Supernatant was removed in 
a magnetic base and beads were washed 10 times with 500 μL PBS-T (0.1% Tween20). 
Elution of phage was done with 500 μL 0.2 M GlycinHCl at pH 2.2 for 10 min at room 
temperature. Eluate was collected and neutralized with 75 μL of 1 M TrisHCl, pH 9.1. For 
amplification of eluted phage, 30 mL E. coli (ER2738 OD600 ~ 0.05) were infected with 
these and grown for 4.5 h at 37 °C and 250 rpm. Bacteria were removed by centrifugation for 
20 min at 4000 rpm and 4 °C, supernatant was added to 1/5 volume of PEG/NaCl (20% (w/v) 
PEG 6000, 2.5 M NaCl) and incubated over night at 4 °C. Phage-PEG/NaCl suspension was 
centrifuged at 4000 rpm and 4 °C for 1 h. Supernatant was discarded and phage pellet was 
suspended in 500 μL PBS, centrifuged again for 2 min at 14,000 rpm and stored at 4 °C. For 
titration, 10 μL of two dilutions (10–1 and 10–3) of the eluted phage, resulting in 10–3 and 10–5, 
were plated in top agar. 200 μL of E. coli (ER2738 OD600 ~ 0.5) were added to 10 μL of the 
dilution and incubated for 2 min. Culture was added to 3 mL of top agar (~ 45–50 °C, 0.7% 
Agar) and poured on pre-heated LB/IPTG/Xgal plates (1.5% Agar, 50 mg/L IPTG, 40 mg/L 
Xgal). After cooling of agar the plates were incubated at 37 °C over night. Titration of the 
eluted phage of the first panning round resulted in 2.6 × 10
6
 pfu/mL. 
Panning round 2: ProteinA Dynabeads were washed blocked and incubated with serum as 
in panning round 1. For pre-incubation of amplified phage 10 μL of beads were washed twice 
with PBS-T, blocked with blocking buffer for 20 min, washed again three times, added to 
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~ 1 × 10
11
 amplified phage of the last panning round in 200 μL PBS-T (0.5% Tween20) and 
incubated for 20 min at room temperature under shaking. Pre-incubated phage were added to 
the antibody beads and incubated for 1 h at room temperature under shaking. Washing, 
elution and neutralization was again done as in panning round 1. Amplification of eluted 
phage was performed as done in panning round 1. For titration, 10 μL of two dilutions (10–1 
and 10
–3
) of the eluted phage and 10 μL of the 10–9 dilution (resulting in 10–11) of amplified 
phage were plated in top agar. Titration was then performed as in panning round 1. Titration 
of the eluted phage of the second panning round resulted in 4.64 × 10
7
 pfu/mL, titration of the 
amplified phage of the first panning round resulted in 2.36 × 10
13
 pfu/mL. 
Panning round 3: Panning, amplification and titration were performed as in panning round 2. 
Titration of the eluted phage of the third panning round resulted in 1.112 × 10
9
 pfu/mL, 
titration of the amplified phage of the second panning round resulted in 3.4 × 10
13
 pfu/mL. 
 
4.3 Next generation sequencing 
Preparation of phage DNA for NGS: 10
12–1013 phage particles were mixed with 1/5 volume 
of PEG/NaCl (20% (w/v) PEG 6000, 2.5 M NaCl) and incubated on ice for two hours. Phage-
PEG/NaCl suspension was centrifuged at 14,000 rpm and 4 °C for 15 min. Supernatant was 
discarded and pellet was thoroughly dissolved in 63 μL NaI solution (10 mM Tris-HCl pH 8, 
1 mM EDTA, 4 M NaI). 156 μL ethanol (100%) was added and the solution was incubated on 
ice for two hours to precipitate DNA. Solution was centrifuged at 14,000 rpm and 4 °C for 15 
min and DNA pellet was washed in 200 μL 70% ethanol to remove residual salt. Solution was 
centrifuged again at 14,000 rpm and 4 °C for 15 min. Supernatant was discarded and DNA 
pellet was air dried for 15–20 min at room temperature. The precipitated DNA was further 
purified using phenol–chloroform extraction. The DNA pellet was resuspended in 300 μL 
water and transferred to a 2 mL PhaseLock tube. An equivalent amount of phenol–chloroform 
(1:1 v/v) was added, shook thoroughly and centrifuged at 14,000 rpm for 1 min. An additional 
equivalent amount of phenol–chloroform (1:1 v/v) was added, shook and centrifuged again at 
14,000 rpm for 1 min. The aqueous layer (~ 300 μL) was transferred into a new microfuge 
tube and 30 μL NaAc solution (3 M, 30 μL) and 600 μL 100% ethanol was added. The 
solution was incubated at − 20 °C for 2 h to precipitate DNA. Solution was centrifuged at 
14,000 rpm and 4 °C for 15 min and DNA pellet was washed in 400 μL 70% ethanol to 
remove residual salt. Solution was centrifuged again at 14,000 rpm and 4 °C for 15 min. 
Supernatant was discarded and DNA pellet was air dried for 15–20 min at room temperature. 
DNA was resuspended in 30 μL RNAse free water and stored at − 20 °C. 
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Peptide DNA amplification for NGS: DNA isolated from the amplified phage was 
subjected to PCR amplification with primers flanking the variable region (For-primer: 
TATTCTCACTCT, Rev.-primer: CGAACCTCCACC). For each panning round, unique 
nucleotide-barcodes were added to the 5` end of the primer. The PCR mixture contained 1 × 
Phusion HF buffer, 1 U Hot Start Phusion Polymerase, 200 μM dNTPs (each), 500 nM For- 
and Rev.-primer and 100 ng phage DNA template. For amplification the following 
temperature regimen was employed: 30 s incubation at 98 °C, followed by 35 cycles of PCR 
amplification at 98 °C (10 s), 54 °C (10 s), and 72 °C (30 s) and a final step at 72 °C (5 min). 
The PCR products were run on a 2% (w/v) agarose gel in TBE buffer. Peptide DNA bands (~ 
75 bp) were excited from the gel and DNA was extract from the gel slices using the 
NucleoSpin Gel and PCR Clean-up Kit (Macherey-Nagel). DNA was eluted in 20 μL Buffer 
NE (5 mM TrisHCl pH 7.5) and stored at − 20 °C. 
NGS: Next generation sequencing libraries were made with the TruSeq ChIP library prep 
kit (Illumina). Briefly, PCR amplified fragments, 75 bp long, from the second and third 
panning rounds were pooled to reach a final concentration of 20 ng/μL in a final volume of 60 
μL. End repair and ends adenylation were made following manufacturer's instruction 
(Illumina) and DNA purified with the Minilute kit (Qiagen) following recommendations. 
Adapters with specific barcodes were ligated, libraries amplified by 10 cycles of PCR and 
finally purified on Minilute columns followings recommendations. Quality of the libraries 
was assessed on DNA1000 Chip (Bianalyser 2100, Agilent) and DNA concentration 
determined by fluorometric method (QBit HS kit, Life Technologies). Up to 3 libraries were 
sequenced on a single lane at 2 × 100 bp on a HiSeq1500 (Illumina). Demultiplexing and 
generation of the fastq files were performed with CASAVA v1.7 (Illumina). Bioinformatics 
processing of the reads were made using an in-house bash script. Briefly, reads (R1) passing 
the Illumina chastity filters were selected for subsequent analysis. First, reads with Phred 
score > 25 and perfect match to the generic phage display adapter (CGAACCTCCACC) in 
forward or reverse orientation were selected using fastx_toolkit v0.0.13 using the options -q 
25 -p 70. Barcodes were then trimmed and insert translated into peptide sequence using 
EMBOSS transeq. Finally, occurrence of distinct peptide sequences was computed in bash. 
 
 
4.4 Peptide arrays 
Validation arrays: The list of peptides obtained from sequencing was first filtered for peptides 
with the length of exact 12 amino acids. Peptide sequences of shorter length were discarded; 
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those with longer length were trimmed to the correct length by cutting the protruding amino 
acids at the C-terminus. Peptides containing a stop (*) were substituted by peptides with a 
glutamine at the respective position since the “*” was generated by amber (TAG) stop codons, 
which should have been translated as a glutamine since the employed E. coli strain was an 
amber suppressor line. Randomly appearing “X” was substituted by alanine. The remaining 
38,533 peptides were synthesized on 10 peptide arrays for validation. Each array contained a 
maximum of 4128 different 12mer peptide sequences as spot duplicates. Peptide arrays were 
obtained from PEPperPRINT GmbH, Germany, produced by combinatorial synthesis with a 
laser printer.  
Substitution analysis arrays: peptides showing a significant higher signal then the 
background on the validation arrays were analyzed in a substitution analysis. Every amino 
acid in the sequence of a peptide was substituted by all other amino acids while the rest of the 
sequence was conserved. Arrays were manufactured by PEPperPRINT GmbH, Germany by 
combinatorial synthesis with a laser printer [67].  
Incubation of peptide arrays with human serum: All incubation and washing steps were 
performed in PEPperCHIP incubation trays (PEPperPRINT GmbH, Germany), which allow 
for a minimized sample incubation volume and, in different variants, also the subdivision of 
the array substrate glass slide (1″ × 3″) into 2 to 16 separate incubation wells for each slide. 
The assay for the incubation of peptide arrays consists of two steps, each followed by a 
fluorescence scan based on an immune assay: the pre-incubation for revealing false positive 
signals by binding of the fluorescently labelled secondary antibody followed by the main 
incubation with serum and the secondary antibodies. Each step starts with a pre swelling of 
the array with PBS-T (1 × PBS, Sigma Aldrich, pH 7.4, 0.05% v/v Tween 20, Sigma Aldrich) 
for 10 min. Each array was blocked when incubated the first time with blocking buffer 
(Rockland Blocking Buffer, Rockland) for 30 min and washed afterwards shortly with PBS-T. 
For the pre incubation step the array was incubated with secondary DL680 conjugated anti-
human antibodies (Rockland), diluted to 0.2 μg/mL in PBS-T with 10% v/v blocking buffer 
for 30 min. In the main step the array was incubated with serum, diluted 1:500 (1:00 for 
substitution analyses) in PBS-T with 10% v/v blocking buffer over night at 4 °C. After 
washing shortly in PBS-T it was incubated with secondary antibody as described above. After 
each incubation step the array was washed shortly with PBS-T and di-ionized water, dried 
with Argon and scanned using an Odyssey scanner (LI-COR) at 680 nm with a resolution of 
21 μm/pixel. 
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Evaluation of peptide arrays: Fluorescence intensities were evaluated with the software 
PepSlide Analyzer. The median fluorescence intensity of each peptide spot was calculated and 
intensities of spot duplicates were averaged. Global background intensities were deduced of 
the spot intensity to obtain the foreground intensity of each peptide. The intensity values of 
the peptide spots on the control slide were transformed with the inverse hyperbolic sine 
(arsinh) [160].  
For evaluating the influence of individual amino acids in the substitution analysis, the 
fluorescence intensity of each peptide with a substituted amino acid was related to the 
fluorescence intensity of the peptide with the original amino acid in each row. 
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Abstract  
Peptide arrays enable high throughput screening of antibody-protein interactions. Thousands 
of peptides can be screened simultaneously with a minimum of sample volume. Besides the 
information whether an antibody binds specifically to a peptide, it is of interest to characterize 
the peptide-antibody interaction. Therefore, we developed a microfluidic system for the 
automated incubation of peptide arrays with biological samples and for the optical 
characterization of antibody-peptide interactions in the array format. 
 
1. Introduction 
The study of protein binding is the basis of fundamental research regarding cancer related 
signaling cascades as well as for diagnostics regarding detection of disease-related antibodies 
[167]. For the interrogation of protein binding events, peptide arrays are a well-established 
method [66]. They enable multiplexed high-throughput assays and require minimal sample 
volume. At the Institute of Microstructure Technology at KIT, high-density peptide arrays and 
their applications are developed and optimized [88, 91]. Peptide arrays can be used to search 
for linear epitopes in the immune response to diseases or vaccines: displaying the whole 
amino acid sequence of a toxoid as overlapping peptides, the toxoid specific antibodies in a 
patient serum can be analyzed and characterized [168] (see fig. 1 a-c). We were especially 
interested to set up a system that – in addition to mere antibody binding – would also deliver 
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kinetic data in an array format for many different anti-body-peptide pairs. Therefore, our 
experimental setup allows incubating 120 different peptides with different biological samples 
(e.g. sera or cell culture supernatant), while binding events are detected by time resolved 
fluorescence imaging. 
 
Figure 1: a) The amino acid sequence of a protein is cut in silico into peptides with overlapping 
sequences. b) These sequences are synthesized onto a peptide array. c) The peptide array is incubated 
with fluorescently la-belled antibodies. d) The fluorescence signal is detected with a camera over time 
for different antibody concentrations. Example protein structure from [169] modeled with PyMOL.  
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1.1 Microfluidic system 
All incubation steps are automatically performed in a microfluidic system. A continuous, 
laminar flow allows the contact and interaction of the sample antibodies with the peptides, 
which are immobilized in array format. 
The core part of the experimental setup is a microfluidic channel of the MicCell system by 
GeSiM (see fig. 2). The walls and the top of the channel are molded into Polydi-
methylsiloxane (PDMS). The actual channel is formed when the peptide array is attached to 
the PDMS. A cover plate contains threads to connect the tubing. By screwing the cover plate 
onto the frame, a defined pressure is applied to the PDMS and the peptide array to seal the 
microfluidic channel. There are two parallel channels molded into the PDMS, each 150 µm in 
height and 3.5 mm in width. A continuous flow is realized by an automated peristaltic pump 
(Reglo ICC, Ismatec). All process relevant buffers are connected to the system via a 
motorized valve. 
 
 
 
 
Figure 2: MicCell system by GeSiM (left) and schematic of experimental setup (right). 
 
1.2 Optical setup 
For the detection of binding events, we chose fluorescence, due to the high sensitivity. 
Fluorescence on the peptide array is excited by a high-power LED at 530 nm. A filter set 
(F41-007 HQ-Set, AHF Analysetechnik) separates excitation and emission. The signal is 
detected with a CCD-Camera (ProgRes C5, Jenoptik) (see fig. 2). Exposure times of up to 10 
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seconds are possible. The fluorescence signal increases over time as more anti-bodies bind to 
the peptides. 
 
1.3 Peptide arrays and antibodies 
To establish the system, a monoclonal Anti-FLAG M1 antibody (Sigma-Aldrich) binding to 
the FLAG peptide (amino acid sequence DYKDDDDK) is used. The anti-body is 
fluorescently labelled with a Lightning-Link™ Rapid conjugation kit (Innova Biosciences) 
with the fluorophore Dylight550 according to the instructions. Peptides were ordered from 
Peps4LS and spotted with a Spotting Roboter (MicroGrid II, Genomic Solutions) onto 3D-
maleimide functionalized surfaces (PolyAn). 
The peptides are functionalized with a C-terminal cysteine, which contains a thiol in the 
side chain that binds to the maleimide. After the completion of the spotting procedure, 
unreacted maleimides on the surface are blocked by washing the surface with 
mercaptoethanol. Unbound peptides from the spotting process are removed by a washing step 
with 0.1% trifluoroacetic acid in acetonitrile. 
 
2. Experiments 
All buffers used for washing, blocking and incubation are degassed and filtered sterile. In the 
first step the microfluidic channel is filled with phosphate buffered saline with 0.05 % 
Tween20 (PBS-T, Sigma Aldrich) and the array is preswollen for 10 minutes under flow with 
a volume flow rate of 600 µl/min. Next, the system is blocked with Rockland buffer 
(Biotrend) for 30 minutes to prevent any unspecific binding of antibodies in the system. The 
incubation of the array with antibodies is realized at a flow velocity of 16.4 mm/s, resulting in 
a Reynolds number of 2.1 for the microfluidic channel. 
Every minute, the CCD camera takes an image with an exposure time of 8 seconds and a 
digital gain of 8. Bias and flat field correction is performed with ImageJ. The intensity of the 
signal is calculated as the average grey scale value of all pixels of one peptide spot. Finally, 
the intensity of designated background control areas is subtracted from the intensity of the 
peptide spots. For the calculation of the equilibrium dissociation rate constant K_D, a pseudo-
first-order model according to O’Shannassay and Winzor [170] is used.  
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3. Results and Outlook 
With the above described system, we detected kinetic profiles of a monoclonal antibody (see 
fig. 4). We calculated an equilibrium dissociation rate constant KD of 6.1∙10
-8
M. 
In the future, we plan to investigate different peptide-antibody combinations with our 
system and establish reference measurements for validation. Potentially, our system will 
allow for obtaining dissociation rate constants for 120 different peptide spots simultaneously. 
Figure 4: Fluorescence intensity detected over time for anti-FLAG antibodies labelled with Cy3 
incubated in different concentrations on peptides: ■ 30 nM, ♦ 50 nM, ● 70 nM, ▲ 90 nM. Fitting 
according to [170]. I = Imax (1 – e
-kobst
) with Imax representing the fluorescence intensity at equilibrium 
and kobs = ka c + kd. ka and kd are the respective association and dissociation rate constants. 
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4 Conclusion and outlook 
In this doctoral thesis, it was evaluated, whether antibody fingerprints are suitable for the 
investigation of the etiology of infectious diseases and, whether this knowledge can be 
employed for diagnostics. Antibody fingerprints, which are deciphered in high density peptide 
array screenings, describe the key residues that are indispensable for the binding of an 
antibody to its epitope. They define the specificity of antibodies in a very detailed manner. In 
this work, the basis to exploit antibody fingerprints was established. 
In two model studies, it was evaluated, whether antibody fingerprints are disease specific. 
In these studies, the immune responses of different individuals were examined with high 
density peptide arrays. In a first step, immunogenic peptides were identified in epitope 
mappings. Subsequently, the fingerprints of identified antigenic peptides were determined 
with substitution analyses. 
In the first model study, the antibody response of vaccinated Europeans toward the tetanus 
toxin was examined. The antibodies of different individuals targeted various epitopes on the 
toxin. According to a reference diagnostic experiment, all individuals were sufficiently 
immunized. Thus, either different antibody species provide protection against the toxin, or the 
decisive antibodies recognize conformational or discontinuous epitopes that cannot be 
detected with linear peptide arrays. The substitution analysis of an epitope that was targeted 
by multiple individuals revealed that the antibody fingerprints of different individuals are 
almost identical. The corresponding epitope is located on a domain of the toxin with yet 
unknown function. The neutralizing character of this antibody species should be subject of 
future studies. In the second model study, the immune response of Lyme disease patients 
toward the immunodominant antigen VlsE of the disease-causing spirochete B. burgdorferi 
was investigated. Similar to the first study, different combinations of epitopes were targeted, 
but, the antibody fingerprints for shared epitopes were again almost identical. For both 
studies, queries of protein databases confirmed that the study of potential cross-reacting 
proteins is possible, whereas especially fingerprints consisting of several amino acids have 
shown to be highly disease specific. 
To exploit antibody fingerprints to pinpoint antigens in enigmatic infectious diseases, the 
antibody specificities of an individual were screened in a proof-of-principle with a random 
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peptide library. First, antibody-peptide interactions were investigated with a large phage 
display peptide library. Then, the identified binders from the error-prone phage display 
approach were validated with peptide arrays. Afterwards, the validated binders were studied 
in substitution analyses to determine the antibody fingerprints. As a result, 73 antibody 
species fingerprints could be identified, which might represent significant parts of the 
antibody diversity of the examined individual. Potential causing antigens of the antibody 
species could be identified in bioinformatical analyses by querying public protein databases. 
Most likely, one of the identified prominent motifs correlates with an antibody species 
induced by the vaccination against the polio virus. 
Furthermore, a microfluidic system with an optical set-up was established and validated. 
The binding curves of a monoclonal antibody in different concentrations towards its epitope 
were detected in a time-resolved manner. 
In conclusion, the antibody fingerprints deciphered with high density peptide arrays were 
disease-specific in both investigated model studies. Therefore, they have a great potential in 
diagnostics, enabling studies of inducing and cross-reacting antigens. The specificity to other 
diseases needs to be subject of future studies. For the identification of pathogens in hitherto 
enigmatic infectious diseases, the immune responses of large groups of diseased vs. healthy 
patients should be compared in the future. It should be investigated, whether it is possible to 
identify shared antibody species in these groups without a priori knowledge. Then, the 
targeted antigens and pathogens could be pinpointed with bioinformatic analyses. A 
prerequisite for the latter is the presence of a correlating antibody species that targets a linear 
epitope, which can be detected with current peptide array technology. The examination of the 
kinetics of the antibody-antigen interaction will even increase the knowledge of antibody-
antigen interactions in the future.  
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A Supporting Information 
A.1 Supporting Information for: Identification of a tetanus toxin specific 
epitope in single amino acid resolution   
 
Anti-tetanus titer 
According to the WHO standard, tetanus antitoxin levels are expressed in international units 
(IU) and are classified according to international standards for standard ELISA: <0.01 IU/ml, 
no protection; 0.01–0.1 IU/ml, uncertain, short-term protection and ≥0.1 IU/ml, full 
protection.  
. 
Table S1: IgG anti-tetanus antibody levels 
Serum IU/ml 
Tetanus 
1 4.07 
2 5.88 
3 1.76 
4 2.53 
5 2.02 
6 0.80 
7 1.59 
8 7.88 
9 2.85 
10 0.75 
11 1.02 
12 0.23 
13 2.21 
14 1.99 
15 0.93 
16 0.95 
17 4.80 
18 3.34 
19 0.75 
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Substitution analysis 
 
 
Figure S1: Heatmaps of the evaluation of the substitution analysis for 8 different sera. From top to 
bottom left, the original sequence is shown. Substituted amino acids are shown on top of each 
heatmap. The intensity of the peptide with the original amino acid in each row is set to 100 %. The 
relative fluorescence intensities are calculated in relation to these intensities. 
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Figure S2: (A) Fluorescence scan image of the epitope mapping of serum 9. The peptide chosen for 
substitution analysis corresponds to the second visible spot in the enlarged area. Scale bar 0.5 cm. (B) 
Fluorescence scan image of the corresponding substitution analysis of a 15mer peptide. Each amino 
acid position is substituted by all 19 other amino acids resulting in an array of 15 rows and 20 
columns. From top to bottom left, the original sequence is shown. (C) Heatmap of the evaluation of 
the substitution analysis. The intensity of the peptide with the original amino acid in each row is set to 
100 %. The relative fluorescence intensities are calculated in relation to these intensities. From top to 
bottom left, the original sequence is shown; letters in red indicate original amino acids that are 
essential for binding. In some positions two or more amino acids allow for the binding, alternative 
amino acids are depicted left of the original amino acid if the intensity is lower and right of the 
original amino acid if the intensity is higher.  
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Validation of antibody-peptide interaction 
Figure S3: Results of validation experiments to prove that the antibody-peptide interaction is 
independent from the individual surfaces. Sera of 8 individuals that showed interaction with the most 
prominent epitope identified in the epitope mapping were incubated on arrays containing peptides with 
the sequence IHLVNNESSEVIVHK. The peptide was pre-synthesized, purified and spotted onto 
functionalized glass slides. For each serum, 36 peptide spots were incubated and the median 
fluorescence intensity was calculated.  
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Figure S4: Exemplary fluorescence scans of validation of antibody peptide interaction with 4 different 
peptides: 1 (MVPEFSGSFPMR): positive control, the peptide sequence was identified in a separate 
study, 2 (IHLVNNESSEVIVHK): antigenic peptide used for isolation of antibody species, 3 
(IHLVNNESSEVIVHR): negative control 1 and 4 (IHLVNNESSEVIAHK): negative control 2. Both 
negative controls were identified in the substitution analysis to prevent the binding of the 
corresponding antibody species. Arrays consisted of 36 spots per peptide; peptides were pre-
synthesized and spotted onto functionalized surfaces. The array on the left was incubated with serum 
19 as negative control; the array on the right was incubated with serum 11.  
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Isolation of epitope specific antibodies 
 
 
Figure S5: Fluorescence scan images of the epitope mapping of serum 11 before and upon isolation of 
epitope-specific antibodies. Scale bar 0.5 cm. The white ellipse highlights the respective epitope 
including the antigenic peptide used for isolation of the antibody species.  
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Bioinformatic analysis of identified fingerprint 
Table S2: Hits of a protein database query for the identified fingerprint. The table shows the protein 
on which the motif is located, the organism in which the protein was found, the amino acid position 
and the exact sequence. The query was conducted with the following settings: include splice variants 
(Swiss-Prot); exclude fragments; Hits for motif on all UniProtKB/Swiss-Prot (release 2016_11 of 30-
Nov-16: 553231 entries) database sequences found 47 hits in 47 sequences. All hits within the same 
protein of the same organism are shown in the same row. Hits in different versions of the same protein 
were deleted. 
Organism Sequence Query result Protein Aa position 
Aeropyrum pernix EtgEIIISK 
>sp|Q9YC05|RRP42_AERPE  
(276 aa) 
Exosome complex component 177 - 185 
Alteromonas mediterranea 
DvlEVIVN
K 
>sp|B4RVA8|LEPA_ALTMD  
(598 aa) 
Elongation factor 4 (EF-4) 173 - 181 
Archaeoglobus fulgidus 
EhdEVIVE
K 
>sp|O28387|RS12_ARCFU  (142 
aa) 
30S ribosomal protein S12 94 - 102 
Caenorhabditis briggsae EndEIIVEK 
>sp|Q60MF5|RN207_CAEBR  
(836 aa) 
Probable RING finger protein 207 
homolog 
745 - 753 
Caenorhabditis elegans EkeEIIIVK 
>sp|O44199|RAD50_CAEEL  
(1298 aa) 
DNA repair protein rad-50 708 - 716 
Caenorhabditis elegans EenEVIIEK 
>sp|Q09353|SENP_CAEEL  (697 
aa) 
Sentrin-specific protease 114 - 122 
Caenorhabditis elegans EirEIIVSK 
>sp|Q09372|YS44_CAEEL  (655 
aa) 
Uncharacterized protein ZK177.4 64 - 72 
Clostridium acetobutylicum EtgEIIVEK 
>sp|Q97EG9|RPOB_CLOAB  
(1241 aa) 
DNA-directed RNA polymerase 
subunit beta 
298 - 306 
Clostridium tetani EssEVIVHK 
>sp|P04958|TETX_CLOTE  
(1315 aa) 
Tetanus toxin 929 - 937 
Deinococcus geothermalis 
EvkEVIVD
K 
>sp|Q1J195|ACP_DEIGD  (76 aa) Acyl carrier protein (ACP) 6 – 14 
Dictyostelium discoideum EkiEIIVDK 
>sp|Q54NW7|VAM7A_DICDI  
(216 aa) 
Vesicle-associated membrane 
protein 7A 
153 - 161 
Emericella nidulans EhdEIIVEK 
>sp|Q5BB57|RRF2M_EMENI  
(921 aa) 
Ribosome-releasing factor 2, 
mitochondrial 
299 - 307 
Enterococcus faecium EtgEIIVEK 
>sp|Q8GCR6|RPOB1_ENTFC  
(1208 aa) 
DNA-directed RNA polymerase 
subunit beta 
306 - 314 
Finegoldia magna DtgEIIVHK 
>sp|B0S2E5|RPOC_FINM2  
(1202 aa) 
DNA-directed RNA polymerase 
subunit beta 
831 - 839 
Flavobacterium 
psychrophilum 
DtcEVIVEK 
>sp|A6GX63|SECA_FLAPJ  
(1116 aa) 
Protein translocase subunit SecA 833 - 841 
Homo sapiens EekEIIVIK  
>sp|Q5JQC9|AKAP4_HUMAN  
(854 aa) 
A-kinase anchor protein 4 (AKAP-
4) 
66 – 74         75 
- 83 
Homo sapiens EseEVIIEK 
>sp|A4UGR9|XIRP2_HUMAN  
(3374 aa) 
Xin actin-binding repeat-containing 
protein 2 
647 - 655 
Human rhinovirus 14 EleEVIVEK 
>sp|P03303|POLG_HRV14  
(2179 aa) 
Genome polyprotein 572 - 580 
Human rhinovirus 3 EleEVIVEK 
>sp|Q82081|POLG_HRV3  (2178 
aa) 
Genome polyprotein 572 - 580 
Ignicoccus hospitalis EgvEVIISK 
>sp|A8AA20|RS3_IGNH4  (241 
aa) 
30S ribosomal protein S3 181 - 189 
Lactobacillus salivarius DtgEIIVNK 
>sp|Q1WVA5|RPOB_LACS1  
(1199 aa) 
DNA-directed RNA polymerase 
subunit beta 
307 - 315 
Lecanicillium sp. DleEVIINK 
>sp|A0A024F910|VLMS_LECSP  
(8903 aa) 
Nonribosomal peptide synthetase 
vlms 
1760 - 1768 
Methanocaldococcus 
jannaschii 
DrdEIIINK 
>sp|Q57958|Y538_METJA  (260 
aa) 
Uncharacterized protein MJ0538 176 - 184 
Mus musculus EekEIIVIK  
>sp|Q60662|AKAP4_MOUSE  
(849 aa) 
A-kinase anchor protein 4 (AKAP-
4) 
66 – 74           
75 - 83 
Mus musculus EgtEIIITK 
>sp|Q8C0Q2|ZHX3_MOUSE  
(951 aa) 
Zinc fingers and homeoboxes 
protein 3 
171 - 179 
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Mycoplasma capricolum 
subsp. capricolum 
DqaEIIIDK 
>sp|Q2SSW4|SYA_MYCCT  
(896 aa) 
Alanine--tRNA ligase 728 - 736 
Neosartorya fumigata 
DnaEVIVE
K 
>sp|Q4WAW3|FTMA_ASPFU  
(2211 aa) 
Nonribosomal peptide synthetase 13 477 - 485 
Oceanobacillus iheyensis EtgEVIVEK 
>sp|Q8ETY7|RPOC_OCEIH  
(1203 aa) 
DNA-directed RNA polymerase 
subunit beta 
856 - 864 
Petrotoga mobilis EfkEIIIDK 
>sp|A9BF51|MOAA_PETMO  
(323 aa) 
GTP 3',8-cyclase 207 - 215 
Physcomitrella patens subsp. 
patens 
DemEVIIIK 
>sp|A9SVH7|RBR_PHYPA  
(1116 aa) 
Retinoblastoma-related protein 1013 - 1021 
Rattus norvegicus EekEIIVIK 
>sp|O35774|AKAP4_RAT  (847 
aa) 
A-kinase anchor protein 4 (AKAP-
4) 
74 - 82 
Rattus norvegicus EgtEIIITK 
>sp|Q80Z36|ZHX3_RAT  (951 
aa) 
Zinc fingers and homeoboxes 
protein 3 
170 - 178 
Saccharomyces cerevisiae DteEVIVIK 
>sp|Q08951|AP3D_YEAST  (932 
aa) 
Adaptor-related protein complex 3 
subunit delta 
889 - 897 
Schizosaccharomyces pombe EqnEIIITK 
>sp|Q7Z992|SST6_SCHPO  (487 
aa) 
ESCRT-I complex subunit vps23 260 - 268 
Xenopus laevis DsrEIIVEK 
>sp|Q9PTD7|CING_XENLA  
(1360 aa) 
Cingulin 304 - 312 
Yarrowia lipolytica EvfEVIITK 
>sp|P41925|RYL2_YARLI  (209 
aa) 
Ras-like GTP-binding protein RYL2 164 - 172 
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A.2 Supporting Information for: Antibody fingerprints in Lyme disease 
deciphered with high density peptide arrays 
 
Table S1: Maximum fluorescence intensities of the epitope mappings 
 
Serum Maximum 
fluorescence 
intensity a.u. 
1 65284 
2 8337 
3 1328 
4 5912 
5 1462 
6 10135 
7 14885 
8 664 
9 3122 
10 47726 
11 26523 
12 65300 
13 37291 
14 24483 
15 1750 
16 394 
17 395 
  
NC 1 134 
NC 2 409 
NC 3 583 
NC 4 130 
NC 5 277 
NC 6 590 
NC 7 678 
 
  
104 Supporting Information  
 
 
The following Supplementary Figures S1 – S5 show the antibody fingerprints of all 
investigated individuals, deciphered with substitution analyses on high density peptide arrays 
for immunodominant epitopes of the VlsE antigen.  
 
 
Figure S1: Antibody fingerprints of 6 sera for the epitope at position 20 – 40 on the VlsE antigen. The 
original amino acids of the peptide sequence were one by one substituted by all other amino acids. The 
resulting peptides were printed as array duplicates (not shown) and incubated with the corresponding 
serum. The results are visualized as a heat map. The relative fluorescence intensities of all peptides in 
a row are calculated according to the intensity of the peptide with the original amino acid set to 100 %. 
The original sequence is shown from top to bottom left; essential amino acids are indicated in red. 
Substituted amino acids are shown from left to right on top of the substitution arrays. 
 
 
 
 
 
 
 
 
 
A C D E F G H I K L M N P Q R S T V W Y A C D E F G H I K L M N P Q R S T V W Y
V 84 75 85 94 114 98 107 94 95 82 78 114 106 97 99 117 114 100 104 112 V 88 89 119 147 174 93 86 120 67 76 79 85 107 82 85 97 185 100 114 231
A 100 80 93 115 115 106 99 103 95 88 107 105 111 124 95 98 121 112 93 107 A 100 88 188 122 209 110 109 203 79 82 96 121 134 111 104 124 201 193 151 128
D 99 78 100 112 96 97 90 117 99 86 113 121 138 116 121 112 120 121 109 119 D 91 77 100 94 72 79 74 79 58 65 85 72 91 96 82 87 100 98 108 97
K 8,9 8,4 6,1 7,1 16 9,5 10 14 100 13 9,7 10 8,9 13 18 9,5 9,8 12 16 16 K 99 83 130 92 85 69 93 83 100 72 74 68 98 81 89 138 105 102 144 117
D 46 54 100 99 46 37 63 58 70 26 56 77 19 93 82 85 121 77 39 48 D 72 67 100 84 52 51 50 65 58 48 61 53 53 70 80 84 95 82 86 82
D 19 21 100 35 38 14 15 14 21 13 9,8 32 11 29 26 23 26 13 20 26 D 59 54 100 54 50 50 44 44 48 46 44 46 61 59 67 64 58 57 66 65
P 19 7,8 41 31 13 6,3 5,6 8 5,2 24 14 12 100 19 22 22 17 19 7,8 22 P 64 59 143 78 53 129 49 50 42 47 49 50 100 60 61 75 67 61 67 67
T 1,5 0 0,4 0,8 1,4 0,2 0,5 0,5 1,4 0,2 0,4 1 2,1 2,4 7,2 43 100 1,4 0,5 16 T 56 53 64 52 51 45 46 56 41 50 50 45 58 54 58 62 100 57 67 69
N 0,8 0,4 1,4 0,8 0,4 0,3 0,6 0,7 2 0,2 1,4 100 0,8 2,1 2,6 1,5 1,1 2,7 1,1 1,9 N 67 57 85 68 56 57 50 50 48 51 50 100 63 56 58 59 59 58 65 63
K 74 59 106 188 81 54 55 79 100 97 125 119 4,1 96 60 141 158 110 57 102 K 138 109 182 242 119 89 82 110 100 125 139 135 85 132 116 172 174 144 99 131
F 5,4 5 9,2 12 100 9,3 9,7 7,4 8,1 13 9,6 12 2,4 20 5,6 11 12 8,3 37 32 F 70 58 69 72 100 57 54 56 47 52 54 63 66 61 62 58 60 58 66 72
Y 95 75 114 201 113 93 93 100 95 107 145 92 172 119 98 160 183 134 81 100 Y 97 85 136 158 88 87 68 85 75 74 83 93 120 90 80 110 112 95 78 100
Q 95 75 121 119 93 57 58 95 75 75 108 78 109 100 70 151 149 135 55 83 Q 118 97 208 229 90 88 72 111 74 84 101 93 131 100 83 141 121 134 77 102
S 75 78 115 101 73 44 66 76 86 77 82 91 76 87 73 100 113 89 63 83 S 98 87 169 157 82 74 73 85 78 74 94 90 317 92 99 100 137 101 80 99
V 83 97 130 134 102 87 93 95 82 100 113 122 102 94 85 108 104 100 64 105 V 88 89 132 122 89 77 78 94 70 85 111 90 99 93 92 107 103 100 112 122
A C D E F G H I K L M N P Q R S T V W Y A C D E F G H I K L M N P Q R S T V W Y
I 67 68 63 54 63 52 56 100 49 39 38 40 27 38 38 37 37 40 44 42 I 94 105 92 102 104 93 105 100 90 84 90 89 78 61 60 57 52 52 58 65
N 161 155 151 121 138 115 114 118 102 93 98 100 57 91 93 93 104 96 104 95 N 129 135 154 150 140 131 139 140 128 124 96 100 76 55 63 63 56 69 82 84
C 114 100 87 72 78 66 64 65 61 52 57 55 41 58 60 54 55 56 66 61 C 103 100 108 98 106 113 113 98 110 102 86 92 62 49 66 66 64 74 90 100
K 193 167 142 117 129 109 115 122 100 95 99 99 79 97 110 97 109 100 122 112 K 116 123 127 127 134 120 117 121 100 110 103 111 92 77 83 86 92 104 112 125
S 148 155 141 117 134 105 115 113 101 96 102 106 77 102 100 100 106 107 123 113 S 104 105 115 119 124 129 140 132 117 115 105 112 111 102 98 100 103 104 125 122
Q 147 141 119 126 120 92 106 111 87 99 102 91 72 100 103 99 107 113 123 125 Q 102 94 106 101 112 118 100 116 101 110 96 119 101 100 100 102 98 90 105 116
V 82 71 58 58 59 38 46 69 38 63 47 54 51 54 53 53 64 100 73 62 V 92 100 93 89 138 95 106 103 72 101 76 113 86 85 81 89 90 100 138 139
A 100 80 107 56 65 33 46 50 23 53 47 62 49 54 45 74 64 55 84 69 A 100 56 66 79 79 82 64 71 40 49 44 61 61 52 51 86 74 63 78 74
D 5,4 6,4 100 5,6 3,3 1,3 1,3 1,8 0 1,3 0,5 1,3 0,5 2,8 2,8 1,8 1,8 2,8 4,4 4,4 D 13 21 100 27 24 18 19 21 11 19 18 36 16 17 15 20 19 23 28 33
K 56 35 14 13 114 14 34 68 100 113 35 47 11 46 78 38 150 64 67 102 K 93 82 85 68 113 69 154 82 100 111 100 139 122 90 91 106 95 70 90 110
D 0 14 100 1,3 0 0 0 0 0 0 0 17 0 0 0 1,3 1,9 0 2,9 1,3 D 18 23 100 23 35 14 9,6 7,4 5,4 6,4 8,2 28 30 12 10 25 17 10 19 17
D 3,2 6,2 100 2,2 0 0 0 0 0 1,2 2,7 6,5 0 1,5 1,2 0,5 0 0 6,5 1,2 D 12 29 100 28 12 5,9 6,5 7,8 9,1 13 9,9 16 6,4 15 21 23 19 12 14 15
P 0 0 0 0 0 0 0 0 0 0 0 5,2 100 0 0 0 0 0 0 0 P 8,2 4,4 11 27 7,2 6,3 5,2 11 5,4 5,3 9,2 16 100 9,9 6,3 5,2 19 30 5,2 7,2
T 42 33 39 26 28 25 20 23 14 47 21 16 12 20 15 22 100 25 20 26 T 96 88 146 279 119 126 81 128 42 73 93 98 97 65 47 135 100 121 109 137
N 35 46 37 32 26 24 26 24 36 21 32 100 26 26 24 24 24 24 25 25 N 55 70 105 97 72 66 64 65 34 63 79 100 77 61 42 63 63 71 74 72
A C D E F G H I K L M N P Q R S T V W Y A C D E F G H I K L M N P Q R S T V W Y
I 93 89 94 120 106 80 83 100 106 75 104 93 80 92 87 104 100 90 106 107 I 101 115 94 106 99 88 104 100 100 105 95 102 116 110 91 87 101 101 111 70
N 89 105 95 116 111 93 100 120 96 113 100 100 88 98 113 119 102 104 120 135 N 100 117 96 102 99 89 101 100 100 115 99 100 95 101 93 92 119 107 124 78
C 88 100 117 106 110 95 96 119 89 123 94 101 96 103 123 114 106 111 111 163 C 89 100 86 91 98 79 94 92 91 107 93 99 87 94 95 76 91 95 106 76
K 118 137 150 160 154 123 113 118 100 145 137 124 102 140 132 149 151 122 147 157 K 100 107 93 102 108 101 113 106 100 134 110 104 112 95 104 93 96 101 126 91
S 69 81 78 87 75 67 72 93 74 76 78 77 75 99 103 100 91 92 97 107 S 110 108 81 113 110 100 102 117 116 125 111 118 104 109 105 100 96 106 128 77
Q 73 86 95 120 100 89 99 100 66 111 93 98 79 100 136 122 90 98 94 129 Q 94 109 82 109 100 86 98 98 86 116 97 109 88 100 106 78 90 89 119 85
V 99 105 96 115 100 110 113 115 76 104 99 103 104 113 126 128 109 100 135 157 V 111 112 98 125 128 98 112 103 76 123 108 111 100 105 101 97 107 100 146 104
A 100 104 105 128 149 120 121 97 55 122 103 128 105 134 120 129 122 115 148 165 A 100 108 93 109 168 89 106 88 66 104 88 93 74 91 87 77 98 91 146 95
D 112 105 100 131 159 385 122 115 65 124 115 113 112 124 138 118 117 138 170 195 D 103 129 100 127 175 211 109 126 70 124 108 108 105 109 96 86 101 118 150 120
K 130 108 94 111 149 196 139 110 100 150 110 354 240 137 154 145 117 129 193 206 K 133 201 151 145 228 194 156 126 100 155 131 266 177 158 161 173 132 129 290 149
D 11 39 100 79 160 16 44 45 5,7 44 24 80 5 32 39 63 106 42 94 151 D 17 39 100 65 68 12 28 31 30 31 11 42 20 37 45 27 54 36 68 34
D 0 0 100 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1,3 0 D 9,3 2,2 100 0 0 0 0 0 0 0 0 1 2,1 2,2 0,1 1,2 0 0 1,7 0
P 0 0 0 0 0 0 0 0 0 0 0 0 100 0 0 0 0 0 0 0 P 4,1 3,1 8,1 2,1 0 0 0 0,1 0 0 1,1 0,4 100 8 0 0 0 0,9 2,3 1,5
T 0 0 0 0 0 0 0 0 0 4,9 68 0 0 0 0 0 100 0 0 0 T 3,4 0,9 2,8 1,6 2,1 0 0 0,5 0 8 0 25 0 7,1 2,9 2,8 100 9,3 6,7 3,9
N 0 0 0 0 0 0 0 0 0 0 0 100 0 0 0 0 0 0 0 0 N 0 1,5 2,7 0 0 0 0 0 0 0 0 100 0 0 0 0 0 0 6,9 2,5
PS 1
PS 6
PS 4PS 3
PS 2
PS 7
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Figure S2: Antibody fingerprints of 3 sera for the epitope at position 171 – 186 on the VlsE antigen. 
The original amino acids of the peptide sequence were one by one substituted by all other amino acids. 
The resulting peptides were printed as array duplicates (not shown) and incubated with the 
corresponding serum. The results are visualized as a heat map. The relative fluorescence intensities of 
all peptides in a row are calculated according to the intensity of the peptide with the original amino 
acid set to 100 %. The original sequence is shown from top to bottom left; essential amino acids are 
indicated in red. Substituted amino acids are shown from left to right on top of the substitution arrays. 
 
 
 
A C D E F G H I K L M N P Q R S T V W Y A C D E F G H I K L M N P Q R S T V W Y
K 44 51 177 46 39 52 62 77 100 62 34 68 65 9,7 53 30 36 44 24 12 G 138 149 150 137 126 100 106 124 91 102 138 98 114 110 112 122 132 131 141 164
G 24 42 258 235 60 100 36 23 45 31 42 77 23 28 25 121 197 15 15 4,3 I 92 98 80 95 102 68 69 100 65 82 129 77 68 84 75 96 82 90 111 127
I 1,1 2,5 7 5,5 2,3 5,1 6,7 100 15 45 1,9 7 47 2 4,8 0 6,3 22 0,4 0 K 207 168 192 343 220 104 139 438 100 189 475 155 107 224 134 189 154 196 211 266
K 791 112 557 1295 75 626 171 356 100 56 66 1375 22 62 82 773 624 441 26 3,2 E 84 82 135 100 61 61 58 63 53 64 75 71 62 70 55 110 110 92 112 109
E 8,1 5,5 69 100 8,4 6,8 5,9 5,6 5,9 5,1 0,6 6,8 2,2 0 4,8 3,9 8,6 3,6 0,3 0,5 I 142 128 161 592 114 60 87 100 90 119 125 91 127 115 128 208 231 129 157 177
I 0,2 0 0 1,2 0 0 4,7 100 0 0 0 0 0 0 0 0 0 0 0 0 V 60 73 76 129 114 39 60 98 46 93 200 103 47 86 78 69 71 100 102 115
V 0 0 0 0 0 0 24 7,4 0 0 0 0 0 0 0 0 0 100 0 41 E 74 72 99 100 65 54 45 50 24 53 59 50 48 60 54 60 66 70 97 107
E 11 0 134 100 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 A 100 97 95 104 110 60 69 82 64 87 77 67 90 90 95 94 95 121 126 147
A 100 0 15 129 0 11 0 0 0 0 0,2 0 0 0 0 24 9,6 0 0 0 A 100 78 70 72 88 53 60 115 50 118 66 61 77 81 94 85 198 144 119 130
A 100 0 0 0 0 0 0 6,5 19 0 5,1 0 0 0 15 13 5,7 13 0 0 G 131 124 127 120 136 100 85 103 55 105 107 98 119 171 124 115 193 163 205 217
G 407 18 15 52 19 100 29 153 80 51 30 0,8 0 23 86 222 123 389 7,8 6,5 G 136 134 126 121 239 100 124 174 96 144 318 134 136 213 172 115 144 182 230 277
G 245 139 151 244 207 100 154 444 320 302 258 70 4,7 101 228 272 305 603 105 80 S 86 37 37 181 340 65 40 268 69 301 424 37 20 293 127 100 94 273 91 261
S 66 30 69 52 74 50 50 122 82 52 43 18 18 26 108 100 183 162 77 50 E 0 0 7,5 100 7,6 0 0 0 0 0 7,3 5,7 0 10 0 0 0 2,9 14 3
E 68 41 98 100 60 27 45 73 68 40 36 30 20 34 44 77 75 90 33 33 K 286 96 102 207 341 46 78 141 100 227 151 82 252 123 262 220 101 175 161 485
K 87 92 117 132 141 43 73 139 100 94 55 40 68 31 56 75 110 143 73 62 L 3,4 4,1 8 12 29 0 11 71 26 100 5,4 13 0,9 16 37 2 18 57 47 57
A C D E F G H I K L M N P Q R S T V W Y
G 147 65 123 119 103 100 88 96 62 68 70 76 117 97 74 119 113 128 96 99
I 30 25 16 14 90 5 25 100 32 129 39 15 31 32 29 19 33 67 86 63
K 190 83 181 182 107 89 96 94 100 119 104 109 68 133 142 157 115 95 117 137
E 65 17 101 100 11 21 13 14 18 19 30 22 11 40 12 45 35 17 20 23
I 0,1 0 0 0,1 1,2 0 0,1 100 0 15 0 0 0 0,3 0,2 0 0,3 15 1,6 0
V 74 11 1,2 60 100 4,1 35 99 33 98 86 5,3 0,2 72 48 46 66 100 40 57
E 67 18 94 100 25 18 14 30 28 47 40 30 0 39 16 49 47 35 22 34
A 100 1,6 14 14 0,7 3,2 0,3 1,3 15 0,3 14 2,7 0 14 10 34 14 4 4,2 1,2
A 100 0 0 0 0 0,6 0 0 1 0 0 0 0 0 0 12 0,2 3,3 0 0
G 86 0,4 0,1 0 0 100 0 0 2,7 0 0 3 0 0,8 0 52 3,9 5 1,5 0,1
G 110 18 65 49 47 100 25 15 41 15 60 55 9,6 50 36 119 98 24 58 25
S 76 15 47 57 47 38 11 39 33 10 41 15 38 17 16 100 65 41 32 25
E 90 48 135 100 91 46 21 71 42 54 53 40 18 30 23 107 78 69 40 55
K 174 124 161 169 204 87 94 162 100 140 133 62 68 93 85 172 187 186 100 127
L 97 63 105 111 136 46 53 141 42 100 70 44 54 42 38 122 125 147 64 104
PS 5 PS 8
PS 12
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Figure S3: Antibody fingerprints of 6 sera for the epitope at position 228 – 242 on the VlsE antigen. 
The original amino acids of the peptide sequence were one by one substituted by all other amino acids. 
The resulting peptides were printed as array duplicates (not shown) and incubated with the 
corresponding serum. The results are visualized as a heat map. The relative fluorescence intensities of 
all peptides in a row are calculated according to the intensity of the peptide with the original amino 
acid set to 100 %. The original sequence is shown from top to bottom left; essential amino acids are 
indicated in red. Substituted amino acids are shown from left to right on top of the substitution arrays. 
 
A C D E F G H I K L M N P Q R S T V W Y A C D E F G H I K L M N P Q R S T V W Y
V 82 71 109 69 83 60 48 91 61 107 105 61 118 65 63 113 118 100 77 90 V 48 21 16 31 52 13 29 73 20 47 35 30 70 50 49 82 94 100 55 73
S 63 59 107 67 63 61 50 58 51 47 55 56 53 55 58 100 99 60 69 68 S 52 26 53 48 40 42 28 44 42 56 57 60 106 54 62 100 112 67 45 61
G 58 60 72 63 67 100 44 57 46 49 47 42 57 50 53 63 53 59 69 72 G 70 4 2,8 4,2 5,2 100 6,6 2,2 6,7 7,4 2,4 9,7 20 36 2,8 130 79 14 7,6 5,5
E 64 46 95 100 46 46 32 34 35 31 59 46 31 47 41 57 57 44 45 43 E 50 22 93 100 27 31 20 27 37 43 44 52 38 43 41 84 61 45 20 50
Q 196 69 223 191 78 89 54 73 69 122 120 73 39 100 61 221 164 92 72 80 Q 94 46 113 124 53 46 33 80 81 105 113 70 13 100 72 158 126 114 68 104
I 74 54 64 55 63 48 36 100 33 49 41 44 39 52 50 46 58 90 60 59 I 19 0,4 0,7 1,1 9,5 4,4 3,9 100 1,2 24 1,6 2,6 0,6 3,1 4,1 8,1 50 105 1 11
L 43 43 45 37 47 35 36 36 25 100 30 49 32 39 41 312 37 40 52 50 L 5 2,3 2,1 3,1 39 3,2 3,7 15 5,9 100 21 3,3 2,4 19 5,9 4,9 16 11 33 56
S 78 52 53 76 54 61 43 38 43 43 51 52 30 63 58 100 72 47 58 66 S 45 23 52 83 41 41 16 46 44 71 75 35 1,8 65 52 100 101 65 45 66
A 100 27 41 53 35 33 19 30 30 34 45 22 25 35 33 62 40 40 37 41 A 100 28 104 101 47 99 27 45 49 56 83 58 2,6 67 67 178 99 69 44 75
I 70 29 30 27 41 23 24 100 24 57 31 27 25 32 34 36 41 110 45 42 I 45 6,2 7 17 19 10 6,9 100 16 64 25 18 3,6 27 19 53 50 85 8,8 28
V 64 33 48 71 44 37 30 85 31 68 49 32 32 32 36 63 113 100 45 49 V 59 15 29 59 19 37 11 68 41 53 58 18 23 43 40 105 106 100 15 52
T 67 40 68 89 62 50 31 62 38 46 51 34 43 37 38 77 100 66 48 67 T 30 18 22 57 20 19 8,6 43 29 38 40 13 20 21 26 73 100 74 15 41
A 100 54 76 117 48 64 42 59 51 50 62 40 51 54 43 121 114 85 49 64 A 100 39 65 108 37 74 35 77 82 63 91 34 70 63 76 171 157 140 35 76
A 100 62 157 124 70 69 50 116 59 81 66 61 61 73 58 127 134 116 67 97 A 100 49 74 111 44 70 37 68 81 75 89 56 68 60 67 112 159 123 56 89
D 50 36 100 60 38 32 29 74 38 41 43 41 34 35 35 47 61 54 45 52 D 63 46 100 125 50 59 27 62 66 50 68 43 68 53 39 105 122 89 41 93
A C D E F G H I K L M N P Q R S T V W Y A C D E F G H I K L M N P Q R S T V W Y
V 79 34 89 82 103 49 82 211 71 121 74 63 126 118 75 82 117 100 97 115 V 52 46 100 91 62 88 81 96 51 80 110 114 126 107 107 123 126 100 103 87
S 34 13 26 8,4 12 13 8,3 4 11 7,4 11 37 42 15 17 100 56 4,4 8,8 13 S 50 38 86 94 59 80 67 65 60 76 93 111 89 106 90 100 100 93 71 82
G 0,6 7,7 5,1 2,3 10 100 3,1 0,3 14 0,6 1,8 2 1,8 4,1 2 1,2 0,8 0,5 1,3 6,4 G 30 20 53 47 20 100 42 16 22 12 25 37 120 71 31 61 51 18 37 28
E 16 6,2 82 100 6,3 8,2 4,6 7 8,2 8,3 19 9,7 0,9 20 5,2 27 15 8,9 2,7 8,3 E 8,8 12 29 100 8 7,4 8,1 8,4 7,3 7,5 7,1 9,3 39 15 7,9 9,5 9,4 8,7 12 13
Q 56 17 143 111 43 41 22 38 37 55 82 35 2,5 100 24 78 57 30 13 35 Q 43 9,4 26 83 8,9 9,3 19 69 22 81 67 14 86 100 34 38 83 64 23 20
I 1,3 2,6 1,5 6 16 0,4 1,2 100 4,1 45 7 3,1 0,8 2,4 1,7 1,6 28 74 6,1 15 I 5,1 5 6,5 5,7 4,8 3,8 4,1 100 4,3 6,8 5,7 5,2 8,5 6,1 5,5 4,8 5,1 14 7,6 8,3
L 0,7 0,5 1 1,2 12 0,7 1,1 34 1,2 100 1,6 1,9 0,6 1,3 1,5 1,4 2,1 4,6 1 1,5 L 6,8 5,6 8,2 6,8 11 5,7 5,5 8,3 5,5 100 18 7,1 12 8,7 11 8,1 6,3 7,9 10 13
S 43 19 66 81 45 74 25 74 53 83 100 34 4,2 41 33 100 58 49 19 60 S 58 21 54 136 47 31 22 53 44 62 82 40 6,7 73 38 100 101 71 32 74
A 100 56 144 255 83 93 46 124 100 105 144 70 32 93 68 157 110 140 41 121 A 100 7,8 12 13 11 11 7,9 12 7,7 10 19 11 9,2 10 12 31 17 13 14 17
I 79 48 111 197 62 72 35 100 66 86 83 40 43 67 53 97 121 131 36 95 I 8 5,5 6,7 6,6 12 4,9 5,9 100 5 74 14 6,7 6,3 8,5 6,5 8,3 8 64 9,9 14
V 45 30 56 89 30 29 14 86 31 59 39 18 19 26 25 43 88 100 21 53 V 35 16 17 32 48 19 13 92 32 105 71 21 6,9 33 29 73 131 100 28 45
T 30 33 49 81 27 20 16 52 32 38 33 17 31 22 23 64 100 78 17 46 T 29 25 50 84 27 35 13 28 26 36 41 21 15 22 18 88 100 59 24 45
A 100 81 154 211 84 100 53 103 94 77 102 45 60 67 57 138 175 146 45 114 A 100 46 111 193 65 112 42 83 71 69 137 65 66 91 68 243 203 180 53 129
A 100 97 191 230 100 102 91 140 117 89 103 57 63 88 66 211 243 177 88 180 A 100 61 161 206 74 102 59 107 108 85 111 83 95 103 72 221 271 186 97 166
D 42 35 100 88 40 34 28 39 44 40 38 26 34 18 19 60 94 83 46 95 D 32 29 100 97 35 41 26 44 48 36 56 36 56 41 32 101 109 75 34 82
A C D E F G H I K L M N P Q R S T V W Y A C D E F G H I K L M N P Q R S T V W Y
V 82 44 110 108 65 32 37 67 28 70 57 68 84 69 62 96 128 100 53 64 V 44 46 91 106 70 78 75 143 46 77 93 81 108 113 86 109 122 100 88 79
S 46 27 99 62 24 36 25 19 14 25 32 55 38 45 45 100 144 47 39 35 S 39 30 86 93 29 74 56 63 47 56 62 95 66 69 63 100 150 50 37 40
G 79 25 38 47 17 100 15 11 14 6,9 19 32 115 28 21 126 61 19 19 40 G 17 0,2 7,5 0,6 5 100 4,2 0 4,3 0 0 12 22 54 1,9 5,5 0 0,6 1,9 0,4
E 35 14 95 100 15 19 7 8 5,6 5,8 20 16 32 23 7 47 32 24 5,8 11 E 9,3 8,6 482 100 1,9 1,7 1,5 0,2 1,2 0,3 9,2 85 1,6 9,5 2,2 76 64 2,4 1,5 1,6
Q 132 43 222 216 50 47 29 52 48 62 101 56 25 100 47 128 126 99 38 64 Q 151 46 289 278 42 51 31 94 69 123 114 43 16 100 43 218 209 98 35 73
I 11 9,8 10 11 17 8 7,9 100 6,9 94 9,7 12 9,1 12 11 9,5 12 181 12 13 I 6,3 0 0 0 5,2 1,6 0 100 0,4 9,1 0,1 0 0 1,7 1 0 12 56 0,1 13
L 11 10 13 11 22 7,5 9,8 17 6,9 100 9,9 11 7,6 9,9 12 9,8 9,5 10 12 19 L 0 0 0,1 0,7 6,6 0 0 0,8 3,2 100 1,6 1 0 3,8 3,2 4,8 0 0 2 0,3
S 69 22 100 129 45 26 11 29 22 41 70 26 3,1 55 36 100 72 52 27 44 S 84 21 61 131 62 49 23 48 64 80 87 33 0 72 36 100 91 40 29 81
A 100 5,9 8,4 16 6,1 5,5 4,4 6,4 4 5 7 4,9 4,4 13 11 51 9,3 21 6,9 6,5 A 100 15 91 132 12 0 6,6 0,5 33 67 102 29 0 52 22 60 14 1,1 18 21
I 8,7 6,9 7,4 6,6 7,5 6,2 6,2 100 5,3 7,4 7 6,7 5,8 6,8 7,5 7,1 8,5 28 9,9 9,8 I 0 0 0,4 0 0 0 0 100 0 0,3 0 0 0 0 0 0 0 31 0 0
V 17 7,5 11 16 9,9 9,3 7,5 53 7,4 19 19 7,9 6,5 12 18 37 134 100 13 13 V 1,3 0,6 1,7 0 0 0 0 134 0,8 6,7 0,3 1,2 0 0,1 0 0,9 20 100 1,4 0,7
T 57 23 69 237 25 20 16 40 15 12 37 20 32 40 21 166 100 79 21 34 T 23 7,8 10 41 12 9,3 0,9 27 18 17 22 3,6 6,4 6,7 8,5 65 100 24 6,6 12
A 100 37 76 159 38 59 12 27 25 17 37 18 50 38 26 124 90 77 24 66 A 100 20 39 59 11 45 7,9 22 30 19 75 8,2 20 32 23 163 155 49 8,6 34
A 100 41 103 92 38 25 16 29 21 16 21 45 32 43 30 124 107 101 27 70 A 100 25 64 125 29 69 30 74 66 25 75 28 53 44 26 655 605 154 33 61
D 34 33 100 86 19 13 12 19 13 12 16 16 34 16 22 63 63 52 22 63 D 46 43 100 157 47 56 29 70 54 46 80 30 47 45 28 153 209 78 36 92
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Figure S4: Antibody fingerprints of 5 sera for the epitope at position 249 – 267 on the VlsE antigen. 
The original amino acids of the peptide sequence were one by one substituted by all other amino acids. 
The resulting peptides were printed as array duplicates (not shown) and incubated with the 
corresponding serum. The results are visualized as a heat map. The relative fluorescence intensities of 
all peptides in a row are calculated according to the intensity of the peptide with the original amino 
acid set to 100 %. The original sequence is shown from top to bottom left; essential amino acids are 
indicated in red. Substituted amino acids are shown from left to right on top of the substitution arrays. 
 
A C D E F G H I K L M N P Q R S T V W Y A C D E F G H I K L M N P Q R S T V W Y
K 130 114 152 160 111 148 118 138 100 109 137 142 206 140 122 114 151 128 88 93 P 94 91 104 90 106 87 114 122 84 196 130 99 100 92 111 98 112 96 114 95
K 81 68 50 78 65 57 64 79 100 51 71 75 64 50 56 60 68 63 55 54 E 85 66 134 100 96 103 106 186 76 154 87 93 122 110 89 116 168 134 113 77
P 63 55 39 54 52 42 48 68 34 38 51 56 100 77 50 45 53 55 48 47 E 93 83 136 100 90 100 96 105 76 90 87 91 129 119 125 137 121 91 97 88
E 63 46 47 100 43 42 42 54 31 38 50 48 46 35 49 43 48 44 32 37 A 100 93 171 186 122 99 101 117 88 122 110 120 123 138 132 151 167 106 100 123
E 48 34 31 100 33 43 33 41 23 30 34 43 28 29 36 33 43 35 29 24 K 88 71 116 96 93 66 69 102 100 158 111 113 76 108 102 110 139 98 84 95
A 100 58 251 241 59 89 51 86 84 73 131 176 68 84 95 169 282 110 31 43 N 30 24 31 26 25 23 27 22 21 21 23 100 23 29 29 28 25 25 34 30
K 0 0 0 0 0 0 0 0 100 0 0 0 0 0 0 0 0 0 0 0 P 75 32 34 35 48 33 34 36 26 43 37 32 100 41 34 37 151 49 39 49
N 75 66 148 182 42 33 47 45 127 55 192 100 68 93 103 122 107 84 29 39 I 41 22 26 25 26 21 19 100 17 23 20 24 22 34 23 24 26 30 25 26
P 18 18 60 58 15 26 16 25 45 15 38 22 100 18 23 22 38 26 12 13 A 100 34 62 185 50 47 27 36 29 37 80 40 29 67 41 79 38 31 38 44
I 49 86 121 200 112 56 71 100 103 100 102 130 81 57 71 80 91 118 41 130 A 100 49 130 137 54 45 38 61 48 62 66 64 29 64 50 106 86 69 48 57
A 100 87 185 175 46 59 44 64 92 50 105 86 117 65 48 104 86 89 25 42 A 100 17 20 24 16 17 16 24 15 17 18 17 19 18 20 21 19 23 22 20
A 100 177 209 386 70 178 79 265 130 102 188 105 155 81 165 119 111 387 74 48 I 31 23 26 35 42 23 17 100 23 112 60 25 27 27 28 26 47 56 36 31
A 100 69 117 151 43 50 36 84 50 52 65 77 201 70 49 57 89 106 40 49 G 125 67 100 170 67 100 43 87 58 97 86 59 48 64 61 189 222 106 57 62
I 34 45 58 62 33 28 37 100 52 45 39 45 78 40 47 49 98 72 31 26 D 54 42 100 69 55 41 34 41 39 40 57 48 38 54 42 72 72 46 45 47
G 55 89 61 81 49 100 42 69 96 64 91 85 93 75 42 49 71 91 49 49 K 108 103 196 147 127 95 74 109 100 118 117 92 123 105 96 137 179 144 96 129
A C D E F G H I K L M N P Q R S T V W Y A C D E F G H I K L M N P Q R S T V W Y
P 66 70 107 125 111 226 125 129 91 133 119 108 100 85 106 84 118 36 89 82 E 60 33 95 100 69 113 94 92 64 102 135 119 140 112 99 136 142 119 110 100
E 167 81 89 100 86 72 102 339 94 737 113 132 106 93 73 224 217 554 68 103 A 100 116 280 238 161 252 206 203 211 256 295 257 322 264 272 364 350 243 205 219
E 71 64 102 100 71 79 81 99 88 100 106 88 87 69 55 83 60 36 66 51 K 52 36 59 79 79 72 48 95 100 99 108 80 109 81 91 112 115 107 62 96
A 100 80 131 224 102 80 108 215 109 224 135 146 165 117 86 103 98 104 68 81 N 1,8 3,3 2,6 2,8 2,4 1,7 2 1,8 1,7 1,7 2,1 100 2,6 2,8 1,9 11 2,4 2,1 5,4 2,6
K 20 17 21 32 29 14 26 42 100 51 66 34 17 33 30 16 16 10 25 22 P 8,8 3,8 6,1 14 6 3,7 3,3 5,2 9,2 8,7 16 9,2 100 20 10 10 7,5 6,8 6 5,9
N 13 6,1 8,1 8,6 7,2 2,4 1,9 3,8 3,4 3,5 2,1 100 3,4 2,9 2,3 1,4 1,5 3 6,8 9,9 I 6,9 1,9 2,4 2,5 4,9 2,1 5,6 100 14 44 14 3,1 1,8 8,9 12 5,4 42 50 2,6 3,3
P 7,7 4,1 11 15 23 4,5 6,9 19 4,6 37 9,2 6,5 100 7,9 11 3,4 1,5 6,3 7,7 24 A 100 16 58 210 31 52 21 31 16 31 86 38 20 63 25 96 29 14 18 42
I 6,6 5,1 11 10 10 4,8 1 100 2,2 6,8 2,5 3,7 3,7 4,4 3,7 2,4 2,1 8,3 9,9 8,6 A 100 30 110 170 92 80 40 110 103 133 149 87 26 91 62 139 140 125 47 94
A 100 27 53 808 43 23 11 7,7 11 9 110 38 56 122 10 71 5,9 6,3 25 30 A 100 32 80 122 80 62 54 90 86 106 132 77 11 91 69 137 116 90 45 77
A 100 23 110 115 30 18 13 28 31 50 60 42 8,4 36 24 54 36 20 18 26 I 10 4 5,6 5,5 15 8 11 100 5,7 100 65 14 3,2 12 7,3 16 66 59 6,5 7,7
A 100 9,6 15 14 9,4 5,2 2,4 18 1,2 5,3 3,7 4,2 12 5,2 7,6 2,1 4,1 6,1 21 11 G 45 49 69 77 48 100 54 67 53 66 93 78 91 70 45 159 165 74 31 62
I 7,2 6,5 22 11 52 3,7 4,3 100 2,2 69 39 3,5 3,7 5,2 5,8 4,7 4,9 18 13 12 D 50 65 100 89 61 69 72 90 81 87 96 91 108 90 74 109 124 102 59 96
G 64 57 95 158 61 100 38 90 76 116 153 68 18 69 46 135 301 55 47 46 K 63 60 87 101 78 97 77 102 100 93 108 94 137 100 85 137 154 108 73 111
D 33 39 100 92 59 38 36 70 36 42 67 45 32 35 29 47 25 41 26 52 D 60 53 100 88 75 77 69 96 91 89 99 88 100 80 66 127 130 112 60 94
K 84 65 140 140 100 84 59 120 100 114 192 119 161 73 57 107 94 85 84 129 G 81 80 121 137 118 100 79 145 111 133 142 114 123 108 101 159 149 145 96 149
A C D E F G H I K L M N P Q R S T V W Y
P 67 77 82 83 68 42 57 41 47 62 60 76 100 74 77 99 106 89 102 85
E 78 66 100 100 54 43 59 54 48 61 56 90 114 94 84 98 125 113 80 89
E 61 65 109 100 62 45 41 14 16 48 44 64 93 77 70 87 77 86 69 73
A 100 100 154 204 89 76 62 27 23 68 58 121 130 113 109 134 141 143 101 108
K 154 118 193 241 154 71 119 43 100 129 157 207 195 249 239 198 259 218 161 180
N 4,5 9,4 5,7 6,2 3,6 3,3 3,2 3 2,8 2,8 3,3 100 3,8 4,4 3,7 5,7 3,8 3,4 4,8 4,3
P 30 7,3 21 27 28 5,1 7 9,8 7,9 17 14 8,4 100 16 22 19 18 46 7,5 41
I 12 8,7 12 11 18 7,8 7,2 100 6,5 6,8 7,9 8,2 9,9 12 18 9,5 8,3 54 9 13
A 100 23 73 189 36 35 15 12 12 26 69 32 5,8 79 27 99 21 16 30 54
A 100 26 91 140 38 24 10 22 31 32 43 50 8 61 31 91 87 80 24 59
A 100 5,3 6,4 6,1 4,8 9,9 4,2 5,5 3,2 5,4 5,2 5,3 5,1 6,5 7,5 25 8,8 19 8,1 7,1
I 19 11 13 12 33 7,3 25 100 7,4 110 64 17 16 25 14 19 96 109 23 34
G 103 78 148 161 55 100 38 47 61 88 123 94 88 93 74 209 318 160 65 81
D 46 44 100 74 43 33 22 14 33 29 42 36 59 64 54 78 94 82 44 77
K 120 170 245 258 108 96 80 43 100 101 117 117 170 173 162 240 323 269 157 261
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Figure S5: Antibody fingerprints of 7 sera for the epitope at position 338 – 357 on the VlsE antigen. 
The original amino acids of the peptide sequence were one by one substituted by all other amino acids. 
The resulting peptides were printed as array duplicates (not shown) and incubated with the 
corresponding serum. The results are visualized as a heat map. The relative fluorescence intensities of 
all peptides in a row are calculated according to the intensity of the peptide with the original amino 
acid set to 100 %. The original sequence is shown from top to bottom left; essential amino acids are 
indicated in red. Substituted amino acids are shown from left to right on top of the substitution arrays. 
 
 
 
 
  
A C D E F G H I K L M N P Q R S T V W Y A C D E F G H I K L M N P Q R S T V W Y
R 98 98 97 105 99 96 117 156 89 98 108 114 138 105 100 112 122 78 121 103 D 110 85 100 101 109 97 96 120 101 111 111 98 118 125 127 115 112 123 121 129
K 107 118 113 129 142 114 157 232 100 119 130 106 153 109 118 112 145 106 181 125 S 103 78 89 85 100 88 73 96 87 101 103 90 101 108 114 100 107 116 116 119
V 102 92 89 90 117 98 141 143 99 96 100 92 154 96 99 86 97 100 132 109 V 95 72 80 89 98 86 76 101 91 95 93 85 94 94 91 89 101 100 97 99
G 79 73 70 95 104 100 109 108 96 87 105 80 104 104 135 93 104 91 116 109 K 115 97 99 105 110 90 75 110 100 99 98 85 90 103 109 92 110 112 99 101
D 93 85 100 93 94 85 88 79 84 70 76 77 70 79 90 88 78 76 91 99 A 100 72 80 86 88 78 72 97 78 79 87 77 83 84 90 77 88 89 76 76
S 1443 76 64 62 67 60 55 55 48 46 46 47 68 61 59 100 66 108 66 66 A 100 64 79 79 83 77 67 91 74 82 82 70 79 82 84 72 81 84 65 67
V 312 110 88 271 133 91 78 113 193 78 156 71 117 107 136 156 74 100 115 164 S 108 81 102 125 117 112 93 138 116 128 137 115 108 117 110 100 116 116 89 98
K 103 86 84 80 93 79 77 75 100 65 118 71 69 82 112 92 81 78 92 89 K 7,5 9,5 5,6 7,8 15 6,2 9,2 20 100 16 13 10 9,9 13 18 6,4 9,6 13 7,2 8,8
A 100 63 64 60 63 54 52 50 40 41 50 51 50 59 58 57 58 53 62 62 E 19 18 45 100 7 8,7 9,4 18 21 12 40 14 4,5 36 10 14 16 17 6,1 5
A 100 55 56 58 62 50 45 50 37 43 49 46 50 50 56 51 54 54 57 61 T 112 47 109 150 55 30 35 90 92 120 126 76 119 111 84 86 100 86 39 48
S 83 64 66 69 70 60 51 52 45 46 63 59 122 57 64 100 85 61 66 69 P 7,7 0 0,7 1 1 2,9 0,9 4 1,9 3,6 2,5 3,2 100 2,6 1,6 1,5 2,5 5,4 0,5 0,7
K 90 91 80 82 100 72 71 72 100 68 78 77 82 85 94 78 77 82 108 96 P 4,1 1,8 6,8 6,1 2,5 2,8 4,1 4,9 2,2 1 2,1 5 100 3,2 7,2 4 2,8 3 3,5 4,4
E 81 71 74 100 67 57 51 73 63 66 74 67 87 75 71 73 75 86 77 76 A 100 39 63 76 50 58 37 82 60 57 79 79 78 93 78 77 76 83 52 49
T 78 65 89 83 71 65 50 69 65 70 77 55 50 66 65 64 100 76 67 78 L 0,1 0,1 0,2 0,7 5,3 0,3 1,1 27 3,7 100 4,1 1,4 0,7 1,5 1,2 0,5 3,5 2,8 0,9 1
P 106 76 124 123 81 90 66 127 96 114 90 68 100 74 77 112 109 112 83 113 N 0,7 0,7 1,1 0,1 0,5 4,5 3,7 0,7 0,3 1,5 3,3 100 0,9 4,4 1,4 13 3,4 1 0,8 0,5
A C D E F G H I K L M N P Q R S T V W Y A C D E F G H I K L M N P Q R S T V W Y
D 91 84 100 91 112 113 117 108 125 127 107 115 119 116 126 124 142 117 122 112 D 83 88 100 79 94 96 88 95 94 99 94 99 105 95 115 111 125 91 98 113
S 69 75 89 85 94 92 93 97 102 104 89 98 104 82 91 100 111 93 99 104 S 80 79 89 78 84 93 85 85 92 97 86 87 93 92 107 100 123 66 91 102
V 87 97 99 90 102 105 96 96 100 112 98 105 109 103 107 116 121 100 119 112 V 104 92 124 112 107 117 114 112 118 136 114 118 123 120 138 130 147 100 116 151
K 92 91 96 99 93 109 98 91 100 109 85 99 103 100 106 113 116 104 110 116 K 104 90 102 85 91 113 100 99 100 107 99 105 105 115 125 118 121 99 111 128
A 100 104 120 103 108 120 111 109 115 133 109 108 119 111 125 122 128 100 120 117 A 100 85 97 80 84 98 89 81 90 103 95 97 104 110 118 113 114 95 98 107
A 100 91 114 113 97 119 91 101 108 117 102 119 125 127 119 119 129 101 112 110 A 100 90 117 103 101 112 90 88 95 112 122 103 127 118 123 126 124 101 117 104
S 80 65 88 87 81 91 86 82 91 92 89 107 102 98 97 100 110 105 91 94 S 82 74 102 94 84 104 95 95 97 107 105 103 116 120 112 100 106 104 93 106
K 40 48 41 60 94 41 60 107 100 122 88 76 85 74 76 65 99 122 70 76 K 6,3 5,2 6,6 5,4 9,3 6,9 8,5 12 100 14 10 9,8 9,7 11 11 7,6 9,3 9,1 9,2 12
E 18 17 53 100 21 16 12 21 29 24 36 20 16 38 16 27 32 31 12 22 E 78 55 107 100 72 44 63 109 108 138 143 102 15 118 94 126 157 101 69 71
T 48 28 64 83 46 23 35 73 63 92 65 53 52 70 63 61 100 71 34 44 T 22 28 102 58 26 8,5 26 28 20 50 35 36 21 27 27 128 100 29 20 25
P 20 1,6 1,5 2,4 4,9 17 3,5 14 1,3 9,9 4,7 6,5 100 6,9 2,8 7,3 10 14 3 5,7 P 7,6 0 1,9 1,8 7 20 5,4 9,8 5,9 4,7 1 4,8 100 6,1 0,6 8,5 7,9 12 0 0,4
P 66 11 37 42 28 38 28 30 48 41 38 58 100 46 57 86 59 35 13 29 P 73 32 112 56 23 31 30 17 50 58 52 88 100 69 57 93 36 20 21 26
A 100 149 264 155 291 194 128 141 97 138 146 275 123 162 129 183 233 123 245 271 A 100 29 71 51 26 67 43 29 32 47 42 55 131 57 45 136 81 34 26 39
L 20 7,3 2,7 3,4 21 7,6 3,4 22 2,7 100 3,5 13 95 6,7 6,9 14 3,4 8,6 10 21 L 0 0,1 0 0 69 35 35 8,3 7,7 100 49 7,5 0,2 57 22 3,6 0,8 2,8 51 77
N 3,1 7,2 13 7 6,1 6,2 4,5 4,1 2,3 6,6 6 100 9,8 8,1 4,6 8,1 5,3 4,1 6,4 5,9 N 0 0 0 0 0 0,5 0 0 0 0 0,1 100 0,5 0,8 0,8 0,2 0 0,1 0,5 7,2
A C D E F G H I K L M N P Q R S T V W Y A C D E F G H I K L M N P Q R S T V W Y
L 122 120 111 157 152 156 148 136 105 100 136 111 110 147 146 147 155 148 130 143 L 78 76 88 80 84 83 96 77 95 100 97 109 96 105 86 80 95 67 92 61
R 98 80 83 102 104 101 86 93 73 79 78 81 95 92 100 102 104 91 83 96 R 60 90 86 87 95 84 98 107 115 101 102 106 109 104 100 80 98 76 100 93
K 136 111 120 135 127 127 138 116 100 101 114 119 132 133 130 133 130 130 125 140 K 78 79 84 95 88 86 96 85 100 91 102 103 102 101 83 98 86 76 69 70
V 110 70 82 109 95 95 94 80 57 71 81 82 119 86 75 103 97 100 74 100 V 148 131 145 152 143 145 139 129 138 154 139 148 206 158 114 137 132 100 104 112
G 2,6 2,7 3,7 2,3 18 100 16 2,3 25 0,5 9,5 8,5 2,2 4,7 5 7,7 4,3 10 7,7 13 G 7,2 16 12 9,6 24 100 27 13 29 15 15 31 10 44 19 28 17 7 16 7,3
D 5,7 7,5 100 63 8,4 12 22 1,2 6,8 0 3,5 34 2,1 14 4,6 0,9 6 11 9,6 15 D 5,8 21 100 76 8 12 14 8,3 18 9,7 19 30 7,3 18 17 9,8 13 8 8,6 3,6
S 162 3,6 3,3 1,3 9,9 111 14 9,6 5,2 8,4 2,4 12 3,7 8,1 3,9 100 7,7 0,9 4,9 7,8 S 151 17 18 12 20 147 23 26 25 9 12 24 11 19 16 100 19 8,7 11 8
V 130 65 98 126 121 99 77 96 89 55 98 80 91 94 96 138 89 100 80 141 V 95 97 113 159 127 76 79 84 123 84 129 108 96 99 87 128 93 100 105 100
K 42 6,2 0 10 32 17 30 39 100 24 85 12 0 44 80 57 49 46 9,6 41 K 40 16 7 31 44 36 43 59 100 45 117 38 0,2 58 84 72 86 63 23 42
A 100 0 0 0 1,6 24 0 0 0,8 0 0 0 0 0,1 1,8 29 1,4 0 0,9 0,2 A 100 0 1,7 0,6 1,8 22 0,8 0 0 0 0,1 0 0 2,5 5,9 32 1,7 0 0 0
A 100 3,7 5,6 32 20 31 8,5 2,7 40 5,9 27 1,7 0 24 21 56 32 30 2,7 19 A 100 6,9 15 92 25 20 11 4,6 53 11 51 7,9 0 45 25 57 29 14 0,2 14
S 61 9,5 25 48 40 46 11 62 50 25 55 31 27 30 32 100 93 83 7,9 33 S 43 16 42 85 43 35 16 59 59 36 60 29 37 29 29 100 103 66 10 18
K 0 0 0 0 0 0 0 3,7 100 0 0 0 0 0 0,8 0 7,4 14 0 0 K 0 0 0 0 0 0 0,7 17 100 1,7 0 0 0 0 1,6 0,1 23 34 0,4 0,3
E 82 48 59 100 63 53 47 98 80 68 69 40 56 40 33 92 103 107 33 51 E 56 44 62 100 55 51 44 64 83 73 58 37 51 38 48 64 81 62 30 33
T 58 40 51 66 67 54 42 83 73 55 59 39 52 39 44 80 100 119 35 61 T 37 57 50 70 65 59 42 91 81 75 76 57 66 47 48 58 100 100 29 34
A C D E F G H I K L M N P Q R S T V W Y
L 61 85 69 92 78 95 119 82 92 100 117 103 72 85 73 183 90 69 64 73
R 90 95 86 116 96 106 148 101 108 98 127 125 108 123 100 106 105 102 87 96
K 77 86 61 110 92 96 112 79 100 104 103 94 80 103 83 77 91 74 71 72
V 90 215 85 84 125 150 267 105 219 94 80 346 108 344 139 70 93 100 347 120
G 0 0 0 0 0 100 3,5 5,8 39 0 0 0 0 0 0 0 0 0 0 0
D 0 0 100 0 0 0 0 0 0 0 0 203 0 0 0 193 123 0 4,4 0
S 0 0 0 0 0 0 0 7 0 0 0 0 0 0 0 100 0 0 0 0,3
V 284 39 187 104 109 310 115 64 583 94 201 331 0 224 447 1071 998 100 23 147
K 0 0 73 0 0 0 0 0 100 0 0 0 0 0 0 0 0 0 0 5,4
A 100 46 110 117 73 65 42 72 110 110 97 111 140 80 38 85 75 72 37 73
A 100 31 104 152 101 85 81 942 152 126 97 94 73 106 76 179 124 117 36 54
S 69 53 410 123 115 70 52 130 95 109 86 89 53 74 72 100 101 108 46 57
K 94 73 108 134 141 91 82 94 100 122 127 114 61 98 83 85 103 111 65 79
E 51 73 99 100 72 34 51 58 65 70 51 56 40 48 52 55 55 54 29 31
T 64 123 108 98 160 87 107 106 109 122 92 129 61 72 83 63 100 90 90 85
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Supplementary Tables S2 – S6 list all potentially cross-reacting human proteins that have 
been identified with queries of the antibody fingerprints in protein databases. 
Table S2: Results of the query of all human proteins of the “UniProtKb/TrEMBL” and 
“UniProtKb/Swiss-Prot” protein databases with the “ScanProsite tool” for the epitope VlsE 20 – 40 
and the fingerprint D-P-T-N. The table lists the proteins on which the motif is located, the amino acid 
position and the exact sequence. The query included splice variants and fragments. Similar entries, 
corresponding to the same protein, were deleted. The proteins printed in bold are linked to 
autoimmune disorders. 
Protein Database entry Aa sequence Position 
2'-5'-oligoadenylate synthetase 2 >sp|P29728|OAS2_HUMAN DPTN 296-299 
Activating signal cointegrator 1 complex subunit3 >sp|Q8N3C0|ASCC3_HUMAN DPTN 1226-1229 
ADAM10 protein >tr|A0AV88|A0AV88_HUMAN DPTN 285-288 
ADAM metallopeptidase domain 10 
>tr|A0A024R5U5|A0A024R5U5_HUMA
N 
DPTN 285-288 
alpha-1,2- Mannosidase >tr|B4DEE1|B4DEE1_HUMAN DPTN 221-224 
Alternative protein CFP, >tr|L0R836|L0R836_HUMAN DPTN 105-108 
ATPase family AAA domain-containing protein 5, 
Chromosome fragility-associated gene 1 protein 
>sp|Q96QE3|ATAD5_HUMAN DPTN 1740-1743 
Attractin, DPPT-L >sp|O75882|ATRN_HUMAN DPTN 1099-1102 
Attractin-like protein 1 >sp|Q5VV63|ATRN1_HUMAN DPTN 1050-1053 
Bardet-Biedl Syndrome 4 isoform 1, Bardet-Biedl 
Syndrome 4 
>tr|A0A0S2Z3A9|A0A0S2Z3A9_HUM
AN 
DPTN 232-235 
Coiled-coil domain-containing protein 60 >tr|F5H2N8|F5H2N8_HUMAN DPTN 94-97 
Constitutive coactivator of peroxisome proliferator-
activated receptor gamma, Constitutive coactivator of 
PPAR-gamma 
>sp|Q96EK7|F120B_HUMAN DPTN 556-559 
DEAD box polypeptide 5, ets variant protein 4 fusion 
protein 
>tr|C1IK54|C1IK54_HUMAN DPTN 388-391 
Death-associated protein 6 
>tr|A0A024RCS3|A0A024RCS3_HUM
AN 
DPTN 167-170 
Death-associated protein 6 variant >tr|Q53F85|Q53F85_HUMAN DPTN 167-170 
Disintegrin and metalloproteinase domain-containing 
protein 10, ADAM10 
>sp|O14672|ADA10_HUMAN DPTN 285-288 
DNA polymerase delta subunit 2, DNA polymerase delta 
subunit p50 
>sp|P49005|DPOD2_HUMAN DPTN 300-303 
Dynein heavy chain 8 >sp|Q96JB1|DYH8_HUMAN DPTN 3919-3922 
Epididymis secretory sperm binding protein Li94n, Stress-
induced-phosphoprotein 1(Hsp70/Hsp90-organizing protein 
>tr|V9HW72|V9HW72_HUMAN DPTN 255-258 
ER degradation-enhancing alpha-mannosidase-like protein 2 >sp|Q9BV94|EDEM2_HUMAN DPTN 442-445 
ER membrane protein complex subunit 2, Tetratricopeptide 
repeat protein 35 
>sp|Q15006|EMC2_HUMAN DPTN 117-120 
ETS translocation variant 4, Adenovirus E1A enhancer-
binding protein 
>sp|P43268|ETV4_HUMAN DPTN 353-356 
Ets variant gene 4, E1A enhancer binding protein >tr|D3DX44|D3DX44_HUMAN DPTN 179-182 
EWS protein, E1A enhancer binding protein chimera >tr|A2NIV0|A2NIV0_HUMAN DPTN 347-350 
Glycoprotein receptor gp330, Megalin, LRP-2 >tr|Q7Z5C0|Q7Z5C0_HUMAN DPTN 1016-1019 
GPRIN family member 3 >tr|A0AVI5|A0AVI5_HUMAN DPTN 528-531 
G protein-regulated inducer of neurite outgrowth 3, GRIN3 >sp|Q6ZVF9|GRIN3_HUMAN DPTN 528-531 
Homeobox protein DLX-3 >sp|O60479|DLX3_HUMAN DPTN 246-249 
Intraflagellar transport protein 74 homolog, Capillary 
morphogenesis gene 1 protein 
>sp|Q96LB3-2|IFT74_HUMAN DPTN 352-355 
KIAA0103 variant (ER membrane protein complex subunit 
2) 
>tr|Q53HG5|Q53HG5_HUMAN DPTN 117-120 
Kin of IRRE-like protein 1, Kin of irregular chiasm-like >sp|Q96J84|KIRR1_HUMAN DPTN 600-603 
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protein 1 
Kin of IRRE-like protein 2, Kin of irregular chiasm-like 
protein 2 
>sp|Q6UWL6|KIRR2_HUMAN DPTN 598-601 
Kin of IRRE-like protein 3, Kin of irregular chiasm-like 
protein 3 
>sp|Q8IZU9|KIRR3_HUMAN DPTN 632-635 
Laforin >sp|B3EWF7|EP2A2_HUMAN DPTN 327-330 
Mitogen-activated protein kinase-binding protein 1, JNK-
binding protein 1 
>sp|O60336|MABP1_HUMAN DPTN 353-356 
MSSP-2 >tr|Q5CZ65|Q5CZ65_HUMAN DPTN 5-8 
NCF4 protein >tr|Q6FGM9|Q6FGM9_HUMAN DPTN 235-238 
Neutrophil cytosol factor 4, NCF-4 >sp|Q15080|NCF4_HUMAN DPTN 235-238 
Non-receptor tyrosine-protein kinase TYK2, EC2.7.10.2 >sp|P29597|TYK2_HUMAN DPTN 917-920 
Peptidyl-prolyl cis-trans isomerase-like 2, PPIase >sp|Q13356|PPIL2_HUMAN DPTN 160-163 
Peptidylprolyl isomerase (Cyclophilin)-like 2 
>tr|A0A024R1C1|A0A024R1C1_HUM
AN 
DPTN 160-163 
PGAP2-interacting protein, Cell wall biogenesis protein 43 
C-terminal homolog 
>sp|Q9H720|PG2IP_HUMAN DPTN 648-651 
Phosphatidylcholine:ceramide choline phosphotransferase 2, 
EC2.7.8.27 
>sp|Q8NHU3|SMS2_HUMAN DPTN 19-22 
Probable maltase-glucoamylase 2, Maltase-glucoamylase 
(alpha-glucosidase) 
>sp|Q2M2H8|MGAL_HUMAN DPTN 1012-1015 
Proprotein convertase subtilisin/kexin type 1 (NEC1) >tr|A1L3V6|A1L3V6_HUMAN DPTN 201-204 
ProteinFAM214A, >sp|Q32MH5|F214A_HUMAN DPTN 751-754 
ProteinkinaseC-bindingprotein1, CutaneousT-
celllymphoma-associatedantigense14-3 
>sp|Q9ULU4|PKCB1_HUMAN DPTN 380-383 
Proteinkinase C-binding protein 1 
>tr|A0A087WV57|A0A087WV57_HU
MAN 
DPTN 355-358 
Putative stereocilin-like protein, Stereocilin Pseudogene 1 >sp|A6NGW2|STRCL_HUMAN DPTN 199-202 
RNA-binding motif, single-stranded-interacting protein 1 
>tr|A0A0S2Z499|A0A0S2Z499_HUMA
N 
DPTN 139-142 
RNA-binding motif, single-stranded-interacting protein 2 
>tr|A0A0S2Z4B3|A0A0S2Z4B3_HUM
AN 
DPTN 138-141 
SAM domain-containing protein SAMSN-1 (Hematopoietic 
adaptor containing SH3 and SAM domains 1) 
>sp|Q9NSI8|SAMN1_HUMAN DPTN 48-51 
SET-binding protein SEB >sp|Q9Y6X0|SETBP_HUMAN DPTN 412-415 
Sideroflexin-4, Breastcancer resistance marker 1 >sp|Q6P4A7|SFXN4_HUMAN DPTN 51-54 
Solute Carrier Family 12 Member 1, Bumetanide-
sensitivesodium-potassium 
>sp|Q13621|S12A1_HUMAN DPTN 296-299 
Spectrin alpha chain, erythrocytic 1 >sp|P02549|SPTA1_HUMAN DPTN 83-86 
Stereocilin >sp|Q7RTU9|STRC_HUMAN DPTN 199-202 
STRC protein, >tr|A1L379|A1L379_HUMAN DPTN 199-202 
Stress-induced-phosphoprotein1, STI1 >sp|P31948|STIP1_HUMAN DPTN 255-258 
Tubby-related protein 1, Tubby-likeprotein1 >sp|O00294|TULP1_HUMAN DPTN 355-358 
Tyrosine-protein kinase 
>tr|A0A024R7E4|A0A024R7E4_HUM
AN 
DPTN 917-920 
Ubiquitin Carboxyl-terminal hydrolase 4 >sp|Q13107|UBP4_HUMAN DPTN 147-150 
Ubiquitin conjugation factor E4A >sp|Q14139|UBE4A_HUMAN DPTN 318-321 
Ubiquitin Specific Peptidase 4, Proto-oncogene 
>tr|A0A024R2T0|A0A024R2T0_HUM
AN 
DPTN 147-150 
Ubiquitin Specific Protease >tr|Q53H56|Q53H56_HUMAN DPTN 147-150 
ZMYND8 protein >tr|A6H8Y8|A6H8Y8_HUMAN DPTN 375-378 
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Table S3: Results of the query of all human proteins of the “UniProtKb/TrEMBL” and 
“UniProtKb/Swiss-Prot” protein databases with the “ScanProsite tool” for the epitope VlsE 171–186 
and the fingerprint I-x-(ADE)-I-x-(ADE)-A-A. The table lists proteins on which the motif is located, 
the amino acid position and the exact sequence. The query included splice variants and fragments. 
Similar entries, corresponding to the same protein, were deleted.  
Protein Database entry Aa sequence Position  
Calpain small subunit 1 >sp|P04632|CPNS1_HUMAN IsAIsEAA 66-73 
Erlin-1, Endoplasmic reticulum lipid raft-associated protein 1 >sp|O75477|ERLN1_HUMAN IsEIeDAA 242-249 
Erlin-2, Endoplasmic reticulum lipid raft-associated protein 2 >sp|O94905|ERLN2_HUMAN IsEIeDAA 242-249 
Helicase SRCAP >sp|Q6ZRS2|SRCAP_HUMAN ItDIaAAA 584-591 
Pentatricopeptide repeat domain-containing protein 3, 
mitochondrial, 28S ribosomal protein S39, mitochondrial 
>sp|Q96EY7|PTCD3_HUMAN IkDIsEAA 149-156 
SPFH domain family, member 1, isoform CRA_a. >tr|D3DR65|D3DR65_HUMAN IsEIeDAA 244-251 
 
Table S4: Results of the query of all human proteins of the “UniProtKb/TrEMBL” and 
“UniProtKb/Swiss-Prot” protein databases with the “ScanProsite tool” for the epitope VlsE 249-267 
and the fingerprint N-P-I-(SAMQE)-x-A-(TLI). The table lists proteins on which the motif is located, 
the amino acid position and the exact sequence. The query included splice variants and fragments. 
Similar entries, corresponding to the same protein, were deleted. The proteins printed in bold are 
linked to autoimmune disorders. 
Protein Database entry Aa sequence Position  
Carboxypeptidase E , CPE >sp|P16870|CBPE_HUMAN NPIAnAT 386-392 
Dedicator of cytokinesis protein 10  >tr|H0YFC5|H0YFC5_HUMAN NPIEvAI 177-183 
Dedicator of cytokinesis protein 9  >tr|H0Y3S1|H0Y3S1_HUMAN NPIEvAI 508-514 
DOCK9 protein  >tr|Q7Z6H4|Q7Z6H4_HUMAN NPIEvAI 415-421 
Dopamine receptor interacting protein 2  >tr|Q4W4X9|Q4W4X9_HUMAN NPIEvAI 532-538 
PRAME family member 20  >sp|Q5VT98|PRA20_HUMAN NPIStAT 387-393 
PRAME family member 25  >sp|A6NGN4|PRA25_HUMAN NPISmAT 390-396 
PRAME family member 27  >sp|A3QJZ7|PRA27_HUMAN NPISmAT 390-396 
PRAME family member 5  >sp|Q5TYX0|PRAM5_HUMAN NPISmAT 388-394 
PRAME family member 6  >sp|Q5VXH4|PRAM6_HUMAN NPISmAT 388-394 
PRAME family member 9/15   >tr|A0A096LNW4|A0A096LNW4_HUMAN NPISmAT 390-396 
Putative PRAME family member 26   >sp|H0Y7S4|PRA26_HUMAN NPISmAT 294-300 
Transmembrane protein 131 , Protein RW1 >sp|Q92545|TM131_HUMAN NPIElAI 573-579 
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Table S5: Results of the query of all human proteins of the “UniProtKb/TrEMBL” and 
“UniProtKb/Swiss-Prot” protein databases with the “ScanProsite tool” for the epitope VlsE 338-357 
Part 1 and the fingerprint G-(ED)-(SGA)-x-K-A-A-x-K. The table lists proteins on which the motif is 
located, the amino acid position and the exact sequence. The query included splice variants and 
fragments. Similar entries, corresponding to the same protein, were deleted. 
Protein Database entry Aa sequence Position  
GON-4-like protein >sp|Q3T8J9|GON4L_HUMAN GESiKAAgK 1576-1584 
YY1AP-related protein1 >tr|A4PB67|A4PB67_HUMAN GESiKAAgK 1576-1584 
 
Table S6: Results of the query of all human proteins of the “UniProtKb/TrEMBL” and 
“UniProtKb/Swiss-Prot” protein databases with the “ScanProsite tool” for the epitope VlsE 338-357 
Part 2 and the fingerprint K-E-x-P-(ASP)-x-L-N. The table lists proteins on which the motif is located, 
the amino acid position and the exact sequence. The query included splice variants and fragments. 
Similar entries, corresponding to the same protein, were deleted. 
Protein Database entry Aa sequence Position 
Ataxin-1-like (Brother of ataxin-1) >sp|P0C7T5|ATX1L_HUMAN KEePSpLN 357-364 
Structure-specific endonuclease subunit SLX4 (BTB/POZ 
domain-containing protein 12) 
>sp|Q8IY92|SLX4_HUMAN KEaPPgLN 1684-1691 
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A.3 Supporting Information for: Single amino acid fingerprinting of the 
human antibody repertoire with high density peptide arrays 
 
Validation of biological significance 
To validate that the fingerprint analysis can be performed with other patient samples, and also 
reveal different peptide binders, we have analyzed the serum of a patient in a similar 
approach. Results are shown in Supplementary Figures S1 and S2 and Supplementary Table 
S1. 
 
 
Figure S1: Peptide array with 4,128 different random peptides. (A) Pre-staining with the European 
control serum, and (B) subsequent staining with a patient serum ID 102. Some peptide binders that 
only show interactions with the patient serum are highlighted in an exemplary way. 
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Figure S2: Amino acid substitution analysis of the top 27 peptide binders derived from the random 
peptide array staining (Figure S1). Each of the 27 peptides was synthesized in a subarray of 300 
different substitution variants (15 x 20 spots) on one big array (left) of 8,100 peptide spots (27 x 300 
spots). The array was stained with the patient serum. A magnified example of a subarray (center) and 
the corresponding heat map of the staining intensities (right) is shown. Each row in these fields 
represents the substitution analysis in one position of the sequence. On the left of each row, the 
original amino acid and its position in the peptide are shown. Each column is headed by an amino acid 
letter, which substitutes the current amino acid (row) position. Thus, in each spot, a single amino acid 
is substituted; the rest of the sequence is conserved. 
Table S1: Identified peptide binders for the patient serum. 22 of 27 substituted peptide binders 
resulted in fingerprints. Original amino acid sequences and essential amino acids at each position of 
the respective peptide are depicted. Essential amino acids of the original peptides are depicted in red.  
Original  
peptide  
sequence 
Amino acid position in epitope    
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 
DLMLAEMHMGEVMS
N X X X X X X X X X F,G E X X X X 
ENMWKPTLNTTTEPV X X X X X X X X X X X X T,E P X 
FRTGEYEEDLDKLGG X X X G E X I,M,E,G I,D,L,E L,F,E,H,D X X X X X X 
FWELPPSPETDQKRW X X X X X X X X X X D X K X C,W,Y,L,F 
GHVISAVGEERKLGK X X X X X X X G E E X X X X X 
GPIQNPGHNGSVEDT X X X X X X X X N G X X D,E D,E X 
HIRDYPHYYWGELRL X X X X X X X X X X G E X X X 
HKQPEMPWVYMFGGE X X X X X X X X X X X X X G,E E 
IMAIGINATFAKENK X X X X X X X X X X A,G X E N K 
INAMEGELQMQETVH X X X X X G A,E I,D,L,E M,E,I,Q X D,E,Q X X X X 
IRMYEKSKPPVIQPS X X X X X X X X X X X X Q X S 
MFTLFSSWTVDEQQV X X X X X X X X X X G,E,D E M,Q,T,V,I Q V 
MIQQQFLFYRTPQPL X X X X X X X X X X T P Q P X 
MTKYWGHLETHYQPS X X X X X X X X X S,P,T X X Q P S 
NAPRHEEWLVATEQP X X X X X S,W,Y,D,E W,Y,D,E E,W,D X X Q,A,E,T,P T X D,Q,E P 
NMHNIEETVDQKFRD X X X X X X X X P,V,I D X K I,L,F X F,D 
SHSQSLEHTTMNALH X X X X X L,I X H I,T,V T X N X X X 
SNGSIYSKPHNGTMM X X X X X X X X P X N G T X X 
TAGGKPPFGTDGSGS X X X X X X X X X X X S,G C,G,D,S,E Q,G X 
TENYQKFTDIMPAFV X X X X X X F,Q X D,E X X X X F,P X 
WKYSISWGFTRGFFN X X X X X X X X X X X F,E,G,Y F,E F E,N,D 
WLITEGREQATTAAI X X X X X X X D,E X X M,T,Q T X X F,Y,K,I,R 
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Bioinformatic analysis of fingerprints 
The four most abundant fingerprints, shown in Figure 5, were queried in the 
“UniProtKb/Swiss-Prot” protein database (release 2016_11 of 30-Nov-16: 553231 entries) 
with the “ScanProsite tool”. All results of the query are listed in Supplementary Tables S2 – 
S5.  
 
Table S2: Results of the query of the “UniProtKb/Swiss-Prot” protein database with the “ScanProsite 
tool” for the NPVEXXX motif with the amino acids A/N/D-N/P-V-E-E/D/A/F-F/Y-I/V/L. The table 
lists the organism and protein on which the motif is located, the amino acid position and the exact 
sequence. The query included splice variants and excludes fragments. 
Organism Antigen Database entry 
Position & 
Epitope 
Acanthamoeba polyphaga 
mimivirus (APMV) 
Uncharacterized protein R261. 
sp|Q5UP22|YR261_MIMIV  
(181 aa) 
32-38 
DNVEAYI 
Archaeoglobus fulgidus 
(strain ATCC 49558 / 
VC-16 / DSM 4304 / 
JCM 9628 / NBRC 
100126) 
Sulfite reductase, dissimilatory-type subunit beta (EC 
1.8.99.5) (Hydrogensulfite reductase subunit beta). 
sp|Q59110|DSRB_ARCFU  
(366 aa) 
88-94 
NNVEFFV 
Autographa californica 
nuclear polyhedrosis 
virus (AcMNPV) 
Late expression factor 7. 
sp|P41677|LEF7_NPVAC  (226 
aa) 
50-56 
NNVEDYL 
Bacillus phage B103 
(Bacteriophage B103) 
Proximal tail tube connector protein (Gene product 11) 
(gp11) (Lower collar protein) (Protein p11). 
sp|Q37892|TUB11_BPB03  
(293 aa) 
245-251 
NNVEDYI 
Bacillus thuringiensis 
subsp. morrisoni 
Pesticidal crystal protein Cry3Aa (73 kDa crystal 
protein) (Crystaline entomocidal protoxin) (Insecticidal 
delta-endotoxin CryIIIA(a)). 
sp|P0A380|CR3AA_BACTM  
(644 aa) 
138-144 
NNVEDYV 
Bacillus thuringiensis 
subsp. san diego 
Pesticidal crystal protein Cry3Aa (73 kDa crystal 
protein) (Crystaline entomocidal protoxin) (Insecticidal 
delta-endotoxin CryIIIA(a)). 
sp|P0A381|CR3AA_BACTD  
(644 aa) 
138-144 
NNVEDYV 
Bacillus thuringiensis 
subsp. tenebrionis 
Pesticidal crystal protein Cry3Aa (73 kDa crystal 
protein) (Crystaline entomocidal protoxin) (Insecticidal 
delta-endotoxin CryIIIA(a)). 
sp|P0A379|CR3AA_BACTT  
(644 aa) 
138-144 
NNVEDYV 
Bos taurus (Bovine) 
Dihydroxyacetone phosphate acyltransferase (DAP-AT) 
(DHAP-AT) (EC 2.3.1.42) (Acyl-
CoA:dihydroxyacetonephosphateacyltransferase) 
(Glycerone-phosphate O-acyltransferase). 
sp|A4IF87|GNPAT_BOVIN  
(680 aa) 
236-242 
APVEFFL 
Cyanothece sp. (strain 
PCC 7424) 
(Synechococcus sp. 
(strain ATCC 29155)) 
RNA 3'-terminal phosphate cyclase (RNA cyclase) 
(RNA-3'-phosphate cyclase) (EC 6.5.1.4). 
sp|B7KCF3|RTCA_CYAP7  
(350 aa) 
285-291 
APVEEFL 
Debaryomyces hansenii 
(strain ATCC 36239 / 
CBS 767 / JCM 1990 / 
NBRC 0083 / IGC 2968) 
(Yeast) (Torulaspora 
hansenii) 
Protein STU1. 
sp|Q6BK07|STU1_DEBHA  
(1529 aa) 
1106-1112 
DNVEEYV 
Homo sapiens (Human) 
Dihydroxyacetone phosphate acyltransferase (DAP-AT) 
(DHAP-AT) (EC 2.3.1.42) (Acyl-
CoA:dihydroxyacetonephosphateacyltransferase) 
(Glycerone-phosphate O-acyltransferase). 
sp|O15228|GNPAT_HUMAN  
(680 aa) 
236-242 
APVEFFL 
Homo sapiens (Human) 
Dihydroxyacetone phosphate acyltransferase (DAP-AT) 
(DHAP-AT) (EC 2.3.1.42) (Acyl-
CoA:dihydroxyacetonephosphateacyltransferase) 
(Glycerone-phosphate O-acyltransferase). 
sp|O15228-2|GNPAT_HUMAN  
(619 aa) 
175-181 
APVEFFL 
Human cytomegalovirus 
(strain AD169) (HHV-5) 
(Human herpesvirus 5) 
Protein HHLF1. 
sp|P09695|TRS1_HCMVA  
(788 aa) 
575-581 
ANVEDYL 
Human cytomegalovirus 
(strain Merlin) (HHV-5) 
(Human herpesvirus 5) 
Protein TRS1. 
sp|Q6SVX2|TRS1_HCMVM  
(788 aa) 
576-582 
ANVEDYL 
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Methylobacterium 
extorquens (strain ATCC 
14718 / DSM 1338 / JCM 
2805 / NCIMB 9133 / 
AM1) 
Glycerate dehydrogenase (GDH) (EC 1.1.1.29) 
(Glyoxylate reductase) (Hydroxypyruvate 
dehydrogenase) (NADH-dependent hydroxypyruvate 
reductase) (HPR) (HPR-A). 
sp|Q59516|DHGY_METEA  
(314 aa) 
298-304 
DNVEAFV 
Mus musculus (Mouse) 
Dihydroxyacetone phosphate acyltransferase (DAP-AT) 
(DHAP-AT) (EC 2.3.1.42) (Acyl-
CoA:dihydroxyacetonephosphateacyltransferase) 
(Glycerone-phosphate O-acyltransferase). 
sp|P98192|GNPAT_MOUSE  
(678 aa) 
235-241 
APVEFFL 
Mus musculus (Mouse) Ras-GEF domain-containing family member 1C. 
sp|Q9D300|RGF1C_MOUSE  
(466 aa) 
246-252 
NNVEAYV 
Mus musculus (Mouse) Ras-GEF domain-containing family member 1C. 
sp|Q9D300-2|RGF1C_MOUSE  
(469 aa) 
249-255 
NNVEAYV 
Mus musculus (Mouse) von Willebrand factor A domain-containing protein 3A. 
sp|Q3UVV9|VWA3A_MOUSE  
(1148 aa) 
406-412 
NPVEEFV 
Petrotoga mobilis (strain 
DSM 10674 / SJ95) 
GTPase Obg (EC 3.6.5.-) (GTP-binding protein Obg). 
sp|A9BK05|OBG_PETMO  
(440 aa) 
256-262 
DPVEDYI 
Pseudoalteromonas 
haloplanktis (strain TAC 
125) 
Methionine--tRNA ligase (EC 6.1.1.10) (Methionyl-
tRNA synthetase) (MetRS). 
sp|Q3IL10|SYM_PSEHT  (673 
aa) 
497-503 
DNVEAFL 
Rattus norvegicus (Rat) 
Dihydroxyacetone phosphate acyltransferase (DAP-AT) 
(DHAP-AT) (EC 2.3.1.42) (Acyl-
CoA:dihydroxyacetonephosphateacyltransferase) 
(Glycerone-phosphate O-acyltransferase). 
sp|Q9ES71|GNPAT_RAT  (678 
aa) 
235-241 
APVEFFL 
Rattus norvegicus (Rat) von Willebrand factor A domain-containing protein 3A. 
sp|A1A5Q7|VWA3A_RAT  
(737 aa) 
406-412 
NPVEEFV 
Rhizopus delemar (strain 
RA 99-880 / ATCC 
MYA-4621 / FGSC 9543 
/ NRRL 43880) 
(Mucormycosis agent) 
(Rhizopus arrhizus var. 
delemar) 
FK506-binding protein 4 (EC 5.2.1.8) (Histone proline 
isomerase) (Peptidyl-prolyl cis-trans isomerase) 
(PPIase) (Rotamase). 
sp|P0C1J6|FKBP4_RHIO9  
(382 aa) 
115-121 
DNVEDFL 
Rhodobacter sphaeroides 
(strain ATCC 17023 / 
2.4.1 / NCIB 8253 / DSM 
158) 
Coproporphyrinogen III oxidase, anaerobic 1 
(Coprogen oxidase) (Coproporphyrinogenase) (EC 
1.3.98.3). 
sp|P33770|HEMF_RHOS4  
(452 aa) 
78-84 
APVEAYV 
Rhodobacter sphaeroides 
(strain ATCC 17025 / 
ATH 2.4.3) 
Oxygen-independent coproporphyrinogen III oxidase 
(CPO) (EC 1.3.98.3) (Coproporphyrinogen III 
dehydrogenase) (CPDH). 
sp|P95651|HEMN_RHOS5  
(452 aa) 
78-84 
APVEAYV 
Rhodococcus erythropolis 
(strain PR4 / NBRC 
100887) 
4-hydroxy-2-oxovalerate aldolase 1 (HOA 1) (EC 
4.1.3.39) (4-hydroxy-2-keto-pentanoic acid aldolase 1) 
(4-hydroxy-2-oxopentanoate aldolase 1). 
sp|C0ZPX1|HOA1_RHOE4  
(347 aa) 
241-247 
APVEAFV 
Rhodococcus jostii (strain 
RHA1) 
4-hydroxy-2-oxovalerate aldolase 3 (HOA 3) (EC 
4.1.3.39) (4-hydroxy-2-keto-pentanoic acid aldolase 3) 
(4-hydroxy-2-oxopentanoate aldolase 3). 
sp|Q0S815|HOA3_RHOJR  
(339 aa) 
235-241 
APVEAFV 
Rhodococcus opacus 
(strain B4) 
4-hydroxy-2-oxovalerate aldolase 3 (HOA 3) (EC 
4.1.3.39) (4-hydroxy-2-keto-pentanoic acid aldolase 3) 
(4-hydroxy-2-oxopentanoate aldolase 3). 
sp|C1BAJ4|HOA3_RHOOB  
(339 aa) 
235-241 
APVEAFV 
Staphylococcus 
epidermidis (strain ATCC 
12228) 
CTP synthase (EC 6.3.4.2) (Cytidine 5'-triphosphate 
synthase) (Cytidine triphosphate synthetase) (CTP 
synthetase) (CTPS) (UTP--ammonia ligase). 
sp|Q8CNI2|PYRG_STAES  
(535 aa) 
338-344 
DNVEAYL 
Staphylococcus 
epidermidis (strain ATCC 
35984 / RP62A) 
CTP synthase (EC 6.3.4.2) (Cytidine 5'-triphosphate 
synthase) (Cytidine triphosphate synthetase) (CTP 
synthetase) (CTPS) (UTP--ammonia ligase). 
sp|Q5HM95|PYRG_STAEQ  
(535 aa) 
338-344 
DNVEAYL 
Staphylococcus 
haemolyticus (strain 
JCSC1435) 
CTP synthase (EC 6.3.4.2) (Cytidine 5'-triphosphate 
synthase) (Cytidine triphosphate synthetase) (CTP 
synthetase) (CTPS) (UTP--ammonia ligase). 
sp|Q4L808|PYRG_STAHJ  
(535 aa) 
338-344 
NNVEDYL 
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Table S3: Results of the query of the “UniProtKb/Swiss-Prot” protein database with the “ScanProsite 
tool” for the XPEFXGSXX motif with the amino acids V/I/P-P-E-F-x-G-A/S-x-V/P. The table lists the 
organism and protein on which the motif is located, the amino acid position and the exact sequence. 
The query included splice variants and excludes fragments. 
Organism Antigen Database entry 
Position & 
Epitope 
Mus musculus (Mouse) 
Lambda-crystallin homolog (EC 1.1.1.45) (L-
gulonate 3-dehydrogenase) (Gul3DH).   
sp|Q99KP3|CRYL1_MOUSE  
(319 aa) 
269-277 
VPEFsGAtV 
Oryctolagus cuniculus 
(Rabbit) 
Lambda-crystallin (EC 1.1.1.45) (L-gulonate 
3-dehydrogenase) (Gul3DH).   
sp|P14755|CRYL1_RABIT  (319 
aa) 
269-277 
IPEFsGAtV 
Staphylococcus aureus 
Extracellular matrix protein-binding protein 
emp (40 kDa vitronectin-binding cell surface 
protein) 
sp|P0C6P1|EMP_STAAU  (340 
aa) 
328-336 
VPEFkGSlP 
Staphylococcus aureus (strain 
bovine RF122 / ET3-1) 
Extracellular matrix protein-binding protein 
emp.   
sp|Q2YWL4|EMP_STAAB  
(339 aa) 
327-335 
VPEFkGSiP 
Staphylococcus aureus (strain 
COL) 
Extracellular matrix protein-binding protein 
emp.   
sp|Q5HHM6|EMP_STAAC  
(340 aa) 
328-336 
VPEFkGSlP 
Staphylococcus aureus (strain 
MSSA476) 
Extracellular matrix protein-binding protein 
emp.   
sp|Q6GB43|EMP_STAAS  (340 
aa) 
328-336 
VPEFkGSlP 
Staphylococcus aureus (strain 
Mu50 / ATCC 700699) 
Extracellular matrix protein-binding protein 
emp.   
sp|Q99VJ2|EMP_STAAM  (340 
aa) 
328-336 
VPEFkGSlP 
Staphylococcus aureus (strain 
MW2) 
Extracellular matrix protein-binding protein 
emp.   
sp|Q8NXI8|EMP_STAAW  (340 
aa) 
328-336 
VPEFkGSlP 
Staphylococcus aureus (strain 
N315) 
Extracellular matrix protein-binding protein 
emp.   
sp|Q7A6P4|EMP_STAAN  (340 
aa) 
328-336 
VPEFkGSlP 
Staphylococcus aureus (strain 
NCTC 8325) 
Extracellular matrix protein-binding protein 
emp.   
sp|Q2G012|EMP_STAA8  (340 
aa) 
328-336 
VPEFkGSlP 
Staphylococcus aureus (strain 
Newman) 
Extracellular matrix protein-binding protein 
emp.   
sp|A6QF98|EMP_STAAE  (340 
aa) 
328-336 
VPEFkGSlP 
Staphylococcus aureus (strain 
USA300) 
Extracellular matrix protein-binding protein 
emp.   
sp|Q2FIK4|EMP_STAA3  (340 
aa) 
328-336 
VPEFkGSlP 
 
Table S4: Results of the query of the “UniProtKb/Swiss-Prot” protein database with the “ScanProsite 
tool” for the KXXFPQXT motif with the amino acids KE/-x-F/Y-F/Y-P-Q/Y-T/K/M/F/V-T/V/I. The 
table lists the organism and protein on which the motif is located, the amino acid position and the 
exact sequence. The query included splice variants and excludes fragments. 
Organism Antigen Database entry 
Position & 
Epitope 
Acholeplasma laidlawii (strain 
PG-8A)] 
tRNA-specific 2-thiouridylase MnmA (EC 
2.8.1.13).   
sp|A9NFP7|MNMA_ACHLI  
(375 aa) 
332-339 
KvFYPQKI 
Aster yellows witches'-broom 
phytoplasma (strain AYWB)] 
tRNA-specific 2-thiouridylase MnmA (EC 
2.8.1.13).   
sp|Q2NIM9|MNMA_AYWBP  
(378 aa) 
335-342 
EiYYPQTI 
Bacteroides thetaiotaomicron 
(strain ATCC 29148 / DSM 2079 / 
NCTC 10582 / E50 / VPI-5482)] 
UDP-N-acetylglucosamine--N-
acetylmuramyl-(pentapeptide) 
pyrophosphoryl-undecaprenol N-
acetylglucosamine transferase (EC 2.4.1.227) 
(Undecaprenyl-PP-MurNAc-pentapeptide-
UDPGlcNAc GlcNAc transferase).   
sp|Q8A258|MURG_BACTN  
(372 aa) 
232-239 
KyYYPQVT 
Campylobacter jejuni (strain 
RM1221)] 
Thymidylate kinase (EC 2.7.4.9) (dTMP 
kinase).   
sp|Q5HV26|KTHY_CAMJR  
(192 aa) 
112-119 
EnFFPQKI 
Campylobacter jejuni subsp. 
doylei (strain ATCC BAA-1458 / 
RM4099 / 269.97)] 
Thymidylate kinase (EC 2.7.4.9) (dTMP 
kinase).   
sp|A7H476|KTHY_CAMJD  
(192 aa) 
112-119 
EdFFPQKI 
Campylobacter jejuni subsp. jejuni 
serotype O:2 (strain ATCC 
700819 / NCTC 11168)] 
Thymidylate kinase (EC 2.7.4.9) (dTMP 
kinase).   
sp|Q9PPF3|KTHY_CAMJE  
(192 aa) 
112-119 
EnFFPQKI 
Campylobacter jejuni subsp. jejuni 
serotype O:23/36 (strain 81-176)] 
Thymidylate kinase (EC 2.7.4.9) (dTMP 
kinase).   
sp|A1VZB4|KTHY_CAMJJ  
(192 aa) 
112-119 
EnFFPQKI 
Campylobacter jejuni subsp. jejuni 
serotype O:6 (strain 81116 / 
NCTC 11828)] 
Thymidylate kinase (EC 2.7.4.9) (dTMP 
kinase).   
sp|A8FLH9|KTHY_CAMJ8  
(192 aa) 
112-119 
EnFFPQKI 
Chlorobium tepidum (strain 
ATCC 49652 / DSM 12025 / 
NBRC 103806 / TLS)] 
Uncharacterized N-acetyltransferase CT2212 
(EC 2.3.1.-).   
sp|P59599|Y2212_CHLTE  
(155 aa) 
126-133 
KeYFPQKI 
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Homo sapiens (Human)] 
Gametocyte-specific factor 1-like (Protein 
FAM112A).   
sp|Q9H1H1|GTSFL_HUMAN  
(148 aa) 
118-125 
KtFFPQKV 
Homo sapiens (Human)] Nebulin.   
sp|P20929|NEBU_HUMAN  
(6669 aa) 
468-475 
KgFFPQTI 
Homo sapiens (Human)] Nebulin.   
sp|P20929-2|NEBU_HUMAN  
(8525 aa) 
468-475 
KgFFPQTI 
Homo sapiens (Human)] Nebulin.   
sp|P20929-3|NEBU_HUMAN  
(8525 aa) 
468-475 
KgFFPQTI 
Homo sapiens (Human)] Nebulin.   
sp|P20929-4|NEBU_HUMAN  
(6669 aa) 
468-475 
KgFFPQTI 
Homo sapiens (Human)] Reelin (EC 3.4.21.-).   
sp|P78509|RELN_HUMAN  
(3460 aa) 
1897-1904 
EfYFPQTT 
Homo sapiens (Human)] Reelin (EC 3.4.21.-).   
sp|P78509-2|RELN_HUMAN  
(3458 aa) 
1897-1904 
EfYFPQTT 
Homo sapiens (Human)] Reelin (EC 3.4.21.-).   
sp|P78509-3|RELN_HUMAN  
(3427 aa) 
1897-1904 
EfYFPQTT 
Meyerozyma guilliermondii 
(strain ATCC 6260 / CBS 566 / 
DSM 6381 / JCM 1539 / NBRC 
10279 / NRRL Y-324) (Yeast) 
(Candida guilliermondii)] 
Pro-apoptotic serine protease NMA111 (EC 
3.4.21.-).   
sp|A5DAL3|NM111_PICGU  
(991 aa) 
59-66 
EnYFPQTT 
Mus musculus (Mouse)] Reelin (EC 3.4.21.-) (Reeler protein).   
sp|Q60841|RELN_MOUSE  
(3461 aa) 
1898-1905 
EfYFPQTT 
Mus musculus (Mouse)] Reelin (EC 3.4.21.-) (Reeler protein).   
sp|Q60841-2|RELN_MOUSE  
(3459 aa) 
1898-1905 
EfYFPQTT 
Mus musculus (Mouse)] Reelin (EC 3.4.21.-) (Reeler protein).   
sp|Q60841-3|RELN_MOUSE  
(3428 aa) 
1898-1905 
EfYFPQTT 
Ochrobactrum anthropi (strain 
ATCC 49188 / DSM 6882 / JCM 
21032 / NBRC 15819 / NCTC 
12168)] 
Biotin synthase (EC 2.8.1.6).   
sp|A6X2S8|BIOB_OCHA4  
(336 aa) 
175-182 
ErFYPQVI 
Rattus norvegicus (Rat)] 
Inactive serine protease 45 (Inactive testis 
serine protease 5).   
sp|Q6IE62|PRS45_RAT  (330 
aa) 
214-221 
KtFYPQVI 
Rattus norvegicus (Rat)] Reelin (EC 3.4.21.-).   
sp|P58751|RELN_RAT  (3462 
aa) 
1899-1906 
EfYFPQTT 
Rattus norvegicus (Rat)] Reelin (EC 3.4.21.-).   
sp|P58751-2|RELN_RAT  
(3460 aa) 
1899-1906 
EfYFPQTT 
Rattus norvegicus (Rat)] Reelin (EC 3.4.21.-).   
sp|P58751-3|RELN_RAT  
(3429 aa) 
1899-1906 
EfYFPQTT 
Rhesus cytomegalovirus (strain 
68-1) (RhCMV)] 
Envelope glycoprotein B (gB).   
sp|P89053|GB_RHCM6  (854 
aa) 
756-763 
EhFFPYVV 
 
Table S5: Results of the query of the “UniProtKb/Swiss-Prot” protein database with the “ScanProsite 
tool” for the LXAXETX motif with the amino acids L-D/T-A-x-E-T-G/S. The table lists the organism 
and protein on which the motif is located, the amino acid position and the exact sequence. The query 
included splice variants and excludes fragments. 
Organism Antigen Database entry 
Position & 
Epitope 
Agathobacter rectalis (strain ATCC 
33656 / DSM 3377 / JCM 17463 / 
KCTC 5835 / VPI 0990) 
(Eubacterium rectale) 
Peptide chain release factor 1 (RF-1).   
sp|C4Z911|RF1_AGARV  (358 
aa) 
148-154 
LDAdETG 
Aquifex aeolicus (strain VF5) 
ATP-dependent 6-phosphofructokinase (ATP-
PFK) (Phosphofructokinase) (EC 2.7.1.11) 
(Phosphohexokinase).   
sp|O67605|PFKA_AQUAE  (321 
aa) 
110-116 
LTAeETG 
Arabidopsis thaliana (Mouse-ear 
cress) 
Cysteine-rich repeat secretory protein 39 
(Plasmodesmata-located protein 4) (PDLP4).   
sp|Q6E263|CRR39_ARATH  
(319 aa) 
196-202 
LTAaETG 
Arabidopsis thaliana (Mouse-ear 
cress) 
Cysteine-rich repeat secretory protein 39 
(Plasmodesmata-located protein 4) (PDLP4).   
sp|Q6E263-2|CRR39_ARATH  
(318 aa) 
195-201 
LTAaETG 
Arabidopsis thaliana (Mouse-ear 
cress) 
Bifunctional bis(5'-adenosyl)-
triphosphatase/adenylylsulfatase FHIT (EC 
3.6.1.29) (EC 3.6.2.1) (Fragile histidine triad 
protein) (Purine nucleoside phosphoramidase 
FHIT) (EC 3.9.1.-).   
sp|F4KEV7|FHIT_ARATH  (180 
aa) 
75-81 
LTAdETS 
Arabidopsis thaliana (Mouse-ear 
cress) 
Bifunctional bis(5'-adenosyl)-
triphosphatase/adenylylsulfatase FHIT (EC 
sp|F4KEV7-2|FHIT_ARATH  
(160 aa) 
55-61 
LTAdETS 
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3.6.1.29) (EC 3.6.2.1) (Fragile histidine triad 
protein) (Purine nucleoside phosphoramidase 
FHIT) (EC 3.9.1.-).   
Bos taurus (Bovine) 
Calcium/calmodulin-dependent 3',5'-cyclic 
nucleotide phosphodiesterase 1B (Cam-PDE 
1B) (EC 3.1.4.17) (63 kDa Cam-PDE).   
sp|Q01061|PDE1B_BOVIN  
(534 aa) 
206-212 
LDAlETG 
Chlorobium phaeovibrioides (strain 
DSM 265 / 1930) (Prosthecochloris 
vibrioformis (strain DSM 265)) 
Serine--tRNA ligase (EC 6.1.1.11) (Seryl-
tRNA synthetase) (SerRS) (Seryl-
tRNA(Ser/Sec) synthetase).   
sp|A4SFD5|SYS_CHLPM  (430 
aa) 
93-99 
LTAlETS 
Coxsackievirus A21 (strain Coe) Genome polyprotein  
sp|P22055|POLG_CXA21  (2206 
aa) 
620-626 
LTAvETG 
Coxsackievirus A24 (strain EH24/70) Genome polyprotein  
sp|P36290|POLG_CXA24  (2214 
aa) 
624-630 
LTAvETG 
Coxsackievirus A9 (strain Griggs) Genome polyprotein  
sp|P21404|POLG_CXA9  (2201 
aa) 
599-605 
LTAvETG 
Coxsackievirus B1 (strain Japan) Genome polyprotein  
sp|P08291|POLG_CXB1J  (2182 
aa) 
601-607 
LTAaETG 
Coxsackievirus B2 (strain Ohio-1) Genome polyprotein  
sp|Q9YLG5|POLG_CXB2O  
(2187 aa) 
602-608 
LTAvETG 
Coxsackievirus B3 (strain Nancy) Genome polyprotein  
sp|P03313|POLG_CXB3N  
(2185 aa) 
601-607 
LTAaETG 
Coxsackievirus B3 (strain Woodruff) Genome polyprotein  
sp|Q66282|POLG_CXB3W  
(2185 aa) 
601-607 
LTAaETG 
Coxsackievirus B4 (strain E2) Genome polyprotein  
sp|Q86887|POLG_CXB4E  
(2183 aa) 
599-605 
LTAvETG 
Coxsackievirus B4 (strain JVB / 
Benschoten / New York/51) 
Genome polyprotein  
sp|P08292|POLG_CXB4J  (2183 
aa) 
599-605 
LTAvETG 
Coxsackievirus B5 (strain 
Peterborough / 1954/UK/85) 
Genome polyprotein  
sp|Q03053|POLG_CXB5P  
(2185 aa) 
599-605 
LTAaETG 
Coxsackievirus B6 (strain Schmitt) Genome polyprotein  
sp|Q9QL88|POLG_CXB6S  
(2184 aa) 
599-605 
LTAvETG 
Cyanothece sp. (strain PCC 7425 / 
ATCC 29141) 
ATP synthase epsilon chain (ATP synthase F1 
sector epsilon subunit) (F-ATPase epsilon 
subunit).   
sp|B8HP54|ATPE_CYAP4  (138 
aa) 
41-47 
LTAlETG 
Echovirus 1 (strain 
Human/Egypt/Farouk/1951) (E-1) 
Genome polyprotein  
sp|O91734|POLG_EC01F  (2184 
aa) 
600-606 
LTAvETG 
Echovirus 11 (strain Gregory) Genome polyprotein  
sp|P29813|POLG_EC11G  (2195 
aa) 
600-606 
LTAvETG 
Echovirus 12 (strain Travis) Genome polyprotein  
sp|Q66575|POLG_EC12T  (2193 
aa) 
599-605 
LTAaETG 
Echovirus 30 (strain Bastianni) Genome polyprotein  
sp|Q9WN78|POLG_EC30B  
(2194 aa) 
599-605 
LTAvETG 
Echovirus 5 (strain Noyce) Genome polyprotein  
sp|Q9YLJ1|POLG_EC05N  
(2196 aa) 
601-607 
LTAvETG 
Echovirus 6 (strain Charles) Genome polyprotein  
sp|Q66474|POLG_EC06C  (2191 
aa) 
599-605 
LTAaETG 
Echovirus 9 (strain Barty) Genome polyprotein  
sp|Q66577|POLG_EC09B  (2203 
aa) 
600-606 
LTAaETG 
Echovirus 9 (strain Hill) Genome polyprotein  
sp|Q66849|POLG_EC09H  (2193 
aa) 
600-606 
LTAaETG 
Emericella nidulans (strain FGSC A4 
/ ATCC 38163 / CBS 112.46 / NRRL 
194 / M139) (Aspergillus nidulans) 
Uncharacterized protein AN0679.   
sp|P0C154|Y0679_EMENI  (251 
aa) 
48-54 
LDApETS 
Escherichia coli (strain 55989 / 
EAEC) 
Hydroxylamine reductase (EC 1.7.99.1) 
(Hybrid-cluster protein) (HCP) (Prismane 
protein).   
sp|B7LD66|HCP_ECO55  (550 
aa) 
218-224 
LDAgETG 
Escherichia coli (strain ATCC 8739 / 
DSM 1576 / Crooks) 
Hydroxylamine reductase (EC 1.7.99.1) 
(Hybrid-cluster protein) (HCP) (Prismane 
protein).   
sp|B1IWP9|HCP_ECOLC  (550 
aa) 
218-224 
LDAgETG 
Escherichia coli (strain K12 / 
DH10B) 
Hydroxylamine reductase (EC 1.7.99.1) 
(Hybrid-cluster protein) (HCP) (Prismane 
protein).   
sp|B1X814|HCP_ECODH  (550 
aa) 
218-224 
LDAgETG 
Escherichia coli (strain K12 / 
MC4100 / BW2952) 
Hydroxylamine reductase (EC 1.7.99.1) 
(Hybrid-cluster protein) (HCP) (Prismane 
protein).   
sp|C4ZY45|HCP_ECOBW  (550 
aa) 
218-224 
LDAgETG 
Escherichia coli (strain K12) 
Hydroxylamine reductase (EC 1.7.99.1) 
(Hybrid-cluster protein) (HCP) (Prismane 
protein).   
sp|P75825|HCP_ECOLI  (550 
aa) 
218-224 
LDAgETG 
Escherichia coli (strain K12) Uncharacterized protein YggR.   
sp|P52052|YGGR_ECOLI  (326 
aa) 
212-218 
LTAaETG 
Escherichia coli (strain SE11) Hydroxylamine reductase (EC 1.7.99.1) sp|B6I8U4|HCP_ECOSE  (550 218-224 
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(Hybrid-cluster protein) (HCP) (Prismane 
protein).   
aa) LDAgETG 
Escherichia coli (strain SMS-3-5 / 
SECEC) 
Hydroxylamine reductase (EC 1.7.99.1) 
(Hybrid-cluster protein) (HCP) (Prismane 
protein).   
sp|B1LN27|HCP_ECOSM  (550 
aa) 
218-224 
LDAgETS 
Escherichia coli (strain UTI89 / 
UPEC) 
Hydroxylamine reductase (EC 1.7.99.1) 
(Hybrid-cluster protein) (HCP) (Prismane 
protein).   
sp|Q1RE52|HCP_ECOUT  (552 
aa) 
220-226 
LDAgETG 
Escherichia coli O1:K1 / APEC 
Hydroxylamine reductase (EC 1.7.99.1) 
(Hybrid-cluster protein) (HCP) (Prismane 
protein).   
sp|A1A9B1|HCP_ECOK1  (552 
aa) 
220-226 
LDAgETG 
Escherichia coli O127:H6 (strain 
E2348/69 / EPEC) 
Hydroxylamine reductase (EC 1.7.99.1) 
(Hybrid-cluster protein) (HCP) (Prismane 
protein).   
sp|B7UMW5|HCP_ECO27  (550 
aa) 
218-224 
LDAgETG 
Escherichia coli O139:H28 (strain 
E24377A / ETEC) 
Hydroxylamine reductase (EC 1.7.99.1) 
(Hybrid-cluster protein) (HCP) (Prismane 
protein).   
sp|A7ZJU2|HCP_ECO24  (550 
aa) 
218-224 
LDAgETG 
Escherichia coli O157:H7 (strain 
EC4115 / EHEC) 
Hydroxylamine reductase (EC 1.7.99.1) 
(Hybrid-cluster protein) (HCP) (Prismane 
protein).   
sp|B5YSG9|HCP_ECO5E  (550 
aa) 
218-224 
LDAgETG 
Escherichia coli O157:H7 
Hydroxylamine reductase (EC 1.7.99.1) 
(Hybrid-cluster protein) (HCP) (Prismane 
protein).   
sp|Q8X6L0|HCP_ECO57  (550 
aa) 
218-224 
LDAgETG 
Escherichia coli O17:K52:H18 
(strain UMN026 / ExPEC) 
Hydroxylamine reductase (EC 1.7.99.1) 
(Hybrid-cluster protein) (HCP) (Prismane 
protein).   
sp|B7NAM4|HCP_ECOLU  (550 
aa) 
218-224 
LDAgETG 
Escherichia coli O45:K1 (strain S88 / 
ExPEC) 
Hydroxylamine reductase (EC 1.7.99.1) 
(Hybrid-cluster protein) (HCP) (Prismane 
protein).   
sp|B7MHH8|HCP_ECO45  (550 
aa) 
218-224 
LDAgETG 
Escherichia coli O6:H1 (strain 
CFT073 / ATCC 700928 / UPEC) 
Hydroxylamine reductase (EC 1.7.99.1) 
(Hybrid-cluster protein) (HCP) (Prismane 
protein).   
sp|Q8FJE0|HCP_ECOL6  (550 
aa) 
218-224 
LDAgETG 
Escherichia coli O6:K15:H31 (strain 
536 / UPEC) 
Hydroxylamine reductase (EC 1.7.99.1) 
(Hybrid-cluster protein) (HCP) (Prismane 
protein).   
sp|Q0TJH6|HCP_ECOL5  (550 
aa) 
218-224 
LDAgETG 
Escherichia coli O7:K1 (strain IAI39 
/ ExPEC) 
Hydroxylamine reductase (EC 1.7.99.1) 
(Hybrid-cluster protein) (HCP) (Prismane 
protein).   
sp|B7NPH0|HCP_ECO7I  (550 
aa) 
218-224 
LDAgETS 
Escherichia coli O8 (strain IAI1) 
Hydroxylamine reductase (EC 1.7.99.1) 
(Hybrid-cluster protein) (HCP) (Prismane 
protein).   
sp|B7M801|HCP_ECO8A  (550 
aa) 
218-224 
LDAgETG 
Escherichia coli O81 (strain ED1a) 
Hydroxylamine reductase (EC 1.7.99.1) 
(Hybrid-cluster protein) (HCP) (Prismane 
protein).   
sp|B7MQX7|HCP_ECO81  (550 
aa) 
218-224 
LDAgETG 
Escherichia coli O9:H4 (strain HS) 
Hydroxylamine reductase (EC 1.7.99.1) 
(Hybrid-cluster protein) (HCP) (Prismane 
protein).   
sp|A7ZYH7|HCP_ECOHS  (550 
aa) 
218-224 
LDAgETG 
Escherichia fergusonii (strain ATCC 
35469 / DSM 13698 / CDC 0568-73) 
Hydroxylamine reductase (EC 1.7.99.1) 
(Hybrid-cluster protein) (HCP) (Prismane 
protein).   
sp|B7LN38|HCP_ESCF3  (550 
aa) 
218-224 
LDAgETG 
Eubacterium eligens (strain ATCC 
27750 / VPI C15-48) 
Methionyl-tRNA formyltransferase (EC 
2.1.2.9).   
sp|C4Z520|FMT_EUBE2  (315 
aa) 
155-161 
LDAkETG 
Guillardia theta (Cryptomonas phi) 
Chaperone protein dnaK (HSP70) (Heat shock 
70 kDa protein) (Heat shock protein 70).   
sp|P29215|DNAK_GUITH  (627 
aa) 
281-287 
LTAtETG 
Homo sapiens (Human) Putative butyrophilin subfamily 2 member A3.   
sp|Q96KV6|BT2A3_HUMAN  
(586 aa) 
502-508 
LTAmETS 
Homo sapiens (Human) 
C3 and PZP-like alpha-2-macroglobulin 
domain-containing protein 8.   
sp|Q8IZJ3|CPMD8_HUMAN  
(1885 aa) 
242-248 
LDAcETG 
Homo sapiens (Human) 
C3 and PZP-like alpha-2-macroglobulin 
domain-containing protein 8.   
sp|Q8IZJ3-2|CPMD8_HUMAN  
(1815 aa) 
242-248 
LDAcETG 
Homo sapiens (Human) 
Calcium/calmodulin-dependent 3',5'-cyclic 
nucleotide phosphodiesterase 1B (Cam-PDE 
1B) (EC 3.1.4.17) (63 kDa Cam-PDE).   
sp|Q01064|PDE1B_HUMAN  
(536 aa) 
208-214 
LDAlETG 
Homo sapiens (Human) 
Calcium/calmodulin-dependent 3',5'-cyclic 
nucleotide phosphodiesterase 1B (Cam-PDE 
1B) (EC 3.1.4.17) (63 kDa Cam-PDE).   
sp|Q01064-2|PDE1B_HUMAN  
(516 aa) 
188-194 
LDAlETG 
Human rhinovirus 14 (HRV-14) Genome polyprotein  
sp|P03303|POLG_HRV14  (2179 
aa) 
601-607 
LTAnETG 
Human rhinovirus 16 (HRV-16) Genome polyprotein  
sp|Q82122|POLG_HRV16  
(2153 aa) 
602-608 
LDAaETG 
Human rhinovirus 1A (HRV-1A) Genome polyprotein  sp|P23008|POLG_HRV1A  604-610 
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(2157 aa) LDAaETG 
Human rhinovirus 1B (HRV-1B) Genome polyprotein  
sp|P12916|POLG_HRV1B  
(2157 aa) 
604-610 
LDAaETG 
Human rhinovirus 2 (HRV-2) Genome polyprotein  
sp|P04936|POLG_HRV2  (2150 
aa) 
601-607 
LDAaETG 
Human rhinovirus 3 (HRV-3) Genome polyprotein  
sp|Q82081|POLG_HRV3  (2178 
aa) 
601-607 
LTAnETG 
Human rhinovirus A serotype 89 
(strain 41467-Gallo) (HRV-89) 
Genome polyprotein  
sp|P07210|POLG_HRV8A  
(2164 aa) 
608-614 
LDAaETG 
Klebsiella pneumoniae (strain 342) 
Chaperone protein DnaK (HSP70) (Heat 
shock 70 kDa protein) (Heat shock protein 
70).   
sp|B5Y242|DNAK_KLEP3  (638 
aa) 
569-575 
LTAlETS 
Lecanicillium sp. 
Nonribosomal peptide synthetase vlms (NRPS 
vlmS) (EC 6.3.2.-) (Verlamelin biosynthesis 
protein S).   
sp|A0A024F910|VLMS_LECSP  
(8903 aa) 
711-717 
LDAgETS 
Moorella thermoacetica (strain 
ATCC 39073 / JCM 9320) 
Phosphopentomutase (EC 5.4.2.7) 
(Phosphodeoxyribomutase).   
sp|Q2RID0|DEOB_MOOTA  
(389 aa) 
310-316 
LDAlETS 
Mus musculus (Mouse) 
Interphotoreceptor matrix proteoglycan 2 
(Sialoprotein associated with cones and rods 
proteoglycan) (Spacrcan).   
sp|Q80XH2|IMPG2_MOUSE  
(1243 aa) 
59-65 
LDAtETG 
Mus musculus (Mouse) 
Interphotoreceptor matrix proteoglycan 2 
(Sialoprotein associated with cones and rods 
proteoglycan) (Spacrcan).   
sp|Q80XH2-2|IMPG2_MOUSE  
(1134 aa) 
59-65 
LDAtETG 
Mus musculus (Mouse) 
Photoreceptor-specific nuclear receptor 
(Nuclear receptor subfamily 2 group E 
member 3) (Retina-specific nuclear receptor).   
sp|Q9QXZ7|NR2E3_MOUSE  
(395 aa) 
125-131 
LDAmETG 
Mycobacterium sp. (strain JLS) 
Histidinol-phosphate aminotransferase (EC 
2.6.1.9) (Imidazole acetol-phosphate 
transaminase).   
sp|A3Q130|HIS8_MYCSJ  (377 
aa) 
190-196 
LDAmETG 
Mycobacterium sp. (strain KMS) 
Histidinol-phosphate aminotransferase (EC 
2.6.1.9) (Imidazole acetol-phosphate 
transaminase).   
sp|A1UHK7|HIS8_MYCSK  
(377 aa) 
190-196 
LDAmETG 
Mycobacterium sp. (strain MCS) 
Histidinol-phosphate aminotransferase (EC 
2.6.1.9) (Imidazole acetol-phosphate 
transaminase).   
sp|Q1B7G5|HIS8_MYCSS  (377 
aa) 
190-196 
LDAmETG 
Neisseria gonorrhoeae Twitching motility protein.   
sp|Q06581|PILT_NEIGO  (374 
aa) 
242-248 
LTAaETG 
Neosartorya fumigata (strain ATCC 
MYA-4609 / Af293 / CBS 101355 / 
FGSC A1100) (Aspergillus 
fumigatus) 
Mediator of RNA polymerase II transcription 
subunit 21 (Mediator complex subunit 21).   
sp|Q4X0I5|MED21_ASPFU  
(207 aa) 
189-195 
LTAvETG 
Poliovirus type 1 (strain Mahoney) Genome polyprotein  
sp|P03300|POLG_POL1M  
(2209 aa) 
623-629 
LTAvETG 
Poliovirus type 1 (strain Sabin) Genome polyprotein  
sp|P03301|POLG_POL1S  (2209 
aa) 
623-629 
LTAvETG 
Poliovirus type 2 (strain Lansing) Genome polyprotein  
sp|P06210|POLG_POL2L  (2207 
aa) 
622-628 
LTAvETG 
Poliovirus type 2 (strain W-2) Genome polyprotein  
sp|P23069|POLG_POL2W  
(2205 aa) 
622-628 
LTAvETG 
Poliovirus type 3 (strain 23127) Genome polyprotein  
sp|P06209|POLG_POL32  (2206 
aa) 
620-626 
LTAvETG 
Poliovirus type 3 (strains P3/Leon/37 
and P3/Leon 12A 
Genome polyprotein  
sp|P03302|POLG_POL3L  (2206 
aa) 
620-626 
LTAvETG 
Pseudomonas aeruginosa (strain 
ATCC 15692 / DSM 22644 / CIP 
104116 / JCM 14847 / LMG 12228 / 
1C / PRS 101 / PAO1) 
Twitching mobility protein.   
sp|P24559|PILT_PSEAE  (344 
aa) 
215-221 
LTAaETG 
Rattus norvegicus (Rat) 
Interphotoreceptor matrix proteoglycan 2 
(PG10.2) (Sialoprotein associated with cones 
and rods proteoglycan) (Spacrcan).   
sp|P70628|IMPG2_RAT  (1241 
aa) 
59-65 
LDAtETG 
Saccharomyces cerevisiae (strain 
ATCC 204508 / S288c) (Baker's 
yeast) 
Protein BRE4 (Brefeldin A-sensitivity protein 
4).   
sp|Q07660|BRE4_YEAST  
(1125 aa) 
389-395 
LTAmETS 
Saccharomyces cerevisiae (strain 
ATCC 204508 / S288c) (Baker's 
yeast) 
Ubiquitin fusion degradation protein 1 (UB 
fusion protein 1) (Polymerase-interacting 
protein 3).   
sp|P53044|UFD1_YEAST  (361 
aa) 
71-77 
LTAnETG 
Salinibacter ruber (strain DSM 13855 
/ M31) 
Glutamyl-tRNA(Gln) amidotransferase 
subunit A (Glu-ADT subunit A) (EC 6.3.5.7).   
sp|Q2S4S2|GATA_SALRD  
(514 aa) 
13-19 
LDAgETS 
Schizosaccharomyces pombe (strain 
972 / ATCC 24843) (Fission yeast) 
eIF-2-alpha kinase activator gcn1 
(Translational activator gcn1).   
sp|Q10105|GCN1_SCHPO  
(2670 aa) 
1128-1134 
LDAtETS 
Schizosaccharomyces pombe (strain Nucleoporin nup184 (Nuclear pore protein sp|Q9P7M8|NU184_SCHPO  12-18 
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972 / ATCC 24843) (Fission yeast) nup184).   (1564 aa) LDAfETS 
Shigella boydii serotype 18 (strain 
CDC 3083-94 / BS512) 
Hydroxylamine reductase (EC 1.7.99.1) 
(Hybrid-cluster protein) (HCP) (Prismane 
protein).   
sp|B2TUK6|HCP_SHIB3  (550 
aa) 
218-224 
LDAgETG 
Shigella boydii serotype 4 (strain 
Sb227) 
Hydroxylamine reductase (EC 1.7.99.1) 
(Hybrid-cluster protein) (HCP) (Prismane 
protein).   
sp|Q323M9|HCP_SHIBS  (552 
aa) 
220-226 
LDAgETG 
Shigella dysenteriae serotype 1 
(strain Sd197) 
Hydroxylamine reductase (EC 1.7.99.1) 
(Hybrid-cluster protein) (HCP) (Prismane 
protein).   
sp|Q32DZ1|HCP_SHIDS  (552 
aa) 
220-226 
LDAgETG 
Shigella flexneri serotype 5b (strain 
8401) 
Hydroxylamine reductase (EC 1.7.99.1) 
(Hybrid-cluster protein) (HCP) (Prismane 
protein).   
sp|Q0T8K8|HCP_SHIF8  (550 
aa) 
218-224 
LDAgETG 
Shigella flexneri 
Hydroxylamine reductase (EC 1.7.99.1) 
(Hybrid-cluster protein) (HCP) (Prismane 
protein).   
sp|Q83S05|HCP_SHIFL  (552 
aa) 
220-226 
LDAgETG 
Shigella sonnei (strain Ss046) 
Hydroxylamine reductase (EC 1.7.99.1) 
(Hybrid-cluster protein) (HCP) (Prismane 
protein).   
sp|Q3Z3R0|HCP_SHISS  (552 
aa) 
220-226 
LDAgETG 
Swine vesicular disease virus (strain 
H/3 '76) (SVDV) 
Genome polyprotein  
sp|P16604|POLG_SVDVH  
(2185 aa) 
599-605 
LTAaETG 
Swine vesicular disease virus (strain 
UKG/27/72) (SVDV) 
Genome polyprotein  
sp|P13900|POLG_SVDVU  
(2185 aa) 
599-605 
LTAaETG 
Synechococcus sp. (strain PCC 6716) 
ATP synthase epsilon chain (ATP synthase F1 
sector epsilon subunit) (F-ATPase epsilon 
subunit).   
sp|Q05375|ATPE_SYNP1  (138 
aa) 
41-47 
LTAlETG 
Synechocystis sp. (strain PCC 6803 / 
Kazusa) 
Chromosome partition protein Smc.   
sp|P73340|SMC_SYNY3  (1200 
aa) 
806-812 
LTAlETS 
Thermosynechococcus elongatus 
(strain BP-1) 
ATP synthase epsilon chain (ATP synthase F1 
sector epsilon subunit) (F-ATPase epsilon 
subunit)  
sp|Q8DLG7|ATPE_THEEB  
(138 aa) 
41-47 
LTAlETG 
Xenopus laevis (African clawed frog) 
DDB1- and CUL4-associated factor 8 (WD 
repeat-containing protein 42A).   
sp|Q6NRH1|DCAF8_XENLA  
(601 aa) 
50-56 
LTAdETG 
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Fingerprints of 73 peptide binders 
The Supplementary Figures S3 – S7 show the substitution analysis graphs of all 73 identified 
peptide binders. If the scale on the y-axis does not allow the read-out of the essential amino 
acids, the maximum was set to 200 % and an additional diagram is depicted next to the 
original diagram. The peptides are grouped according to Table 1. 
 
NPVEXXX motif 
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NPVEXXX motif (continued) 
 
 
 
Figure S3: Substitution analyses of 14 peptide binders containing the “NPVEXXX” motif. Relative 
fluorescence intensities in reference to the original amino acid in the substituted peptide sequence. 
Each peptide variant is represented by the letter of the amino acid that was synthesized at the 
respective position. The original sequence is depicted on the x-axis. The intensity of the peptide with 
the original amino acid was set to 100 %. Intensities of peptide variants were correlated to the intensity 
of the original peptide in each row respectively.  
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XPEFXGSXX motif 
 
 
 
Figure S4: Substitution analyses of 8 peptide binders containing the “XPEFXGSXX” motif. Relative 
fluorescence intensities in reference to the original amino acid in the substituted peptide sequence. 
Each peptide variant is represented by the letter of the amino acid that was synthesized at the 
respective position. The original sequence is depicted on the x-axis. The intensity of the peptide with 
the original amino acid was set to 100 %. Intensities of peptide variants were correlated to the intensity 
of the original peptide in each row respectively. 
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KXXFPQXT motif 
 
 
 
Figure S5: Substitution analyses of 6 peptide binders containing the “KXXFPQXT” motif. Relative 
fluorescence intensities in reference to the original amino acid in the substituted peptide sequence. 
Each peptide variant is represented by the letter of the amino acid that was synthesized at the 
respective position. The original sequence is depicted on the x-axis. The intensity of the peptide with 
the original amino acid was set to 100 %. Intensities of peptide variants were correlated to the intensity 
of the original peptide in each row respectively.  
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LXAXETX motif 
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LXAXETX motif (continued) 
 
 
 
Figure S6: Substitution analyses of 13 peptide binders containing the “LXAXETX” motif. Relative 
fluorescence intensities in reference to the original amino acid in the substituted peptide sequence. 
Each peptide variant is represented by the letter of the amino acid that was synthesized at the 
respective position. The original sequence is depicted on the x-axis. The intensity of the peptide with 
the original amino acid was set to 100 %. Intensities of peptide variants were correlated to the intensity 
of the original peptide in each row respectively.  
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Heterogeneous motifs 
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Heterogeneous motifs (continued) 
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Heterogeneous motifs (continued) 
 
 
 
 
 
Figure S7: Substitution analyses of 32 peptide binders containing heterogeneous motifs. Relative 
fluorescence intensities in reference to the original amino acid in the substituted peptide sequence. 
Each peptide variant is represented by the letter of the amino acid that was synthesized at the 
respective position. The original sequence is depicted on the x-axis. The intensity of the peptide with 
the original amino acid was set to 100 %. Intensities of peptide variants were correlated to the intensity 
of the original peptide in each row respectively. 
 
